(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 November 2020 (12.11.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/227430 A1

(51) International Patent Classification:
C12N 9/00 (2006.01) *C12Q 1/6883* (2018.01)

(21) International Application Number:
PCT/US2020/031708

(22) International Filing Date:
06 May 2020 (06.05.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/844,370 07 May 2019 (07.05.2019) US
62/987,151 09 March 2020 (09.03.2020) US

(71) Applicants: **UNIVERSITY OF MIAMI** [US/US]; 1951 NW 7th Avenue, Miami, FL 33136 (US). **UNIVERSITY OF ROCHESTER** [US/US]; 601 Elmwood Avenue, Box URV, Rochester, NY 14642 (US). **UCL BUSINESS LTD** [GB/GB]; The Network Building, 97 Tottenham Court Road, London W1T 4TP (GB).

(72) Inventors: **ZUCHNER, Stephan L.**; c/o Miller School of Medicine, Hussman Institute for Human Genomics,1501 NW 10th Avenue, Room 523, LC: M-860, Biomedical Research Building, Miami, FL 33136 (US). **REBELO, Adriana**; c/o University of Miami, Hihg Organized Research Lab, 1951 NW 7th Ave, Miami, FL 33136 (US). **CORTESE, Andrea**; c/o Miller School of Medicine, Hussman Institute for Human Genomics, 1501 NW 10th Avenue, Room 523, LC: M-860, Biomedical Research Building, Miami, FL 33136 (US). **ZHAI, Rong Grace**; MSOM - Molecular & Cellular Pharmacology, 1600 NW 10th Avenue, Rosentiel Med Science Bldg, Floor 06, Room 6069, Miami, FL 33136 (US). **HERRMANN, David N.**; c/o University of Rochester Medical Center, Strong Memorial Hospital, 601 Elmwood Avenue, AC-1, Rochester, NY 14642-0001 (US).

(74) Agent: **KISSLING, Heather R.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS



FIG. 1A

(57) Abstract: The present disclosure relates to methods of detecting and treating inherited neuropathy. In various aspects, the method comprises detecting the presence of a mutation in the sorbitol dehydrogenase (SORD) gene in a sample from a subject. In various embodiments, th SORD mutation is a DNA variant classified as pathogenic or likely pathogenic according to American College of Medical Genetics and Genomics (ACMG) criteria.

WO 2020/227430 A1

TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS

GRANT FUNDING DISCLOSURE

[0001] This invention was made with government support under grant numbers NS065712 and NS075764 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.

CROSS REFERENCE TO RELATED APPLICATIONS AND INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] This application hereby claims priority to U.S. Provisional Patent Applications No. 62/844,370, filed May 7, 2019, and No. 62/987,151, filed March 9, 2020, each of which are incorporated by reference in their entireties.

[0003] Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: Filename: 54095A _Seqlisting.txt; Size:141,930 Bytes; Created: May 5, 2020.

FIELD OF THE INVENTION

[0004] The present disclosure relates to methods of detecting and treating inherited neuropathy.

BACKGROUND

[0005] Peripheral neuropathies are amongst the most frequent neurodegenerative diseases, with diabetic neuropathy and hereditary origins amongst the most common mechanisms of action. For the inherited neuropathies, also known as Charcot-Marie-Tooth disease (CMT), the remaining diagnostic gap of patients is ~50%. In our understanding, CMT represents an umbrella concept for clinically and genetically heterogeneous inherited monogenic highly phenotypically penetrant conditions affecting the peripheral nerves. CMT is classified depending on conduction velocity as demyelinating (CMT1) and axonal (CMT2) types. Distal hereditary motor neuropathy (dHMN) represents a form of CMT2 in which the burden of disease falls predominantly or exclusively on motor nerves (Rossor, Tomaselli, and Reilly 2016). A similar condition includes ALS4 (juvenile dHMN + brisk reflexes as sign of upper motoneuron involvement). As opposed

to CMT1, for which over 90% of cases have mutations in known genes, only 20 to 30% of CMT2 and distal HMN patients receive a genetic diagnosis (Fridman et al. 2015).

SUMMARY

[0006] The disclosure provides a method of treating and/or detecting inherited neuropathy. In various aspects, the method comprises detecting the presence of a mutation in the sorbitol dehydrogenase (*SORD*) gene in a sample from a subject. In various embodiments, the SORD mutation is a DNA variant classified as pathogenic or likely pathogenic according to American College of Medical Genetics and Genomics (ACMG) criteria. Optionally, the method comprises diagnosing the subject with inherited neuropathy when the presence of a mutation in the *SORD* gene is detected. Optionally, the method comprises administering to the subject a composition that comprises an agent selected from the group consisting of an aldose reductase inhibitor; an aldose reductase antisense oligonucleotide; a polynucleotide that encodes a SORD peptide; a SORD peptide; an agent that blocks expression of a mutant *SORD* gene; and an agent that corrects the mutation in *SORD* gene. In various aspects, the method comprises administering to the subject Alrestatin, Epalrestat, Diepalrestat, Fidarestat, Imirestat, Lidorestat, Minalrestat, Ponalrestat, Ranirestat, Salfredin B_{11}, Sorbinil, Tolrestat, Zenarestat, or Zopolrestat (or a combination thereof). In various aspects, the method comprises administering to the subject an aldose reductase antisense oligonucleotide; a polynucleotide that encodes a SORD peptide; an agent that blocks expression of a mutant *SORD* gene; an agent that corrects the mutation in SORD gene; or a combination of any of the foregoing. In various aspects, the method comprises administering to the subject a SORD peptide. Administration of a combination of any of the foregoing is also contemplated. Optionally, the method comprises measuring sorbitol levels in a sample from the subject.

[0007] Also provided is use of an (i) aldose reductase inhibitor (e.g., Alrestatin, Epalrestat, Diepalrestat, Fidarestat, Imirestat, Lidorestat, Minalrestat, Ponalrestat, Ranirestat, Salfredin B_{11}, Sorbinil, Tolrestat, Zenarestat, and/or Zopolrestat); (ii) an aldose reductase antisense oligonucleotide, a polynucleotide that encodes a SORD peptide, an agent that blocks expression of a mutant *SORD* gene, and/or an agent that corrects the mutation in a SORD gene; and/or (iii) a SORD peptide for the treatment of inherited neuropathy (or use in the preparation of a

medicament for treatment of inherited neuropathy) in a subject which has been tested for the presence of a mutation in the sorbitol dehydrogenase (SORD) gene.

[0008] The disclosure further provides a method of characterizing a neuropathy in a mammalian subject, the method comprising measuring the level of sorbitol in a subject suffering from a neuropathy, wherein a sorbitol level of greater than about 10 g/L indicates that the neuropathy is associated with a mutation in the sorbitol dehydrogenase (SORD) gene. The disclosure also provides a method of evaluating the efficacy of a treatment for an inherited neuropathy in a subject, the method comprising administering to the subject an agent selected from the group consisting of an aldose reductase inhibitor (e.g., Alrestatin, Epalrestat, Diepalrestat, Fidarestat, Imirestat, Lidorestat, Minalrestat, Ponalrestat, Ranirestat, Salfredin B_{11}, Sorbinil, Tolrestat, Zenarestat, and/or Zopolrestat), an aldose reductase antisense oligonucleotide, a polynucleotide that encodes a SORD peptide, a SORD peptide, an agent that blocks expression of a mutant *SORD* gene, and an agent that corrects the mutation in SORD gene (or a combination of any of the foregoing); and measuring the level of sorbitol in a subject.

[0009] It is understood that each feature or embodiment, or combination, described herein is a non-limiting, illustrative example of any of the aspects of the disclosure and, as such, is meant to be combinable with any other feature or embodiment, or combination, described herein. For example, where features are described with language such as "one embodiment," "some embodiments," "various embodiments," "related embodiments," each of these types of embodiments is a non-limiting example of a feature that is intended to be combined with any other feature, or combination of features, described herein without having to list every possible combination. Such features or combinations of features apply to any of the aspects of the invention.

[0010] The headings herein are for the convenience of the reader and not intended to be limiting. Additional aspects, embodiments, and variations of the invention will be apparent from the Detailed Description and/or drawings and/or claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figures 1A-F. SORD gene and pedigrees. Biallelic mutation in *SORD* cause autosomal recessive dHMN/CMT2. (Fig. 1A) Representative pedigrees of dHMN/CMT2 families carrying biallelic mutations in *SORD*. The squares indicate males and the circles females. The diagonal

lines are used for deceased individuals. Patients are indicated with filled shapes. (Fig. 1B) Schematic diagram showing all exons, introns and untranslated regions (UTRs) of SORD on the basis of NCBI Reference Sequence: NM_003104.6. The gray and white boxes represent the coding sequence and UTRs of *SORD*, respectively. Variants identified in the families considered in the present study map throughout the coding region of the gene. The nonsense c.757delG; p.(Ala253GlnfsTer27) variant on exon 7, was identified at particular high frequency. (Fig. 1C) Distribution of mutation across SORD protein domains. (Fig. 1D) SORD protein orthologs alignments showing that the four missense substitutions identified in dHMN/CMT2 families in this study are located at highly conserved residues across species from humans to elephants (Figs. 1E and 1F) Magnification the nucleotide sequence of a highly homologous region in exon 7 in SORD (reverse strand) and SORD2P (forward strand). Nucleotides differing in *SORD2P* from *SORD* are indicated with an arrow, including a Fig. 1C deletion in *SORD2P*. Representative electropherograms shows that in SORD the c.757delG; p.(Ala253GlnfsTer27) variant found in homozygous state in dHMN/CMT2 patients and heterozygous state in available patents (right box, upper plot) is absent in biallelic state from healthy controls (right box, lower plot), but it is fixated in *SORP2P* (left box, lower plot).

[0012] Figures 2A-C. Decreased SORD expression and sorbitol accumulation in patients fibroblasts. (Fig. 2A) Schematic representation of the two-step polyol pathway converting glucose to fructose. (Fig. 2B) Immunoblot showing protein level of SORD using the polyclonal antibody ab189248 and normalized to Tubulin in healthy control (n = 4, lane 1-4), heterozygous carriers of c.757delG; p.(Ala253GlnfsTer27) variant in *SORD* (n=2, lane 10-11) and patients carrying homozygous c.757delG; p.(Ala253GlnfsTer27) change (n=4, lane 5-8) or compound heterozygous c.757delG; p.(Ala253GlnfsTer27) variant together with a second nonsense c.895C>T; p.(Arg299Ter) mutation (n=1, lane 9). (Fig. 2C) Levels of intracellular sorbitol as measured by UPLC and normalised to protein content in healthy controls (n=5) and patients carrying biallelic nonsense mutations in *SORD* (n=5). The graphs show the mean ± s.d. and data distribution (dots). A two-tailed t-test was performed to compare *SORD* encoded protein (Fig. 2B) or sorbitol level (Fig. 2C) across groups. Statistical significance is indicated as *, ** or *** if P-value <0.05, <0.01 or <0.001, respectively. All experiments were repeated independently twice with similar results.

[0013] Figures 3A-F. Loss of *Drosophila* Sord2 causes age-dependent synaptic degeneration. (Fig. 3A) 3D structure of *Drosophila* visual system showing the lamina, medulla, and lobula. The xy- and xz-planes showing the photoreceptor terminals and lamina neurons are indicated. (Fig. 3B) Lamina of yw control fly at 2 DAE. The organized lamina cartridges and columnar photoreceptor neurons are shown in the xy-plane and xz-plane, respectively. (Fig. 3C) Laminae of $Sodh2^{MB01265/MB01265}$ homozygous flies at 2 DAE and 10 DAE. Arrowheads indicate the lamina vacuoles. Boxes indicate higher magnification areas of the lamina. The intensity of BRP is indicated. Dotted lines indicate the area of lamina vacuoles. Scale bar: 30 μm. (Fig. 3D) Quantification of the vacuole number, size, and BRP intensity. A total of 3 laminae of each group were quantified. Data are presented as mean ± s.d. Statistical analysis was performed using Two-Way ANOVA followed by post-hoc Tukey's multiple comparison test. *P<0.05, **P<0.01, ****P<0.0001. (Figs. 3E-3F) Locomotor activity of control flies (yw) and $Sodh2^{MB01265/MB01265}$ (Fig. 3E) or Sodh1 and Sodh2 pan-neuronal double knockdown (RNAi) (Fig. 3F) flies. n=10 in each group. Data are presented as mean ± s.d. Statistical analysis was performed using Two-Way ANOVA followed by post-hoc Tukey's multiple comparison test. ****P<0.0001

[0014] Figures 4A-G. Treatment with aldose reductase inhibitors Epalrestat and Ranirestat decrease sorbitol level and restore function. (Fig. 4A) Intracellular sorbitol level as measured by UPLC and normalised to protein content in fibroblasts from healthy controls (n=5, circle dots) and patients carrying biallelic nonsense mutations in *SORD* (n=5, square dots) after three days of treatment with Epalrestat 100 μM, Ranirestat 10 μM or DMSO. (Fig. 4B) Sorbitol level as measured by UPLC from brain/head homogenates and normalised to protein concentration from wild-type (yw, empty circle dots), $Sodh2^{MB01265/MB01265}$ (full circle dots) and neuron-specific knock-down of Sodh1 and Sodh1 by RNAi (square dots) *Drosophilae* at 10 days after eggs enclosure. Sodh2 Mimic and Sodh1 and Soh2 RNAi Drosophilae were fed with either 80 μM Epalrestat, 80 μM Ranirestat or DMSO. The graphs show the mean ± s.d. A two-tailed t-test was performed to compare sorbitol level. Statistical significance is indicated as *, ** or *** if P-value <0.05, <0.01 or <0.001, respectively, unless otherwise specified. All experiments were repeated independently twice with similar results. (Fig. 4C) Locomotor activity of control flies (yw) feeding with DMSO, $Sodh2^{MB01265/MB01265}$ flies feeding with DMSO, 80 μM Epalrestat, or 80 μM Ranirestat (n=10 in each group). Data are presented as mean ± s.d. Statistical analysis

was performed using Two-Way ANOVA followed by post-hoc Tukey's multiple comparison test. * P<0.05, *** P<0.001 (Figs. 4D-4F) Laminae of *Sodh2*$^{MB01265/MB01265}$ homozygous flies at 10 DAE and 40 DAE fed with DMSO (Fig. 4D), 80 μM Epalrestat (Fig. 4E), or 80 μM Ranirestat (Fig. 4F). Arrowheads indicate the lamina vacuoles. Boxes indicate higher magnification areas of the lamina. The intensity of BRP is indicated. Dotted lines indicate the area of lamina vacuoles. Scale bar: 30 μm. (Fig. 4G) Quantification of the vacuole number, size, and BRP intensity of (Figs. 4D-4F). n=3. Data are presented as mean ± s.d. Statistical analysis was performed using Two-Way ANOVA followed by post-hoc Tukey's multiple comparison test. *P<0.05, **P<0.01, ****P<0.0001.

[0015] Figure 5. Pedigrees of families carrying biallelic mutations in *SORD.* The squares indicate males and the circles females. The diagonal lines are used for deceased individuals. Patients are indicated with filled shapes.

[0016] Figures 6A-B. Double knockdown of *Drosophila* Sodh1 and Sodh2 lead to age-dependent synaptic degeneration. (Fig. 6A) Laminae of Sodh1 and Sodh2 double knockdown homozygous flies at 2 DAE and 10 DAE. Arrowheads indicate the lamina vacuoles. Boxes indicate higher magnification areas of the lamina. The intensity of BRP is indicated. Dotted lines indicate the area of lamina vacuoles. Scale bar: 30 μm. (Fig. 6B) Quantification of the vacuole number, size, and BRP intensity. A total of 3 laminae of each group were quantified. Data are presented as mean ± s.d. Statistical analysis was performed using Two-Way ANOVA followed by post-hoc Tukey's multiple comparison test. *P<0.05, **P<0.01, ****P<0.0001.

[0017] Figure 7. Treatment with aldose reductase inhibitors Epalrestat and Ranirestat restore locomotor function in Sodh1 and Sodh2 double knockdown flies. Locomotor activity of control flies (yw) feeding with DMSO (dots, first data point from the left for each DAE point indicated), or flies with neuronal specific knockdown of Sodh1 and Sodh2 feeding with DMSO (squares, second data point from the left for each DAE point indicated), 80 μM Epalrestat (squares, third data point from the left for each DAE point indicated), or 80 μM Ranirestat (squares, forth data point from the left for each DAE point indicated). n=10 in each group. Data are presented as mean ± s.d. Statistical analysis was performed using Two-Way ANOVA followed by post-hoc Tukey's multiple comparison test. ***P<0.001, ****P<0.0001.

[0018] Figure 8. An illustration of an exemplary expression vector encoding the SORD peptide (pAAV-SORD).

[0019] Figure 9. An exemplary complete AAV vector DNA sequence including the SORD coding sequence (pAAV-SORD) (SEQ ID NO: 1).

[0020] Figure 10. SORD primer sequences and thermocycling conditions. PCR: polymerase chain reaction; Fw: forward; Rv: reverse.

[0021] Figure 11. Clinical features of patients with hereditary neuropathy and carrying biallelic mutations in SORD.

[0022] Figure 12. Clinical features of patients affected by hereditary neuropathy and carrying the biallelic mutations in SORD. Categorical data are expressed as N (%) if data is available in all individuals or N/number individuals considered (%). Continuous variables are expressed as mean ± standard deviation (min-max). CMT, Charcot-Marie-Tooth, dHMN, distal hereditary motor neuropathy.

[0023] Figure 13. Fasting sorbitol level in serum from ten unrelated healthy controls and ten patients carrying biallelic p.Ala253GlnfsTer27 mutations in SORD. The graphs show the mean ± s.d. and data distribution (dots), and the p-value of two-tailed t-tests comparing SORD protein and sorbitol levels across groups - * $p<0.05$, ** $p<0.01$, and *** $p<0.001$. All experiments were twice repeated independently.

[0024] Figures 14A-14C. Exemplary vector design for SORD gene replacement therapy. (Fig. 14A) AAV-9 packaged vector design for a SORD gene replacement therapy. CB7 promotors have been shown to be effective in driving high expression, followed by the SORD cDNA (NCBI Reference Sequence: NM_003104.6), a Posttranscriptional Regulatory Element (WPRE) to further enhance expression and target specificity, and the transcription termination poly(A) element. Further origin of replication (pUC-ori) and ITR sequences (inverted terminal repeat). (Fig. 14B) SORD cDNA sequence. (Fig. 14C) SORD polypeptide sequence.

[0025] Figures 15A-15D. Significant knock-down of aldose reductase (AR) (*AKR1B1* gene) via an antisense oligonucleotide (ASO) (AR 1A, (SEQ ID NO: 22)). Targeting ASO (AR 1A) sequence and ASO-S scrambled sequence (AR-S 1A, (SEQ ID NO: 47)) are shown in Fig. 15A. Fig. 15B shows the modifications to the nucleotide backbone of the ASOs. This was carried out

in a SORD patient fibroblast and control fibroblasts and normalized to β-tubulin and measured via Western blot (Figs. 15C- 15D). A further control is a scrambled version of the ASO-S (AR-S 1A) exhibiting random nucleotides was used (Fig. 15C).

[0026] Figure 16. A table of antisense oligonucleotide sequences and target sites in Homo sapiens aldo-keto reductase family 1 member B (*AKR1B1*), exon targets only. Filter criteria: A) 40% <= GC % <= 60%; B) Antisense oligo binding energy <= -8 kcal/mol; C) No GGGG in the target sequence.

[0027] Figure 17. A table of antisense oligonucleotide (ASO) sequences an target sites in *Homo sapiens* aldo-keto reductase family 1 member B (AKR1B1), exon targets only. Filter criteria: A) 40% <= GC % <= 60%; B) No GGGG in the target sequence; C) Average unpaired probability for target site nucleotides >= 0.5; D) For each peak in the accessibility profile that is above the threshold probability of 0.5, all sites targeted to this same peak are ranked by their average unpaired probability (the higher the better) and at most n sites are selected for each peak, where n is determined by max([width of peak/site length], 2); E) Among sites satisfying criteria A-D, the top 20 unique ones with the highest average unpaired probability are listed.

[0028] Figure 18. A table of antisense oligonucleotide (ASO) sequences and target sites in *Homo sapiens* aldo-keto reductase family 1 member B (AKR1B1), hg19_dna range=chr7:134127102-134143944 (intronic targets only). Filter criteria: A) 40% <= GC % <= 60%; B) No GGGG in the target sequence; C) Average unpaired probability for target site nucleotides >= 0.5; D) For each peak in the accessibility profile that is above the threshold probability of 0.5, all sites targeted to this same peak are ranked by their average unpaired probability (the higher the better) and at most n sites are selected for each peak, where n is determined by max([width of peak/site length], 2); E) Among sites satisfying criteria A-D, the top 20 unique ones with the highest average unpaired probability are listed.

DETAILED DESCRIPTION

[0029] The disclosure provides a method of detecting and/or treating inherited neuropathy and related inherited conditions.

[0030] Inherited (or hereditary) neuropathies include, but are not limited to Charcot-Marie-Tooth disease (CMT), hereditary motor and sensory neuropathy, hereditary motor neuropathy, distal hereditary motor neuropathy (dHMN), axonal neuropathies, intermediate neuropathies, and amyotrophic lateral sclerosis type ALS4.

[0031] In various aspects, the disclosure provides a method wherein the presence of a mutation in the sorbitol dehydrogenase (*SORD*) gene is detected in a sample from a subject. The mutation may be detected by examining the DNA sequence of the gene, examining RNA, or examining proteins with mutations that result in some loss of function.

[0032] Disclosed herein is the identification of biallelic mutations in the Sorbitol dehydrogenase gene (*SORD)* associated with the most frequent recessive form of CMT. *SORD* encodes sorbitol dehydrogenase, an enzyme which converts sorbitol to fructose. It belongs to the two-step polyol pathway previously identified as pivotal to nerve damage in hyperglycemic condition of diabetes. Forty-two cases of CMT across different ethnicities were identified as carrying a nonsense mutation in *SORD*, c.757delG; p.Ala253GlnfsTer27, either in homozygous or compound heterozygous state. By screening the p.Ala253GlnfsTer27 change in additional cases and multiple control sets, this variant was established as one of the most common pathogenic alleles in men inherited according to Mendel's law (MAF = 0.003). Patient fibroblast cultures exhibit a complete loss of SORD protein as well as loss of intracellular sorbitol accumulation, which causes tissue damage. Loss of Sodh1 in *Drosophila* led to synaptic degeneration and progressive motor impairment. Notably, reduction of polyol influx by treatment with aldose reductase inhibitors fully rescued intracellular sorbitol levels in patient fibroblasts and a Sodh1 Drosophila model. In the latter model, the treatment also completely ameliorated motor and eye phenotypes. Together, these findings demonstrate a major role of the polyol pathway and sorbitol accumulation in hereditary neuropathies and establish the molecular cause for a potentially treatable condition in a significant fraction of cases. These findings also represent an example of converging pathomechanisms of hereditary and acquired neuropathies with a broader impact in the field of diabetes.

[0033] Thus, in various aspects of the disclosure, the method comprises detecting the *SORD* gene mutation 753delG; p.(Ala253GlnfsTer27), c.757delG; p.Ala253GlnfsTer27, c.28C>T; p.Leu10Phe, c.316_425+165del; p.Cys106Ter, c.329G>C; p.Arg110Pro, c.298C>T;

p.Arg100Ter, c.295C>T; p.Arg299Ter, c.964G>A; p.Val322Ile, c.458C>A; p.Ala153Asp; a deletion of individual or multiple coding exons or the entire SORD gene via a copy number variation; or any protein truncating mutation and/or mutation that leads to a "loss of function" or a hypomorphic function of the protein.

[0034] In various aspects, the *SORD* mutation is detected using DNA sequencing methods such as whole exome sequencing, whole genome sequencing (WGS) and/or next-generation sequencing (NGS), allele specific oligonucleotides, polymerase chain reaction (PCR), quantitative or real-time PCR (qPCR), multiplex PCR, nested PCR, Amplification Refractory Mutation System (ARMS) PCR, Multiplex ligation-dependent probe amplification (MLPA), Denaturing gradient gel electrophoresis (DGGE), Single-Strand Conformation Polymorphism (SSCP), Protein Truncation Test (PTT), RFLP, DNA microarray, RNA-seq, using CRISPR-based mutation detection (e.g., CRISPR-Chip, Hajian et al., *Nature Biomedical Engineering* 3, 427–437 (2019)) or other DNA or RNA mutation detection methods suitable for mutation detection.

[0035] In various aspects, the *SORD* mutation is detected by examining proteins using western blotting (immunoblot), High-performance liquid chromatography (HPLC), Liquid chromatography–mass spectrometry (LC/MS), antibody dependent methods such as enzyme-linked immunosorbent assay (ELISA), protein immunoprecipitation, protein immunostaining, protein chip methods or other protein detection methods suitable for mutation detection.

[0036] Optionally, the method further comprises measuring sorbitol levels in a sample of the subject. Methods of measuring sorbitol include, e.g., enzymatic assays, fluorimetric assays, chromatography-based methods, and spectroscopy-based methods. An exemplary method of sorbitol measurement is provided in the Examples.

[0037] The disclosure further provides a method of characterizing a neuropathy (e.g., inherited neuropathy) and related conditions involving a *SORD* mutation. In various aspects, the method comprises measuring sorbitol levels in a biological sample of a subject suffering from a neuropathy. In various aspects, the method comprises detecting increased levels of sorbitol in the biological sample. By "increased levels of sorbitol" is meant, e.g., sorbitol levels above about 10 mg/L. SORD-related neuropathy leads to high levels of sorbitol in patients, as described in the Examples and Figure 13. As such, detection of sorbitol levels above about 10

mg/L indicates that the neuropathy is an inherited neuropathy associated with a SORD mutation, thereby allowing a clinician to characterize the neuropathy afflicting the subject. Optionally, the method comprises a treatment step comprising administering to the subject an agent selected from the group consisting of an aldose reductase inhibitor; an aldose reductase antisense oligonucleotide; a polynucleotide that encodes a SORD peptide; a SORD peptide; an agent that blocks expression of a mutant *SORD* gene; and an agent that corrects the mutation in *SORD* gene.

[0038] In various aspects, the disclosure provides a method comprising identifying a mutation in the sorbitol dehydrogenase (*SORD*) gene in a sample from a subject before or after a step of measuring sorbitol levels in the subject. In this regard, the method may be used to confirm a diagnosis of inherited neuropathy. Similarly, the disclosure provides a method for identifying a SORD mutation that is pathogenic, the method comprising measuring sorbitol levels in a subject comprising a mutation in the *SORD* gene. The presence of increased sorbitol levels (e.g., greater than about 10 mg/L) indicates that the *SORD* mutation is pathogenic.

[0039] Alternatively (or in addition), the method may be used to evaluate the efficacy of a treatment for an inherited neuropathy in a subject. In this regard, the method comprises administering a therapy to the subject, then measuring sorbitol levels in a biological sample. A decrease in sorbitol levels compared to the level of sorbitol observed pre-treatment (e.g., a reduction of sorbitol levels below about 10 g/L) indicates an improvement in the subject's condition. The materials and methods described herein may also characterize patient compliance in taking medication for treatment of SORD-related inherited neuropathies or monitor the success of candidate therapeutics in clinical trials.

[0040] The sample may be any biological sample taken from the subject, including, but not limited to, any tissue, cell, or fluid (e.g., blood, plasma, serum, or urine) which can be analyzed for a trait of interest, such as the presence or amount of a nucleic acid (e.g., SORD mRNA), a protein (e.g., SORD protein), or sorbitol. In various embodiments, the biological sample is a plasma, serum, saliva, urine, or skin sample.

[0041] A "subject" as referred to herein, can be any mammal, such as humans. Animals of agricultural importance, such as bovine, equine, and porcine animals, are contemplated, as well as animals important as domestic pets, including canines and felines; animals important in

research, including rodents and primates; and large endangered species and zoo animals such as primates, felines, giraffes, elephants, rhinos.

[0042] In various aspects, the method comprises treating the subject by administering to the subject a composition that comprises one or more aldose reductase inhibitors. In some embodiments, the aldose reductase inhibitor is Alrestatin, Epalrestat, Diepalrestat, Fidarestat, Imirestat, Lidorestat, Minalrestat, Ponalrestat, Ranirestat, Salfredin B_{11}, Sorbinil, Tolrestat, Zenarestat, or Zopolrestat. Aldose reductase inhibitors are reviewed in *Expert Opin Ther Pat.* 2019;29(3):199-213; Chatzopoulou et al., *Expert Opin Ther Pat.* 2012;22(11):1303-23 (incorporated by reference in their entirety).

[0043] In some embodiments, enzyme replacement therapy is employed, and a SORD peptide is administered to the subject. As such, the therapy supplements SORD peptide levels where endogenous SORD levels are inadequate or absent. An exemplary SORD peptide is provided in SEQ ID NO: 46. The disclosure contemplates use of a peptide that comprises at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to SEQ ID NO: 46.

[0044] In various embodiments, the method comprises administering to the subject a polynucleotide (e.g., an aldose reductase antisense oligonucleotide, a polynucleotide that encodes the SORD peptide/protein, an agent that blocks expression of a mutant *SORD* gene, and/or an agent that corrects the mutation in *SORD* gene). Polynucleotides are typically delivered to a host cell via an expression vector, which includes the regulatory sequences necessary for delivery and expression, although use of expression vectors are not required in the context of the disclosure. In some aspects, the constructs described herein include a promoter (e.g., cytomegalovirus (CMV) promoter or CB7 promoter), a protein coding region (optionally with non-coding (e.g. 3'-UTR) regions that facilitate expression), transcription termination sequences, and/or regulator elements sequences (e.g., Posttranscriptional Regulatory Element (WPRE), poly(A) element, origin of replication (pUC-ori) and/or ITR sequences (inverted terminal repeat)). In various aspects, the constructs described herein include one or more of vector features listed in Table 1. Vector features are also reviewed in Powell et al., *Discov Med.* 2015; 19(102): 49–57 (incorporated by reference in its entirety). For example, the Cre-loxP system may be utilized to express a peptide of interest (e.g., a SORD peptides, optionally in a specific tissue of interest). Expression vectors may be viral-based (e.g., retrovirus-, adenovirus-, or adeno-associated virus-

based) or non-viral vectors (e.g., plasmids). Non-vector based methods (e.g., using naked DNA, DNA complexes, etc.) also may be employed. Optionally, the vector is a viral vector, such as a lentiviral vector or baculoviral vector, and in various preferred embodiments the vector is an adeno-associated viral vector (AAV). The expression vector may be based on any AAV serotype, including AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, or AAV-13. Polynucleotides also may be delivered via liposomes, nanoparticles, exosomes, microvesicles, hydrodynamic-based gene delivery, or via a "gene-gun."

Ubiquitous Promoters	**Neuronal specific promoter**	**Introns (enhanced expression)**	**Post-transcriptional regulatory elements**	**Polyadenylation signal enhancers**	**Bacterial resistance**
CMV, Cba, CAG, CBh, EF1-α, PGK, UBC	NFL, NFH, synapsin, CaMKII, Hb9, MeCP2	b-Glob, MVM, I.IX, adenovirus SD/ immunoglobulin SA, SV40 late SD/SA	HPRE, WPRE	hGH, bGHpA, SPA, SV40 late	Ampicillin Kanamycin

[0045] Table 1: Vector feature elements

[0046] Titers of AAV to be administered in methods of the disclosure will vary depending, for example, on the particular AAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods known in the art. Titers of AAV may range from about $1x10^6$, about $1x10^7$, about $1x10^8$, about $1x10^9$, about $1x10^{10}$, about $1x10^{11}$, about $1x10^{12}$, about $1x10^{13}$ to about $1x10^{14}$ or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg).

[0047] In various embodiments, a polynucleotide that encodes a SORD peptide is administered to the subject. The amino acid sequence of SORD is provided as SEQ ID NO: 46 (Figure 14C, NCBI Reference Sequence: NP_003095.2). The polynucleotide used in the method optionally encodes the amino acid sequence of SEQ ID NO: 46 or a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to the amino acid sequence of SEQ ID NO: 46 (which retains the function of SORD). Optionally, the polynucleotide comprises

SEQ ID NO: 45 (Figure 14B) or a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to the polynucleotide sequence of SEQ ID NO: 45 (and which encodes SORD). Exemplary expression vectors comprising a polynucleotide encoding the SORD peptide are illustrated in Figures 8 and 14A. The polynucleotide, in at least one aspect of the disclosure, comprises the nucleic acid sequence shown in Figure 9 (SEQ ID NO: 1), which corresponds to the sequence of an AAV vector comprising a polynucleotide encoding SORD.

[0048] In various embodiments, the method comprises administering to the subject an agent that blocks expression of a mutant *SORD* gene. An agent that blocks expression of a mutant *SORD* gene refers to an agent that interferes with expression of a *SORD* gene so that *SORD* gene expression and/or SORD protein levels are reduced compared to basal/ wild-type levels. It will be appreciated that "blocking" expression of a mutant *SORD* gene does not require 100% abolition of expression and SORD production; any level of reduced expression of aberrant SORD may be beneficial to a subject. Exemplary agents include, but are not limited to, antisense oligonucleotides (ASO), short hairpin RNA (shRNA), small interfering RNA (siRNA), or micro RNA (miRNA).

[0049] In various embodiments, the method comprises administering to the subject an aldose reductase antisense oligonucleotide which targets the aldose reductase sequence such that expression of the enzyme is blocked. An aldose reductase, aldo-keto reductase family 1 member B (AKR1B1), is encoded by SEQ ID NO: 48 (NCBI Reference Sequence: NM_001628). An aldose reductase antisense oligonucleotide interferes with expression of an aldose reductase gene (*AKR1B1*), so that *AKR1B1* gene expression and/or aldose reductase protein levels are reduced compared to basal/ wild-type levels. It will be appreciated that "blocking" expression of an aldose reductase gene (the *AKR1B1* gene) does not require 100% abolition of expression and aldose reductase production; any level of reduced expression of aldose reductase may be beneficial to a subject. For example, in various aspects, the aldose reductase antisense oligonucleotide that reduces the expression of aldose reductase. An ASO is a single-stranded deoxyribonucleotide, which is complementary to an mRNA target sequence. In various aspects, the aldose reductase antisense oligonucleotide targets an exonic or intronic sequence of the aldose reductase gene.

[0050] In an exemplary method for identifying ASO sequences targeting aldose reductase, the following criteria were used: A) sequences targeting aldose reductase (*AKR1B1)* were selected which contained <=40% GC or <=60% GC content; B) sequences containing GGGG nucleotides were excluded; C) sequences with an average unpaired probability for target site nucleotides >= 0.5 were selected; D) for each peak in the accessibility profile that was above the threshold probability of 0.5, all sites targeted to the same peak were ranked by their average unpaired probability (the higher the better) and at most n sites are selected for each peak, where n is determined by max width of peak/site length. Exemplary agents satisfying these criteria are provided in Table 2. Additional exemplary ASO sequences and filter criteria are shown in Figures 16-18.

Starting target position	Ending target position	Target Seq (5'-3')	SEQ ID NO	antisense oligo (5'-3')	SEQ ID NO	GC content	Average unpaired probability	Binding site disruption
475	494	AGGUGGAGAUGAUCUUAAAC	21	GTTTAAGATCATCTCCACCT	22	40.00%	0.594	12.5
476	495	GGUGGAGAUGAUCUUAAACA	23	TGTTTAAGATCATCTCCACC	24	40.00%	0.592	12.6
484	503	UGAUCUUAAACAAACCUGGC	25	GCCAGGTTTGTTTAAGATCA	26	40.00%	0.66	12.5
490	509	UAAACAAACCUGGCUUGAAG	27	CTTCAAGCCAGGTTTGTTTA	28	40.00%	0.633	9.2
534	555	CAGGUGGAGAUGAUCUUAAACA	29	TGTTTAAGATCATCTCCACCTG	30	40.90%	0.584	12.6
545	566	GAUCUUAAACAAACCUGGCUUG	31	CAAGCCAGGTTTGTTTAAGATC	32	40.90%	0.611	10.3
548	569	CUUAAACAAACCUGGCUUGAAG	33	CTTCAAGCCAGGTTTGTTTAAG	34	40.90%	0.646	9.5
567	588	AAGUAUAAGCCUGCAGUUAACC	35	GGTTAACTGCAGGCTTATACTT	36	40.90%	0.584	7.7
739	760	UCAAGGCGAUCGCAGCCAAGCA	37	TGCTTGGCTGCGATCGCCTTGA	38	59.10%	0.669	10
741	762	AAGGCGAUCGCAGCCAAGCACA	39	TGTGCTTGGCTGCGATCGCCTT	40	59.10%	0.694	9.3
1025	1046	ACCUGUGUUUCUUGCCUCAUUU	41	AAATGAGGCAAGAAACACAGGT	42	40.90%	0.641	5.5

[0051] Table 2: ASO sequences targeting *AKR1B1/* aldose reductase.

[0052] In various embodiments, the nucleotide backbone of ASO sequences are modified to a chimeric or gapmer design to reduce gene expression when compared to basal/wild-type levels. In various embodiments, a gapmer design requires a designation of 3-5 nucleotides on each end of the antisense oligonucleotide sequence to harbor modifications in the ribose sugar moiety resistant to RNase H recognition and other nucleases, while all other nucleotides contain an RNase H compatible modification. RNase H is responsible for cleaving RNA-DNA duplexes such as those formed between aberrant mRNA transcripts and synthetically designed DNA antisense oligonucleotides. In various embodiments, the modification to the ASO sequences includes, but is not limited to Phosphorothioate (PS) – RNase H recognizable, phosphorodiamidate morpholino (PMO) – RNase H resistant, 2'-O-methyl – RNase H resistant, 2'-O-methoxyethyl (MOE) – RNase H resistant, locked Nucleic Acid (LNA) – RNase H resistant, ethylene-bridged nucleic acid (ENA) – RNase H resistant, or (S)-constrained ethyl (cEt) – RNase H resistant. Exemplary modification of an ASO sequence is shown in Figures

15A-15B. Modifications to ASO sequences are reviewed in Scoles et al., *Neurol Genet. 2019;5(2):e323.* (incorporated by reference in its entirety).

[0053] In various aspects, the method employs RNA interference (RNAi) to regulate expression of SORD. The RNAi pathway is summarized in Duan (Ed.), Section 7.3 of Chapter 7 in Muscle Gene Therapy, Springer Science+Business Media, LLC (2010). Suitable agents include, e.g., siRNA, miRNA, and shRNA. A shRNA/Hairpin Vector is an artificial RNA molecule (nucleotide) with a tight hairpin turn that can be used to silence target gene expression via RNAi. shRNA is an advantageous mediator of RNAi in that it has a relatively low rate of degradation and turnover, but it often requires use of an expression vector. In exemplary aspects, the disclosure includes the production and administration of an AAV vector expressing one or more shRNAs targeting SORD. The expression of shRNAs is regulated by the use of various promoters. In various aspects, polymerase II promoters, such as U6 and H1, and polymerase III promoters are used. In some aspects, U6 shRNAs are used. It will be appreciated that RNAi also may be used to downregulate (i.e., block) expression of aldose reductase (e.g., *AKR1B1*); as such, the disclosure contemplates sue of siRNA, miRNA, and shRNA which targets aldose reductase intronic or extronic sequences to block the expression of aldose reductase.

[0054] Traditional small/short hairpin RNA (shRNA) sequences are usually transcribed inside the cell nucleus from a vector containing a Pol III promoter such as U6. The endogenous U6 promoter normally controls expression of the U6 RNA, a small RNA involved in splicing, and has been well-characterized (Kunkel et al., Nature. 322(6074):73-7 (1986); Kunkel et al., Genes Dev. 2(2):196-204 (1988); Paule et al., Nucleic Acids Res. 28(6):1283-98 (2000)). The disclosure includes both murine and human U6 or H1 promoters. The shRNA containing the sense and antisense sequences from a target gene connected by a loop is transported from the nucleus into the cytoplasm where Dicer processes it into siRNAs.

[0055] In some aspects of the disclosure, an agent that corrects the mutation in the *SORD* gene is employed. An agent that corrects the mutation in *SORD* gene refers to an agent capable of modifying the *SORD* coding sequence or a regulatory element and/or non-coding region associated with the *SORD* gene to achieve a desired change in the sequence. In various aspects, genome editing may be used to replace part or all of the *SORD* gene sequence or alter SORD protein expression levels. In various embodiments, the agent may comprise components

employed in genome-editing techniques, such as designer zinc fingers, transcription activator-like effectors nucleases (TALENs), or CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR associated) systems. An exemplary agent for use in the method of the disclosure is, DNA encoding Cas9 molecules and/or gRNA molecules. Cas9 and gRNA can be present in a single expression vector or separate expression vectors. Adenoviral delivery of the CRISPR/Cas9 system is described in Holkers *et al., Nature Methods* (2014), 11(10):1051-1057 which is incorporated by reference in its entirety.

[0056] Other publications describing the CRISPR systems and Cas9 include the following: Cong *et al. Science* (2013) 339:819-23; Jinek *et al., Elife.* (2013) 2:e00471; Lei *et al. Cell* (2013) 152: 1173–1183; Gilbert *et al. Cell* (2013) 154:442-51; Lei *et al. Elife* (2014) 3:e04766; Perez-Pinela *et al. Nat Methods* (2013) 10: 973–976; Maider *et al. Nature Methods* (2013) 10, 977–979; U.S. Patent No. 8,697,359; U.S. Patent No. 8,771,945; U.S. Patent No. 8,795,965; U.S. Patent No. 8,865,406; U.S. Patent No. 8,871,445; U.S. Patent No. 8,889,356; U.S. Patent No. 8,895,308; U.S. Patent No. 8,906,616; U.S. Patent No. 8,932,814; U.S. Patent No. 8,945,839; U.S. Patent No. 8,993,233; U.S. Patent No. 8,999,641; U.S. Application Publication No. 2014/0068797; and International Patent Publication No. WO 2014/197568, all incorporated by reference in their entirety.

[0057] In some embodiments, CRISPR/Cas9 multiplexing may be used to target multiple genomic loci wherein two or more guide RNAs are expressed as described in CRISPR 101:A Desktop Resource (1st Edition), *Addgene,* January 2016 which is incorporated by reference in its entirety.

[0058] The terms "treating" or "treatment" refer to reducing or ameliorating inherited neuropathy and/or associated disorders and/or symptoms associated therewith. These terms include reducing or delaying the frequency of occurrence or recurrence of the neuropathy or symptoms associated therewith (i.e., lengthening the period of remission in a patient who had suffered from the disorder), as well as reducing the severity of the disorder or any symptoms associated therewith. It is appreciated that, although not precluded, "treating" or "treatment" of a disorder or condition does not require that the disorder, condition, or symptoms associated therewith be completely eliminated.

[0059] A dose of an active agent (e.g., an aldose reductase inhibitor, an aldose reductase antisense oligonucleotide, a polynucleotide that encodes a SORD peptide, a SORD peptide, an agent that blocks expression of a mutant *SORD* gene, or an agent that corrects the mutation in SORD gene) will depend on factors such as route of administration (e.g., local vs. systemic), patient characteristics (e.g., gender, weight, health, side effects), the nature and extent of the inherited neuropathy or associated disorder, and the particular active agent or combination of active agents selected for administration.

[0060] The active agents described herein are provided in a composition (e.g., a pharmaceutically-acceptable composition) which may contain formulation components suitable for administration to a subject, as well as additional therapeutic agents. Suitable methods of administering a physiologically-acceptable composition, such as a pharmaceutical composition comprising an agent described herein, are well known in the art. In various aspects, more than one route can be used to administer one or more of the agents disclosed herein. A particular route can provide a more immediate and more effective reaction than another route. For example, in certain circumstances, it will be desirable to deliver the composition orally; through injection or infusion by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, urethral, vaginal, or rectal means; by controlled, delayed, sustained or otherwise modified release systems; by implantation devices; using nanoparticles; or as a conjugate.

[0061] It is contemplated the two or more active agents described herein may be administered as part of a therapeutic regimen. Alternatively or in addition, one or more of the active agents may be administered with other therapeutics as part of a therapeutic regimen. The active agent(s) may be administered as a monotherapy or as a combination therapy with other treatments administered simultaneously or metronomically. The term "simultaneous" or "simultaneously" refers to administration of two agents within six hours or less (e.g., within three hours or within one hour each other). In this regard, multiple active (or therapeutic) agents may be administered the same composition or in separate compositions provided within a short period of time (e.g., within 30 minutes). The term "metronomically" means the administration of different agents at different times and at a frequency relative to repeat administration. Active

agents need not be administered at the same time or by the same route; preferably, in various embodiments, there is an overlap in the time period during which different active agents are exerting their therapeutic effect. Additional aspects and details of the disclosure will be apparent from the following examples, which are intended to be illustrative rather than limiting.

EXAMPLES

General Methods

Families

[0062] All families provided written informed consent to participate in the study. The study protocol was approved by the institutional review board of giving institutions. All patients were clinically evaluated by neurologists.

Whole Exome and Sanger sequencing

[0063] Whole exome sequencing was performed in index individuals from sporadic and recessive CMT and dHMN families. The SureSelect Human All Exon 50 MB Kit (Agilent) was used for in-solution enrichment, and the HiSeq 2500 instrument (Illumina) was used to produce about 120 bp paired-end sequence reads. The Burrows-Wheeler aligner, and Freebayers were used to align sequence reads and call variants. Final data were uploaded into GENESIS software for analysis. A filtering approach to search for families sharing the same homozygous variants were applied across all exomes in the database. Sanger sequencing, performed by Eurofins Genomics, confirmed segregation of the SORD variants. Polymerase chain reaction (PCR) was carried out in the Veriti Thermocycler (Applied Biosystem) and Platinum Taq (ThermoFisher) was used to amplify the regions containing the target mutations. The following primers were used to target specifically SORD and not SOR2P (Figure 10).

Fibroblasts Culture

[0064] Fibroblasts were obtained from patients and cultured in Dulbecco's Modified Eagle Medium (ThermoFisher) supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin (Gibco). Cells were maintained in 5% CO_2 at 37°C in a humidified incubator. Asynchronous cell cultures were grown to approximately 80% confluency and treated with epalrestat (100μM), ranirestat (10μM) or DMSO for 72 hours. Media containing the drugs or DMSO were changed every 24 hours.

Western Blot

[0065] Fibroblasts were lysed in RIPA buffer (ThermoFisher) containing protease inhibitor (Roche) and sonicated for 5 minutes with the Bioruptor sonication device (Diagenode). Cell lysates were centrifuged at 13,000 x g for 10 minutes at 4 °C, and the supernatant was collected for protein quantification (Pierce BCA Protein Assay Kit). 30 µg of protein sample was mixed with Bolt LDS Sample Buffer and Sample Reducing Agent (ThermoFisher) and heated at 90 °C for 5 min. Samples were loaded on Bolt 4–12% Bis-Tris Plus mini-gel followed by transfer into a nitrocellulose membrane (Bio-Rad). Membrane was blocked with 5% non-fat milk and incubated with anti-SORD (ab189248, Abcam) antibody for 2 hours, washed with TBS containing 0.01% Tween 20 (Bio-Rad) and incubated with a secondary anti-rabbit antibody (Cell Signaling). Membrane was subsequently incubated with GAPDH primary antibody (Santa Cruz) and secondary anti-mouse antibody (Cell Signaling). Chemoluminescence detection was performed with the SuperSignal West Pico PLUS Chemiluminescent Substrate and imaged with the FluorChem E (ProteinSimple).

Sorbitol Measurement

[0066] Fibroblasts were collected and lysed as described in Western blot section in the absence of proteinase inhibitor. Sorbitol determination in human fibroblast lysates was performed in ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) (Waters Acquity UPLC & TQD mass spectrometer - Waters, Milford, MA, USA). Fibroblasts were collected and lysed as described in Western blot section in the absence of proteinase inhibitor. Proteinase inhibitor contains high concentration mannitol, which is a sorbitol enantiomer, and can interfere with UPLC-MS/MS sorbitol determination. Lysate samples underwent protein precipitation with Acetonitrile (1:5), ten-time dilution with Acetonitrile-water (50/50) and clean up on Oasis HLB cartridges (10mg/1ml), before injection in UPLC (3µL). UPLC conditions: column, BEH Amide 1.7 µm (2.1 x 100mm) at 88°C, eluent A, Acetonitrile 90%-water 5%-Isopropanol 5%, eluent B, Acetonitrile 80%-water 20%, gradient elution 0 min., 100% A, 3.6min. 100% B, flow rate, 0.45 ml/min. The retention time of sorbitol was 2.7 min. MS/MS conditions: interface, Electrospray interface in negative ion mode, Multiple Reaction Monitoring acquisition, m/z 180.9 → 88.9 (CV 24, CE 15).

[0067] For fasting sorbitol level testing, blood was collected after overnight fasting (last meal the evening before) in serum separator tubes. Samples were centrifuged at 500 g for 10 min. Serum was separated and frozen within an hour from blood collection. Sorbitol level was tested by UPLC using a method adapted from Li et al. Biochem Biophys Res Commun. 2009 Oct 2;387(4):778–83. Conditions were as follows: column, BEH Amide 1.7 μm maintained at 25°C (instead of 45°C); eluent A, 10mM ammonium acetate pH10; eluent B, Acetonitrile. Flow rate, 0.6 ml/min with the 20 same gradient. The retention time of Sorbitol was 6.0 min. MS/MS conditions were the same of fibroblast analysis. Serum samples underwent protein precipitation with cold Methanol (1:5), five time dilution with Acetonitrile-water (50/50) and clean up on Oasis HLB cartridges (10mg/1ml), before injection in UPLC (3μL). Calibration curve was done in serum in sorbitol concentration range 0.1-20 mg/L.

Drosophila stocks and genetics

[0068] Unless specified, all flies were kept on cornmeal-molasses-yeast medium at 25 °C, 65% humidity, with 12 h light/12 h dark cycles. The following fly strains used in this study were obtained from Bloomington *Drosophila* Stock Center: *elav*^{C155}*-GAL4*, *GMR-GAL4*, *Sdh2*^{MB01265}, *UAS-Sdh1RNAi*, and *UAS-Sdh2RNAi*.

Drug feeding

[0069] Epalrestat or ranirestat was dissolved in dimethyl sulfoxide (DMSO) to achieve a stock concentration of 10 mg/ml, and then mixed into 10 ml fly food at a final concentration of 80 μg/ml. Equal amount of DMSO was mixed into the fly food as control. The vials were dried at room temperature for 12 h before feeding.

Drosophila lifespan assay and negative geotaxis assay

[0070] For lifespan assay, 100 newly enclosed female flies of each group were collected and placed in vials of 20 individuals. Flies were transferred into new vials every 2 days and the number of dead flies was counted. Survival data was plotted using Kaplan-Meier plot and compared between groups using log-rank test. For negative geotaxis behavior assay, 10 age-matched female flies were placed in a vial marked with a black line drawn horizontally 8 cm above the bottom. Flies were given 60 min to fully recover from CO_2 anesthesia, and were gently tapped onto the bottom and given 10 s to climb. Flies that crossed the 8 cm line were

counted. For each vial, this assay was repeated 10 times, and 10 independent vials of each group (a total 100 flies per group) were tested. To minimize observer-expectancy bias, this assay was performed with the examiner masked to the group assignment.

Drosophila brain dissection, immunostaining, and confocal microscopy

[0071] Brain dissection and staining were carried out as previously described (Brazill et al., J Vis Exp. 2018;(138)). Briefly, fly brains were dissected in phosphate-buffered saline (PBS, pH 7.4), fixed in 4% formaldehyde for 10 min, and washed in PBTX (PBS containing 0.4% v/v Triton X-100) for 3 times (15 mins each). Brains were then incubated with primary mouse anti-BRP antibody (nc82, Developmental Studies Hybridoma Bank) at 1:250 dilution in 0.4% PBTX with 5% normal goat serum at 4 °C overnight with gentle shaking. After that, brains were incubated with Cy3-conjugated anti-mouse secondary antibody (Rockland) and Cy5-conjugated anti-HRP (Jackson ImmunoLab) at 1:250 dilution at 4 °C overnight with gentle shaking, followed by 4',6-diamidino-2-phenylindole (DAPI, 1:300, Invitrogen) staining at room temperature for 10 min. Samples were mounted on glass slides with VECTASHIELD Antifade Mounting Medium (Vector Laboratories Inc.). Fly brain slides were imaged using an Olympus IX81 confocal microscope with 60× oil immersion objective lens with a scan speed of 8.0 μs per pixel and spatial resolution of 1024 × 1024 pixels. Images were processed and analyzed using FluoView 10-ASW (Olympus).

[0072] Additional aspects and details of the disclosure will be apparent from the following examples, which are intended to be illustrative rather than limiting.

Example 1: Identification of DNA variants in CMT using GENESIS analysis

[0073] Inherited neuropathies, including Charcot-Marie-Tooth disease (CMT), represent an umbrella concept for clinically and genetically heterogeneous conditions affecting the peripheral nerves. CMT is classified depending on conduction velocity as demyelinating (CMT1) and axonal (CMT2) types. Distal hereditary motor neuropathy (dHMN) represents a form of CMT2 in which the burden of disease falls predominantly or exclusively on motor nerves (Rossor, Tomaselli, and Reilly 2016). As opposed to CMT1, for which over 90% of cases have mutations in known genes, only 20 to 30% of CMT2 and distal HMN patients receive a genetic diagnosis (Fridman et al. 2015). Since up to 70% of CMT2 and dHMN cases are sporadic, it becomes more challenging to identify candidate pathogenic genes from single case whole exome and

genomic sequences; therefore, large collective datasets are necessary. Using the data aggregation of over 1,100 CMT whole exome sequencing (WES) and whole genome sequencing (WGS) available at the GENESIS analysis platform provided the largest collection of such high quality data available (Gonzalez et al. 2015). Genes with significant DNA variants present in multiple families were identified, as well as individual alleles overrepresented in CMT cases. When querying a subset of 598 undiagnosed CMT patients for recessive non-sense variants in genes shared by > 3 families and with minor allele frequency in the gnomAD control database of <1%, 12 cases were identified from 11 unrelated families carrying a homozygous c.757delG; p.(Ala253GlnfsTer27) mutation in *SORD*. Four more cases from three unrelated families carried the heterozygous c.757delG; p.(Ala253GlnfsTer27) variant together with a second variant, c.298C>T; p.(Arg100Ter) in family 2 c.329G>C; p.(Arg110Pro) in family 3, and c.458C>A; p.(Ala153Asp) in II-1 and II-2 of family 14 (Figure 1A-D and Figure 5). All mutations represented loss-of-function (LOF) alleles except c.329G>C; p.(Arg110Pro). Interestingly, the Arg110Pro change is adjacent to the previously reported Tyr111Phe (corresponding to Tyr110Phe in rat), which was shown to abolish SORD enzymatic activity and destabilize the protein (Hellgren et al. 2007).

[0074] Interestingly, SORD has a non-functional highly homologous paralogue, the pseudogene SORD2P, which is thought to arise from the duplication of SORD within a 0.5 Mb region on chromosome 15 (Carr et al. 2016) (Figure 1E). In order to specifically amplify SORD, but not SORD2P, in Sanger confirmation studies, primers were designed that took advantage of nucleotide sequence differences and distinct retrotransposon insertions in both genic regions (Figure 5). Notably, the c.757delG; p.(Ala253GlnfsTer27) mutation in exon 7 of SORD is fixated in the pseudogene SORP2P in over 95% of control chromosomes, along with numerous additional exonic indel mutations, which prevent effective translation of SOPR2P (1000 Genomes Project Consortium et al. 2015; Lek et al. 2016). Because of the high similarity of the regions, a nested PCR approach was necessary to obtain specific amplification of exon 7 of SORD and distinguish it from the homologous region in SORD2P. The presence of the variants detected by WES was confirmed by Sanger sequencing in all cases and segregation data in immediate relative carriers was provided. (Figure 1F and Figure 5).

[0075] An independent set of 103 unresolved CMT2/dHMN cases WES at the (UCL Institute of Neurology in London (UK)) were screened. Nine cases from six unrelated families were

identified carrying the homozygous c.757delG; p.(Ala253GlnfsTer27) mutation in SORD (8.7%). A third independent set of 297 recessive or sporadic CMT2/dHMN patients was screened by targeted Sanger sequencing of exon 7 of SORD, which was extended to the other coding exons if one c.757delG; p.(Ala253GlnfsTer27) was identified, and revealed 20 additional cases (7%) from 18 families with biallelic mutations in SORD: 16 cases with a homozygous c.757delG; p.(Ala253GlnfsTer27) mutation and four cases with c.757delG; p.(Ala253GlnfsTer27) in compound heterozygous state with a second likely pathogenic variant. The latter included c.964G>A; p.(Val322Ile) in family 29, a 275bp deletion c.316_425+165del in exon 4 in family 30, a de novo c.28C>T; p.(Leu10Phe) in family 32, and c.895C>T; p.(Arg299Ter) in family 33. All changes have a minor allele frequency (MAF) of < 0.0001 in gnomAD (Lek et al. 2016). The residues affected by missense mutations are highly conserved across multiple species (Figure 1D) with GERP scores greater than 3. Further, biallelic non-sense variants in SORD were absent from 4,598 index cases affected by distinct neurological disorders other than CMT present in the GENESIS database.

[0076] The allelic carrier frequency of the c.757delG; p.(Ala253GlnfsTer27) variant in the normal population is 0.003% based on an allelic count of 94 out of 30,872 in gnomAD genomes (Lek et al. 2016). Of note, the gnomAD exome set detected the c.757delG; p.(Ala253GlnfsTer27) change at a significantly lower rate at MAF =0.00008, due to failure to pass random forest filters. GENESIS uses the FreeBayes software for variant calling (Gonzalez et al. 2015), which may have resulted in an allele frequency closer to the gnomAD genome based call set ($MAF_{GENESIS}$ = 0.002, 22 out of 9,196). Sanger sequencing of 600 healthy controls was performed, including 200 samples of European, 100 samples of Turkish and 200 samples of Middle Eastern origin, and identified three heterozygous, but no homozygous, c.757delG; p.(Ala253GlnfsTer27) alleles (MAF = 0.0025). These calculations support an estimated prevalence of the homozygous c.757delG; p.(Ala253GlnfsTer27) allele alone of ~1/100,000 individuals, making it the most common individual pathogenic allele in axonal neuropathies and one of the most common alleles for any Mendelian disease.

[0077] Overall 45 individuals affected by hereditary neuropathy from 38 unrelated families were identified in the present study to carry biallelic mutations in SORD (Figure 11 and 12). Of note, 71% of cases were sporadic with no evidence of family history or consanguinity. The formal clinical diagnosis was axonal CMT in 51% (n=16), distal HMN in 40% (n=18), and

intermediate CMT in 9% (n=4) of cases The mean age of onset of the neuropathy was 17 ± 8 years and walking difficulties was the most common complain at onset. Delayed motoric development milestones were uncommon, but two thirds of the patients reported foot deformities, indicating that the neuropathy probably started earlier in life. At first examination all individuals had limb weakness, but only half showed sensory impairment. Weakness was mild in distal upper limbs and ranged from mild to near complete paralysis in the distal lower limbs. Proximal muscles of the upper and lower limbs were typically unaffected. Seven patients had upper limb tremor, four had mild scoliosis and two had mild hearing loss. One case had a concurrent and likely unrelated syndromic disorder encompassing dysmorphic features, non-progressive mental retardation since the age of three years, and spastic ataxia with evidence of cerebellar atrophy at brain MRI. None of the patients had cataract nor involvement of other organs. According to the CMT neuropathy score, the neuropathy was mild in 67% (n=30), moderate in 31% (n=14) and severe in one case. 42% of patients (n=19) needed ankle-foot orthosis to sustain feet during walking, one patient required unilateral support and one patient was wheelchair dependent. Detailed nerve conduction studies were available in 42 patients and invariably showed a motor axonal neuropathy, with intermediate reduction of conduction velocities in 26% (n=11) and decreased sensory action potentials in 26% (n=65).

Example 2: Assessing SORD protein expression in human fibroblasts and SORD levels in blood

[0078] Sorbitol dehydrogenase is a homotetrameric enzyme of 38-kDa subunits, which is widely distributed in mammalian tissues (Johansson et al. 2001; Hellgren et al. 2007; Lindstad, Teigen, and Skjeldal 2013). It represents the second enzyme of the two-step polyol pathway, in which glucose is converted to sorbitol, a relatively non-metabolizable sugar, by the enzyme aldose reductase (AR). Sorbitol is then oxidized to fructose by SORD (Figure 2A). To gather further insights into the functional consequences of recessive mutations in *SORD*, next *SORD* expression was assessed in fibroblasts from five unrelated affected individuals with homozygous c.757delG; p.(Ala253GlnfsTer27) (n=4) or c.757delG; p.(Ala253GlnfsTer27) & c.895C>T; p.(Arg299Ter) (n=1) variants as well as two unaffected carriers of c.757delG; p.(Ala253GlnfsTer27) in heterozygous state. SORD protein was absent in all patients and the wild-type levels were reduced in unaffected carriers compared to controls (Figure 2B). Accordingly, intracellular sorbitol concentrations were over 10 times higher in patients' fibroblasts compared to controls, in keeping with a loss of SORD enzymatic activity (Figure 2C).

Fasting sorbitol levels in serum from ten patients carrying the homozygous p.Ala253GlnfsTer27 mutation and ten unrelated controls and found it was over 100 times higher (14.82 ± 0.780 vs 0.046 ± 0.004 mg/L, $p<0.0001$) was determined, confirming the lack of SORD enzymatic activity in patients (Figure 13). This study also demonstrates that sorbitol is a useful marker for detecting or characterizing inherited neuropathy associated with *SORD* mutation in a mammalian subject.

Example 3: Investigating the SORD mutation in models of SORD deficiency

[0079] To further explore the pathophysiology of SORD mutation *in vivo*, *Drosophila melanogaster* models of SORD deficiency were established. *Drosophila* has two functional SORD genes (Sodh1 and Sodh2) that share 90% residue identity (Luque et al. 1998). SORD is conserved across distant phyla and Drosophila Sodh1 (NP_001287203.1) and Sodh2 (NCBI Reference Sequence: NP_524311.1) encoded proteins share 75% and 73% identity with human SORD protein (NCBI Reference Sequence: NP_003095.2 (SEQ ID NO: 46)), respectively. A mutant allele of Sodh2 was obtained where the gene is disrupted by a transposon Minos mediated integration cassette (MiMIC) insertion ($Sodh2^{MB01265}$) (Bellen et al. 2011). Homozygous Sodh2 ($Sodh2^{MB01265/MB01265}$) mutants are viable with normal life span. To characterize neurodegenerative phenotypes, the *Drosophila* visual system was used to take advantage of the highly organized parallel axons of the compound eye that allow *in vivo* detection of subtle neuronal and synaptic pathological changes (Bausenwein, Dittrich, and Fischbach 1992). Axons of the outer photoreceptor axons traverse the lamina cortex and make synaptic connections with lamina monopolar neurons in the lamina layer (Figure 3A). In the control flies (yw) at 2 days after eclosion (DAE), the organized lamina cartridges of photoreceptor synapses can be visualized in the xy- and xz-planes, respectively (Figure 3B). A loss of photoreceptor terminals in the lamina layer of $Sodh2^{MB01265/MB01265}$ mutants was observed at 2 days after eclosion (DAE) (Figure 3C). The phenotype became progressively severe at 10 DAE, with vacuoles being more numerous and larger in size distributed across the synaptic lamina layer (Figure 3C, D). These vacuoles exhibited a loss of neuronal membrane (marked by HRP labelling), as well as a reduced Bruchpilot (BRP, a synaptic active zone cytomatrix protein) labelling, indicating synaptic degeneration (Figure 3C, D). To validate the findings described herein, a second *SORD* model was generated by specific knockdown of both *Sodh1 and Sodh2* expression in neurons using a pan-neuronal driver $elav^{C155}$. Loss of both Sodh1 and Sodh2

resulted in age-dependent synapse degeneration, similar to that of homozygous Sodh2 (*Sodh2*$^{MB01265/MB01265}$) (Figure 6). The behavioral phenotypes of *SORD* deficiency the *Sodh2*$^{MB01265/MB01265}$ homozygous flies with a systemic loss of function in Sodh2 were characterized and although these flies exhibited a normal life-span, their locomotor activity was significantly compromised at a late-stage (40 DAE) (Figure 3E, F). This indicated a progressive, age-dependent neuromuscular dysfunction reminiscent of hereditary neuropathies. Moreover, the sorbitol levels were measured in fly heads at 10 DAE and observed a significant increase in the *Sodh2*$^{MB01265/MB01265}$ model (Figure 4B), consistent with the observation in patient fibroblasts. Taken together, *Drosophila* models of SORD deficiency were successfully established that recapitulate typical pathological phenotypes in human patients, including (1) a normal lifespan, (2) progressive and age-dependent synaptic degeneration and locomotor deficiency, and (3) increased sorbitol levels.

[0080] After establishing loss-of-function as the mechanism of action and a known enzymatic pathway, treatment options for SORD associated hereditary neuropathy were investigated. It had previously been shown that the pharmacological inhibition of aldose reductase, the enzyme upstream of SORD, represents a successful strategy to reduce toxic sorbitol accumulation in cellular and animal model of diabetes (Kikkawa et al. 1983; Matsumoto et al. 2008; Ramirez and Borja 2008; Hao et al. 2015; Grewal et al. 2016) and, arguably, also humans (Chalk, Benstead, and Moore 2007; Polydefkis et al. 2015; Sekiguchi et al. 2019). The effect of two commercially available aldose reductase inhibitors (ARI), Epalrestat and Ranirestat, were tested on intracellular sorbitol accumulation in patient fibroblasts lacking functional SORD. Patient and control fibroblasts were grown for 72 hrs in the presence or absence of Epalrestat (100 μM) or Ranirestat (10 μM) and intracellular sorbitol levels were measured thereafter. Both ARI, Epalrestat and Ranirestat, achieved a significant reduction of sorbitol to a level comparable to controls (Figure 4A). Further, *Drosophila* models of SORD were fed with Epalrestat and Ranirestat starting at 2 DAE. A significant reduction of sorbitol level was observed in the *Sodh2*$^{MB01265/MB01265}$ fly heads at 10 DAE (Figure 4B). Importantly, the locomotor activities of *Sodh2*$^{MB01265/MB01265}$ flies and flies with neuronal specific knockdown of both Sodh1 and Sodh2 were rescued to the levels of yw control flies (Figure 4C, Figure 7). Furthermore, Epalrestat or Ranirestat feeding restored the age-dependent synaptic defects in *Sodh2*$^{MB01265/MB01265}$ mutant flies. In DMSO vehicle treated flies, the loss of synaptic termini was highly prominent in the

advanced age of 40 DAE where the expansion of neighboring vacuoles resulted in fused, much larger vacuoles encompassing multiple synaptic cartridges (Figure 4D). Remarkably, epalrestat/ranirestat feeding reduced the number of vacuoles and restored the localization of synaptic cytomatrix protein BRP at both 10 and 40 DAE (Figure 4E-G).

[0081] In summary, SORD represents a novel recessive gene causing axonal/intermediate, motor predominant CMT. Genetic data from the cohort as well as from control databases suggest that the predominant pathogenic variant in *SORD*, c.757delG; p.(Ala253GlnfsTer27), with a carrier frequency in of ~3/1,000 individuals in the population, may represent one of the most common specific alleles causing a recessive Mendelian disease. Indeed, with a frequency in undiagnosed CMT2 and dHMN cases of up to ~10%, it will likely account for a significant portion of the diagnostic gap in inherited axonal neuropathies. It is intriguing that, despite their frequency, mutations in *SORD* were not identified as a cause of CMT by previous studies. The presence of the human *SORD2P* gene duplication may have hampered the detection of variants in the functional *SORD*, since available annotation programs are highly dependent on the unique mapping of 150-300bp long reads generated by current next-generation sequencing technologies. Other known pathogenic variants have previously been shown to be concealed by the presence of pseudogenes (De Vos et al. 2004). The pathogenicity of *SORD* mutations is further supported by *in vitro* data in patient-derived fibroblasts, which showed absent SORD protein and intracellular sorbitol accumulation. Two *in vivo Drosophila* models recapitulated the human phenotype with progressive synaptic degeneration and motor impairment, SORD deficiency, and in increased sorbitol levels.

[0082] The studies described herein demonstrate that enzymatic loss-of-function and subsequent sorbitol accumulation is a mechanism of action for *SORD* associated CMT. Previous studies in cellular and animal models of diabetes have shown that an increased polyol influx with intracellular sorbitol accumulation is paralleled by an increase in cellular osmolarity, oxidative stress and decreased NADPH levels, which can all have a detrimental effects on peripheral nerves (Schmidt et al. 2001; Obrosova 2005; Sango et al. 2006). However, previous studies on adult C57BL/LiA mice expressing reduced level of SORD protein due to an intronic splicing mutation did not identify overt neurological defects (Holmes, Duley, and Hilgers 1982; Lee, Chung, and Chung 1995; Ng et al. 1998). Based on patient clinical data and the late-onset phenotype in flies, it will be important to extend the observation to aging C57BL/LiA mice or

create complete knock-out SORD mouse or rat models. The study further unravels a central role of the polyol pathway in peripheral nerve metabolism and survival in normoglycemic conditions. Although the mechanism by which intracellular sorbitol accumulation can lead to selective degeneration of peripheral nerves is yet unknown, the observation of increased sorbitol levels in patient derived cells in this study has promising implications, both as a biomarker of the disease and as a target of future therapeutic interventions, including methods for substrate reduction, gene replacement or correction, and SORD enzyme substitution. Accordingly, disclosed herein are preclinical studies demonstrating the beneficial effects of substrate reduction via ARI application in human derived cells and *Drosophila* models. Epalrestat is currently marketed in few countries for the treatment of diabetic complications (Grewal et al. 2016) while Ranirestat has been advanced into late stages of clinical trials (Polydefkis et al. 2015; Sekiguchi et al. 2019).

[0083] References

[0084] Auton, et al. 1000 Genomes Project Consortium, 2015. "A Global Reference for Human Genetic Variation." Nature 526 (7571): 68–74.

[0085] Bausenwein, et al. 1992. "The Optic Lobe of Drosophila Melanogaster. II. Sorting of Retinotopic Pathways in the Medulla." Cell and Tissue Research 267 (1): 17–28.

[0086] Bellen, et al. 2011. "The Drosophila Gene Disruption Project: Progress Using Transposons with Distinctive Site Specificities." Genetics 188 (3): 731–43.

[0087] Brazill, et al. 2018. "Quantitative Cell Biology of Neurodegeneration in Drosophila Through Unbiased Analysis of Fluorescently Tagged Proteins Using ImageJ." Journal of Visualized Experiments: JoVE, no. 138 (03).

[0088] Callaghan, et al. 2012. "Diabetic Neuropathy: Clinical Manifestations and Current Treatments." The Lancet. Neurology 11 (6): 521–34.

[0089] Carr, et al. 2016. "A Study of the Neuropathy Associated with Transthyretin Amyloidosis (ATTR) in the UK." Journal of Neurology, Neurosurgery, and Psychiatry 87 (6): 620–27.

[0090] Chalk, et al. 2007. "Aldose Reductase Inhibitors for the Treatment of Diabetic Polyneuropathy." The Cochrane Database of Systematic Reviews, no. 4 (October): CD004572.

[0091] De Vos, et al. 2004. "Novel PMS2 Pseudogenes Can Conceal Recessive Mutations Causing a Distinctive Childhood Cancer Syndrome." American Journal of Human Genetics 74 (5): 954–64.

[0092] Dyck, et al. 1993. "The Prevalence by Staged Severity of Various Types of Diabetic Neuropathy, Retinopathy, and Nephropathy in a Population-Based Cohort: The Rochester Diabetic Neuropathy Study." Neurology 43 (4): 817–24.

[0093] Fridman, et al. 2015. "CMT Subtypes and Disease Burden in Patients Enrolled in the Inherited Neuropathies Consortium Natural History Study: A Cross-Sectional Analysis." Journal of Neurology, Neurosurgery, and Psychiatry 86 (8): 873–78.

[0094] Gonzalez, et al. 2015. "Innovative Genomic Collaboration Using the GENESIS (GEM.App) Platform." Human Mutation 36 (10): 950–56.

[0095] Grewal, et al. 2016. "Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-Diabetic Diseases." Mini Reviews in Medicinal Chemistry 16 (2): 120–62.

[0096] Hao, et al. 2015. "Hyperglycemia Promotes Schwann Cell De-Differentiation and De-Myelination via Sorbitol Accumulation and Igf1 Protein Down-Regulation." The Journal of Biological Chemistry 290 (28): 17106–15.

[0097] Hellgren, et al. 2007. "A Hydrogen-Bonding Network in Mammalian Sorbitol Dehydrogenase Stabilizes the Tetrameric State and Is Essential for the Catalytic Power." Cellular and Molecular Life Sciences: CMLS 64 (23): 3129–38.

[0098] Holmes, et al. 1982. "Sorbitol Dehydrogenase Genetics in the Mouse: A 'null' Mutant in a 'European' C57BL Strain." Animal Blood Groups and Biochemical Genetics 13 (4): 263–72.

[0099] Johansson, et al. 2001. "Crystal Structure of Sorbitol Dehydrogenase." Chemico-Biological Interactions 130–132 (1–3): 351–58.

[00100] Kikkawa, et al. 1983. "Effect of a New Aldose Reductase Inhibitor, (E)-3-Carboxymethyl-5-[(2E)-Methyl-3-Phenylpropenylidene]Rhodanine (ONO-2235) on Peripheral Nerve Disorders in Streptozotocin-Diabetic Rats." Diabetologia 24 (4): 290–92.

[00101] Lee, et al. 1995. "Demonstration That Polyol Accumulation Is Responsible for Diabetic Cataract by the Use of Transgenic Mice Expressing the Aldose Reductase Gene in the Lens." Proceedings of the National Academy of Sciences of the United States of America 92 (7): 2780–84.

[00102] Lek, et al. 2016. "Analysis of Protein-Coding Genetic Variation in 60,706 Humans." Nature 536 (7616): 285–91.

[00103] Lindstad, et al. 2013. "Inhibition of Sorbitol Dehydrogenase by Nucleosides and Nucleotides." Biochemical and Biophysical Research Communications 435 (2): 202–8.

[00104] Luque, et al. 1998. "Sorbitol Dehydrogenase of Drosophila. Gene, Protein, and Expression Data Show a Two-Gene System." The Journal of Biological Chemistry 273 (51): 34293–301.

[00105] Matsumoto, et al. 2008. "Long-Term Treatment with Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats." Journal of Pharmacological Sciences 107 (3): 340–48.

[00106] Ng, et al. 1998. "Effects of Sorbitol Dehydrogenase Deficiency on Nerve Conduction in Experimental Diabetic Mice." Diabetes 47 (6): 961–66.

[00107] Obrosova I. 2005. "Increased Sorbitol Pathway Activity Generates Oxidative Stress in Tissue Sites for Diabetic Complications." Antioxidants & Redox Signaling 7 (11–12): 1543–52.

[00108] Polydefkis, et al. 2015. "Safety and Efficacy of Ranirestat in Patients with Mild-to-Moderate Diabetic Sensorimotor Polyneuropathy." Journal of the Peripheral Nervous System: JPNS 20 (4): 363–71.

[00109] Ramirez, et al. 2008. "Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy." Pharmacotherapy 28 (5): 646–55.

[00110] Rossor, et al. 2016. "Recent Advances in the Genetic Neuropathies." Current Opinion in Neurology 29 (5): 537–48.

[00111] Sango, et al. 2006. "High Glucose-Induced Activation of the Polyol Pathway and Changes of Gene Expression Profiles in Immortalized Adult Mouse Schwann Cells IMS32." Journal of Neurochemistry 98 (2): 446–58.

[00112] Schmidt, et al. 2001. "Inhibition of Sorbitol Dehydrogenase Exacerbates Autonomic Neuropathy in Rats with Streptozotocin-Induced Diabetes." Journal of Neuropathology and Experimental Neurology 60 (12): 1153–69.

[00113] Sekiguchi, et al. 2019. "Aldose Reductase Inhibitor Ranirestat Significantly Improves Nerve Conduction Velocity in Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study in Japan." Journal of Diabetes Investigation 10 (2): 466–74.

CLAIMS

What is claimed:

1. A method of treating inherited neuropathy in a mammalian subject, the method comprising:

(a) detecting the presence of a mutation in the sorbitol dehydrogenase (*SORD*) gene in a sample from the subject; and

(b) administering to the subject a polynucleotide that encodes a SORD peptide, an aldose reductase antisense oligonucleotide, an agent that blocks expression of a mutant *SORD* gene, an agent that corrects the mutation in *SORD* gene, or a combination of any of the foregoing.

2. The method of claim 1, wherein the method comprises administering a polynucleotide encoding the SORD peptide.

3. The method of claim 1, wherein the method comprises administering an agent that corrects the mutation in the *SORD* gene, wherein the agent is a CRISPR Cas9 protein and one or more guide RNA molecules.

4. A method of treating inherited neuropathy in a mammalian subject, the method comprising:

(a) detecting the presence of a mutation in the sorbitol dehydrogenase (*SORD*) gene in a sample from the subject; and

(b) administering to the subject Alrestatin, Epalrestat, Diepalrestat, Fidarestat, Imirestat, Lidorestat, Minalrestat, Ponalrestat, Ranirestat, Salfredin B_{11}, Sorbinil, Tolrestat, Zenarestat, or Zopolrestat.

5. A method of treating inherited neuropathy in a mammalian subject, the method comprising:

(a) detecting the presence of a mutation in the sorbitol dehydrogenase (*SORD*) gene in a sample from the subject; and

(b) administering to the subject a SORD peptide.

6. The method of any one of claims 1-5, wherein the mutation in the *SORD* gene is c.753delG; p.Ala253GlnfsTer27, c.329G>C; p.Arg110Pro, c.298C>T; p.Arg100Ter, or c.458C>A; p.Ala153Asp.

7. The method of any one of claims 1-5, wherein the mutation in the *SORD* gene is c.757delG; p.Ala253GlnfsTer27, c.28C>T; p.Leu10Phe, c.316_425+165del; p.Cys106Ter, c.295C>T; p.Arg299Ter, c.964G>A; p.Val322Ile, or a deletion of individual or multiple coding exons or the entire *SORD* gene.

8. The method of any one of claims 1-7, further comprising measuring sorbitol in a sample from the subject.

9. A method of characterizing a neuropathy in a mammalian subject, the method comprising measuring the level of sorbitol in a subject suffering from a neuropathy, wherein a sorbitol level of greater than about 10 g/L indicates that the neuropathy is associated with a mutation in the sorbitol dehydrogenase (*SORD*) gene.

10. A method of evaluating the efficacy of a treatment for an inherited neuropathy in a subject, the method comprising

administering to the subject an agent selected from the group consisting of an aldose reductase inhibitor, an aldose reductase antisense oligonucleotide, a polynucleotide that encodes a SORD peptide, a SORD peptide, an agent that blocks expression of a mutant *SORD* gene, and an agent that corrects the mutation in *SORD* gene, or a combination of any of the foregoing; and

measuring the level of sorbitol in a subject.


Family1
c.757delG (p.Ala253GlnfsTer27)
+/+
+/+
Family 2
1. c.757delG (p.Ala253GlnfsTer27)
2. c.298C>T (p.Arg100Ter)
1.+/-
2.-/-
1.+/-
2.-/+
Family 3
1. c.757delG (p.Ala253GlnfsTer27)
2. c.329G>C (p.Arg110Pro)
1.+/-
2.-/-
1.-/-
2.-/+
1.+/-
2.-/+
Family 18
c.757delG (p.Ala253GlnfsTer27)
-/+
-/+
+/+
+/+

FIG. 1A


c.28C>T
c.316_425+165del
c.329C>T
c.298C>T
c.458C>A
c.757delG
c.895C>T
c.964G>A
5'-
-3'
1
2
3
4
5
6
7
8
9

FIG. 1B


LOF mutations
Missense mutations
Zinc binding
Substrate binding
Leu10Phe
Zn
Cys106Ter
Arg100Ter
Arg110Pro
Alg153Asp
Ala253GlnfsTer27
Arg299Ter
Val322Ile
Zinc binding
Tetramer interface
1 aa
-COOH
357 aa

FIG. 1C

Humans P N N L S L V
Rhesus P K N L S L V
Mouse G E N L S L V
Dog A E N L T L V
Drosophila K D N L T A V
K M G R Y N L
K S G R Y N L
K I G R Y N L
K I G R Y N L
K Q G R Y N L
E E G A L I E
E E G A L I E
E E G A L I E
E E G A L I E
E E G A L L E
K P L V T H R
K P L V T H R
K P L V T H R
K P L V T H R
K R L V T H H
SEQ ID NO:537
SEQ ID NO:538
SEQ ID NO:539
SEQ ID NO:540
SEQ ID NO:541

FIG. 1D



FIG. 1E

ORD exon 7 GTAGATGCCCGCCTGGATGGAGGCCTCTGCCCCCGTGCACTCGATGGTGACTTCCGGCTTGCACCCCAGCTGA SEQ ID NO:43

_ORD2P exon 7 GTAGATGCCTGCCTGGATGGAGGCCTCTG-CCCCGTGCACTCGATGGTGACTTCCGGCTTGCACCCCAGCAGA SEQ ID NO:44



FIG. 1F



FIG. 2A



FIG. 2B

FIG. 2C





FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D



FIG. 3E



FIG. 3F



FIG. 4A



FIG. 4B



FIG. 4D



FIG. 4C



FIG. 4E

FIG. 4F



FIG. 4G


Fam-1
II-1
II-2
c.757delG/
c.757delG
c.757delG/
c.757delG
Fam-2
c.757delG/
wt & wt/wt
c.757delG/wt
& wt/c.298C>T
Fam-3
c.757delG/
wt & wt/wt
wt/wt &
c.329G>C/wt
c.757delG/wt
& wt/c.329G>C
Fam-4
c.757delG/
wt
c.757delG/
wt
c.757delG/
c.757delG
Fam-5
c.757delG/
c.757delG
Fam-6
c.757delG/
c.757delG
Fam-7
c.757delG/wt
c.757delG/wt
c.757delG/
c.757delG
Fam-8
c.757delG/
c.757delG
Fam-9
c.757delG/
wt
c.757delG/
wt
c.757delG/
c.757delG
Fam-10
c.757delG/
c.757delG
Fam-11
c.757delG/
wt
c.757delG/
wt
c.757delG/
c.757delG
Fam-12
c.757delG/
wt
c.757delG/
c.757delG
Fam-13
c.757delG/
wt
c.757delG/
wt
wt/wt
c.757delG/
c.757delG
Fam-14
II-1
II-2
c.757delG/wt
& c.458C>A
c.757delG/wt
& c.458C>A
Fam-15
c.757delG/
c.757delG

FIG. 5


Fam-16
c.757delG/ wt
c.757delG/ wt
c.757delG/ c.757delG
Fam-17
c.757delG/ c.757delG
Fam-18
c.757delG/wt
c.757delG/wt
II-2
II-3
c.757delG/ c.757delG
c.757delG/ c.757delG
Fam-19
I-1
c.757delG/ c.757delG
II-2
II-3
c.757delG/ c.757delG
c.757delG/ wt
c.757delG/ c.757delG
Fam-20
II-3
c.757delG/ c.757delG
Fam-21
c.757delG/ c.757delG
Fam-22
c.757delG/ c.757delG
Fam-23
II-1
II-2
c.757delG/ c.757delG
c.757delG/ c.757delG
Fam-24
c.757delG/ c.757delG
Fam-25
c.757delG/c.757delG
Fam-26
c.757delG/ c.757delG
Fam-27
c.757delG/ c.757delG
Fam-28
II-1
II-2
c.757delG/ c.757delG
c.757delG/ c.757delG
Fam-29
wt/wt & wt/c.964G>A
c.757delG/wt & wt/c.964G>A
Fam-30
c.757delG/wt & wt/wt
wt/wt & wt/c.316_425+165del
c.757delG/wt & wt/c.316_425+165del

FIG. 5CONT.


Fam-31
c.757delG/
c.757delG
Fam-32
wt/wt &
wt/wt
c.757delG/wt
& wt/wt
c.757delG/wt
& wt/c.28C>T
Fam-33
c.757delG/wt &
wt/c.895C>T
Fam-34
c.757delG/
c.757delG
Fam-35
c.757delG/
c.757delG
Fam-36
c.757delG/
c.757delG
Fam-37
c.757delG/
c.757delG
Fam-38
c.757delG/
c.757delG

FIG. 5CONT.


Sodh1+Sodh2 RNAi
****
*
*
Vacuole number
Vacuole size (μm2)
BRP intensity (x10³a.u./μm2)
2 DAE
10 DAE

FIG. 6B


Sodh1+Sodh2 RNAi
2 DAE
10 DAE
XY
XZ

FIG. 6A


Average passing rate (%)
100
80
60
40
20
0
2
10
20
30
40
50
DAE
1-2-3-4
1-2-3-4
1-2-3-4
P = 0.07
P = 0.07
1 yw + DMSO
2 Sodh1+Sodh2 RNAi + DMSO
3 Sodh1+Sodh2 RNAi + Epalrestat
4 Sodh1+Sodh2 RNAi + Ranirestat

FIG. 7


pAAV-SORD.xdna - 5756 nt
1...149 ITR
217...743 CMV promoter
817...1309 bGlob-Intron
1357...2430 SORD
2502...2982 hGH polyA signal
ITR 3011...3159
Amp prom 4006...4034
AmpR 4274...4933
ColE1 origin 5085...5713

FIG. 8

> [pAAV-SORD.xdna] - 5756 bp SEQ ID NO: 48

CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCG
GCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCAACCGTCTAGT
TATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGG
CCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGA
CTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGT
ACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC
TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGC
GGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGAC
TTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAG
AGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGAT
CCAGCCTCCGCGGATTCGAATCCCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTAC
CGCCTATAGAGTCTATAGGCCCACAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTCTAATACTTT
CCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTTGCACCATTCTAAAGAATAACAGTGATAA
TTTCTGGGTTAAGGCAATAGCAATATTTCTGCATATAAATATTTCTGCATATAAATTGTAACTGATGTAAGAGGTTTCAT
ATTGCTAATAGCAGCTACAATCCAGCTACCATTCTGCTTTTATTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCA
AGCTAGGCCCTTTTGCTAATCATGTTCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCT
GGCCCATCACTTTGGCAAAGAATTGGGATTCGAACATCGATCCGAGGAGATCTGCCGCCGCGATCGCCGGCGCGCCATGG
CGGCGGCGGCCAAGCCCAACAACCTTTCCCTGGTGGTGCACGGACCGGGGGACTTGCGCCTGGAGAACTATCCTATCCCT
GAACCAGGCCCAAATGAGGTCTTGCTGAGGATGCATTCTGTTGGAATCTGTGGCTCAGATGTCCACTACTGGGAGTATGG
TCGAATTGGGAATTTTATTGTGAAAAAGCCCATGGTGCTGGGACATGAAGCTTCGGGAACAGTCGAAAAAGTGGGATCAT
CGGTAAAGCACCTAAAACCAGGTGATCGTGTTGCCATCGAGCCTGGTGCTCCCCGAGAAAATGATGAATTCTGCAAGATG
GGCCGATACAATCTGTCACCTTCCATCTTCTTCTGTGCCACGCCCCCCGATGACGGGAACCTCTGCCGGTTCTATAAGCA
CAATGCAGCCTTTTGTTACAAGCTTCCTGACAATGTCACCTTTGAGGAAGGCGCCCTGATCGAGCCACTTTCTGTGGGGA
TCCATGCCTGCAGGAGAGGCGGAGTTACCCTGGGACACAAGGTCCTTGTGTGTGGAGCTGGGCCAATCGGGATGGTCACT
TTGCTCGTGGCCAAAGCAATGGGAGCAGCTCAAGTAGTGGTGACTGATCTGTCTGCTACCCGATTGTCCAAAGCCAAGGA
GATTGGGGCTGATTTAGTCCTCCAGATCTCCAAGGAGAGCCCTCAGGAAATCGCCAGGAAAGTAGAAGGTCAGCTGGGGT
GCAAGCCGGAAGTCACCATCGAGTGCACGGGGGCAGAGGCCTCCATCCAGGCGGGCATCTACGCCACTCGCTCTGGTGGG
AACCTCGTGCTTGTGGGGCTGGGCTCTGAGATGACCACCGTACCCCTACTGCATGCAGCCATCCGGGAGGTGGATATCAA
GGGCGTGTTTCGATACTGCAACACGTGGCCAGTGGCGATTTCGATGCTTGCGTCCAAGTCTGTGAATGTAAAACCCCTCG
TCACCCATAGGTTTCCTCTGGAGAAAGCTCTGGAGGCCTTTGAAACATTTAAAAAGGGATTGGGGTTGAAAATCATGCTC
AAGTGTGACCCCAGTGACCAGAATCCCTGAAGATCTCAAGCTTAACTAGCTAGCGGACCGACGCGTACGCGGCCGCTCGT
TTAAACGGCCGGCCGGATCTACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTC
CAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGG
TGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTG
GAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGT
TGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCC
AGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCAC
TGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTT
GGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGG
CGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGT
ATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACG
CGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGC
CGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAA
AACTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACG
TTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACTCTATCTCGGGCTATTCTTTTGATTTATAAGGGAT
TTTGCCGATTTCGGTCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGT
TTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCC
GCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTG
TCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCA
TGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAG
TATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGG
TGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTT
GAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTAT
TGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAA
AGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTA
CTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGC
GCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCA
GGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGG
TATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGG
ATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATAT
ATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAA
AATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTT
TTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCA
ACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCA
CCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATA
AGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGC
ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCC
CGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAA
ACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
CGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGT

FIG. 9

Supplemental Table 1 | Primers sequences and thermocycling conditions

	Primers	SEQ ID NO:	Reagents	Thermocycling conditions
SORD Exon 1	Fw/sequencing: CAGGCTGGCACAAAGGAG Rv: AGTGAGGCAGGATCGGTATG	2 3	Faststart Master Mix 2X (Roche) Primers 0.5 mM genomic DNA 50 ng	95°C 4 min [95°C 30 s 65°C 30 s - Each cycle decreasing by 0.5°C 72°C 1 min] X18 cycles [95°C 30s 55°C 30s 72°C 1 min] X18 cycles 72°C 5 min
SORD Exon 2	Fw/sequencing: AGCGTGCCATTTAGCGTATC Rv: GCAGTAGACTCTGTTCTCAGCCTAAC	4 5		
SORD Exon 3	Fw ACCTTTTCTCATAAATAGATACGAATCC Rv/sequencing TCTTGTTCCCTGCTGTACCC	6 7		
SORD Exon 4	Fw and sequencing GCATGCAAGCCTTCATAACA Rv CGAGGTCATTGTTGTTATGACG	8 9		
SORD Exon 5	Fw/sequencing CGTGGCCATGTTAACTCCTT Rv GTTCCCTGAATTCCCAGTCA	10 11		
SORD Exon 6	Fw/sequencing ATGTTTAATATTTCACGAACATATTCC Rv GCTGTTTCCCAGTCAAGGAG	12 13		
SORD exon 7	Fw TGAGTCATCAGATTTCTCTTGTTTG Rv AGCCTGGGCGACTGAGTGAG Sequencing AAAAGAAAACATAGATGGCAAAAGA	14 15 16		
SORD exon 8	Fw/sequencing TCCCGCTCAGTTAAGTTTGG Rv GCTTCAAAATCCCCTCCTTC	17 18		
SORD exon 9	Fw/sequencing CACCTGGCTCTTTCCTCTTG Rv CCCTGAGATCCCAAGACTG	19 20		
SORD2P exon 7	Fw Rv			

PCR: polymerase chain reaction; Fw: forward; Rv: reverse

FIG. 10

SUBSTITUTE SHEET (RULE 26)

Case ID	Family ID	Gender	Age of onset	Age at exam	Ethnicity and origin	Family history	Diagnosis	Symptom at onset	Additional symptoms and signs	motor NCS	sensory NCS UL/LL	Disease severity	c.753delG; p.(Ala253GlnfsTer27) variant in SORD	Second variant in SORD
1	Fam 1	female	10	43	White American	yes	CMT2	walking difficulties		axonal	not available	mild	homozygous	
2	Fam 1	female	10	38	White American	yes	CMT2	distal atrophy of lower limbs		axonal	not available	mild	homozygous	
3	Fam 2	male	15	39	White Greek	no	CMT2 (motor predominant)	unable to stand on toes and heels	Rapid onset after flu-like syndrome, upper limb tremor	axonal	reduced/absent	mild	heterozygous (maternal)	c.298C>T; p.(Arg100Ter) (absent in the mother, father deceased)
4	Fam 3	male	13	17	White French	no	CMT intermediate	difficulties running and jumping, ankle sprains	upper limb tremor, mild hearing loss	intermediate	reduced/reduced	moderate	heterozygous (paternal)	c.329G>C; p.(Arg110Pro) (maternal)
5	Fam 4	male	14	20	White American	no	CMT2 (motor predominant)	unable to stand on toes, walking difficulties	muscle ache, raised CK up to 1200 IU, scapular winging	axonal	reduced/normal	mild	homozygous	
6	Fam 5	male	12	23	White American	no	dHMN	walking and running difficulties, decreased sport performance	upper limb tremor	axonal	normal/normal	mild	homozygous	
7	Fam 6	female	28	59	White American	no	dHMN	unsteadiness		axonal	normal/normal	mild	homozygous	
8	Fam 7	male	14	29	Middle Eastern Iraqi	yes	dHMN	not available		axonal	normal/reduced	mild	homozygous	
9	Fam 8	female	20	32	White American	no	dHMN	balance problems during pregnancy	rapid worsening	intermediate	normal/normal	mild	homozygous	
10	Fam 9	male	12	15	White American	no	CMT intermediate	walking difficulty	upper limb tremor	intermediate	reduced/normal	mild	homozygous	
11	Fam 10	female	12	23	Mixed White and African American	no	CMT2	walking difficulty		intermediate	normal/reduced	mild	homozygous	
12	Fam 11	male	15	34	White British	no	dHMN	unable to stand on toes	stress fractures	axonal	reduced/normal	mild	homozygous	

FIG. 11

13	Fam 12	male	13	43	White British	no	dHMN	unable to stand on toes	Left peroneal nerve mononeuropathy	axonal	reduced/normal	moderate	homozygous	
14	Fam 13	male	29	34	White German	no	Complex CMT2	walking difficulties	Complex ataxo-spastic syndrome entailing mental retardation (since age 3), coarse facial features, bulky stature	axonal	not available /normal	mild	homozygous	c.458C>A; p.(Ala153Asp) (parents unavailable)
15	Fam 14 II-1	male	10	27	White Austrian	no	CMT2	walking difficulties	upper limb distal weakness and tremor	intermediate	reduced/not available	moderate	heterozygous (parents unavailable)	
16	Fam 14 II-2	female	20	36	White Austrian	no	CMT2	walking difficulties		intermediate	reduced/not available	mild	heterozygous (parents unavailable)	c.458C>A; p.(Ala153Asp) (parents unavailable)
17	Fam 15	female	18	28	Middle Eastern (Bedouin) Egyptian	no	dHMN	unable to stand on toes, unable to wear high heels	upper limb tremor	axonal	reduced/reduced	mild	homozygous	
18	Fam 16	male	15	55	White British	no	dHMN	walking difficulties		axonal	absent/normal	mild	homozygous	
19	Fam 17	male	12	23	East Asian Singaporean	no	CMT intermediate	walking and running difficulties		axonal	reduced/normal	moderate	homozygous	
20	Fam 18 II-2	female	12	20	Middle Eastern Egyptian	yes	CMT2	walking difficulties	burning pain in hands and feet	axonal	normal/absent	moderate	homozygous	
21	Fam 18 II-3	male	15	17	Middle Eastern Egyptian	yes	CMT2	walking difficulties		intermediate	normal/absent	moderate	homozygous	
22	Fam 19 I-1	male	40	70	Middle Eastern Egyptian	yes	CMT2	walking difficulties		not available	not available	severe	homozygous	
23	Fam 19 II-2	male	29	39	Middle Eastern Egyptian	yes	CMT2	walking difficulties		not available	not available	moderate	homozygous	
24	Fam 19 II-3	male	16	19	Middle Eastern Egyptian	yes	CMT2	walking difficulties		not available	not available	mild	homozygous	
25	Fam 19 II-3	male	18	26	Middle Eastern Kuwaiti	yes	CMT2 (motor predominant)	Difficulties running and jumping		intermediate	normal/reduced	mild	homozygous	

FIG. 11 CONT.

SUBSTITUTE SHEET (RULE 26)

26	Fam 21	female	20	29	White Italian	no	CMT2 (motor predominant)	walking difficulties		axonal	normal/reduced	moderate	homozygous	
27	Fam 22	male	15	31	White Italian	yes	dHMN	distal atrophy of lower limbs		axonal	normal/normal	mild	homozygous	
28	Fam 23 II-1	male	25	52	White Italian	no	dHMN	walking difficulties	epilepsy, vascular encephalopathy, upper limb tremor, scoliosis. Has a normal sural nerve biopsy	axonal	normal/normal	mild	homozygous	
29	Fam 23 II-2	female	20	45	White Italian	yes	CMT2	pes cavus		axonal	reduced/reduced	mild	homozygous	
30	Fam 24	female	20	42	White Italian	no	dHMN	walking difficulties	brisk reflexes	axonal	normal/normal	moderate	homozygous	
31	Fam 25	male	14	46	White Italian	no	dHMN	walking difficulties		axonal	normal/normal	mild	homozygous	
32	Fam 26	male	12	41	White Italian	no	CMT2 (motor predominant)	walking difficulties	split hand	axonal	reduced/normal	moderate	homozygous	
33	Fam 27	male	13	28	White Italian	no	dHMN	walking difficulties	scoliosis, raised CK	axonal	normal/normal	moderate	homozygous	
34	28 II-1	female	40	48	White Italian	yes	dHMN	walking difficulties	brisk reflexes	axonal	normal/normal	mild	homozygous	
35	28 II-2	female	20	52	White Italian	yes	dHMN	walking difficulties	brisk reflexes	axonal	normal/normal	mild	homozygous	
36	Fam 29	male	2	10	White Italian	no	CMT2	retarded developmental milestone	scoliosis	axonal	absent/absent	moderate	heterozygous (absent in the mother, father unavailable)	c.964G>A; p.(Val322Ile) (maternal)
37	Fam 30	male	15	18	White Italian	no	CMT2	falls		intermediate	reduced/absent	mild	heterozygous (paternal)	c.316_425+165del (maternal)
38	Fam 31	male	30	42	White Italian	no	CMT2	walking difficulties	scoliosis	intermediate	reduced/absent	moderate	homozygous	
39	Fam 32	male	18	29	White Italian	no	dHMN	walking difficulties, cramps	raised CK	axonal	normal/normal	mild	heterozygous (mother)	c.28C>T, (p.Leu10Phe) (de novo)
40	Fam 33	male	15	60	White Italian	no	CMT2 (motor predominant)	falls	mild hearing loss	axonal	normal/reduced	moderate	heterozygous (parents unavailable)	c.895C>T; p.(Arg299Ter)
41	Fam 34	male	25	36	White American	no	CMT intermediate	distal atrophy of lower limbs		intermediate	normal/normal	mild	homozygous	
42	Fam 35	male	12	16	Mixed, Native American (Alaska) and White American	no	dHMN	running difficulties		axonal	reduced/normal	mild	homozygous	

FIG. 11 CONT.

43	Fam 36	male	10	29	East Asian (Han) Chinese	sporadic	CMT2 (motor predominant)	foot drop and walking difficulties		axonal	normal/normal	mild	homozygous
44	Fam 37	male	10	24	East Asian (Han) Chinese	sporadic	CMT2	walking difficulties		axonal	normal/reduced	mild	homozygous
45	Fam 38	male	16	26	East Asian (Han) Chinese	sporadic	CMT2	walking difficulties		axonal	normal/reduced	mild	homozygous

FIG. 11 CONT.

	N=45
Male	32 (71%)
Age of onset	17 ± 8 (2-40)
Age at examination	34 ± 14 (10-70)
Family history of neuropathy	13 (29%)
CMT subtype **CMT2** **dHMN** **CMT intermediate**	 23 (51%) 18 (40%) 4 (9%)
Foot deformities	31 (69%)
Upper limb weakness **Proximal muscle groups** **Distal muscle groups**	 0/44 (0%) 26/44 (59%)
Lower limb weakness **Proximal muscle groups** **Distal muscle groups** **Prominent involvement of foot plantar flexion**	 2/44 (5%) 43/44 (98%) 15/37 (41%)
Reduced vibratory sensation	17/40 (42%)
Reduced pinprick superficial sensation	13/39 (33%)
Disease severity **Mild** **Moderate** **Severe**	 30 (67%) 14 (31%) 1 (2%)
Use of ankle-foot orthoses (AFOs) **Other walking aids**	19 (42%) 2 (4%)
Nerve conduction study **Reduced motor conduction velocity** **Reduced sensory action potentials**	 11/42 (26%) 26/40 (65%)

FIG. 12

SUBSTITUTE SHEET (RULE 26)



FIG. 13

FIG. 14A

atggcggcggcggccaagcccaacaacctttccctggtggtgcacggaccgggggacttgcgcctggagaactatcctatccctgaaccaggcccaaatgaggtcttgctgaggatgcattctgttggaatctgtggctcag
atgtccactactgggagtatatggtcgaattgggaatttattattgtgaaaaagcccatggtgctgggacatgaagcttcgggaacagtcgatcatcggtaaagcacctaaaaccaggtgatcgtgttgccatcga
gcctggtgctcccccgagaaaatgatgaattctgcaagatgggccgatacaatctgtcaccttccatcttcttctgtgccacgcccccccgatgacgggaacctctgccggttctataagcacaatgcagcctttgttacaagctt
cctgacaatgtcaccttgaggaaggcgccctgatcgagccacttctgtgggggatccatgcctgcaggagaggcggagttaccctgggacacaaggtccttgtgtggagctgggccaatcgggatggtcacttgctcgt
ggccaaagcaatgggagcagctcaagtagtggtgactgatctgtctgctaccgattgtccaaagccaaggagattgggggctgatttagtcctccagatctccaaggagaagcccttcaggaaatcgccaggaaagtagaag
gtcagctgggtgcaagccggaagtcaccatcgagtgcacgggggcagaggcctccatcaggcgggcatctacgccactcgctctggtgggaacctcgtgcttgtgggctctgagatgaccacccgtaccctact
gcatgcagccatccgggaggtggatatcaagggcgtgtttcgatactgcaacacgtggccagtggcgatttcgatgcttgcgtccaagtctgtgaatgtaaaaccccctcgtcacccataggtttcctctggagaaagctctgg
aggctttgaaacatttaaaaagggattgggttgaaaatcatgctcaagtgtgaccccagtgaccagaatccctga

FIG. 14B (SEQ ID NO: 45)

MAAAAKPNNLSLVVHGPGDLRLENYPIPEPGPNEVLLRMHSVGICGSDVHYWEYGRIGNFIVKKPMVLGHEASGTVEKVGSSVKHLKPGDRVAIEPGAPRENDEFCKMGRYN
LSPSIFFCATPPDDGNLCRFYKHNAAFCYKLPDNVTFEEGALIEPLSVGIHACRRGGVTLGHKVLVCGAGPIGMVTLLVAKAMGAAQVVVTDLSATRLSKAKEIGADLVLQISKES
PQEIARKVEGQLGCKPEVTIECTGAEASIQAGIYATRSGGNLVLVGLGSEMTTVPLLHAAIREVDIKGVFRYCNTWPVAISMLASKSVNVKPLVTHRFPLEKALEAFETFKKGLGLKI
MLKCDPSDQNP

FIG. 14C (SEQ ID NO: 46)

AR 1A

G*T*T*T*A*A*G#*A*T*C*A*T*C*T*C*C*A*C*C*T

[SEQ ID NO: 22]

AR-S 1A

T*A*T*T*A*C*A#*G*C*T*A*C*A*T*C*C*T*G*T*C

[SEQ ID NO: 47]

FIG. 15A



FIG. 15B



FIG. 15C


Aldose Reductase knockdown via AKR1B1 ASO in SORD patient fibroblasts
Fold change relative to untreated control
1.2
1
0.8
0.6
0.4
0.2
0
0 nM
25 nM
50 nM
100 nM
ASO concentration

FIG. 15D

ASO sequences and corresponding target sites in *Homo sapiens* aldo-keto reductase family 1 member B (AKR1B1), exon targets only

Rank	SEQ ID NO:	target sequence (5p --> 3p)	antisense oligo (5p --> 3p)	SEQ ID NO:	GC content	oligo binding energy (kcal/mol)
1	49	UCGCAGCCAAGCACAAUAAA	TTTATTGTGCTTGGCTGCGA	50	45.00%	-16.3
2	51	GCAGCCAAGCACAAUAAAAC	GTTTTATTGTGCTTGGCTGC	52	45.00%	-16.3
3	53	GAUCGCAGCCAAGCACAAUA	TATTGTGCTTGGCTGCGATC	54	50.00%	-16.2
4	55	AUCGCAGCCAAGCACAAUAA	TTATTGTGCTTGGCTGCGAT	56	45.00%	-16.1
5	57	CGCAGCCAAGCACAAUAAAA	TTTTATTGTGCTTGGCTGCG	58	45.00%	-15.9
6	59	GCCAAGCACAAUAAAACUAC	GTAGTTTTATTGTGCTTGGC	60	40.00%	-15.7
7	61	CGAUCGCAGCCAAGCACAAU	ATTGTGCTTGGCTGCGATCG	62	55.00%	-15.6
8	63	AGCACAAUAAAACUACAGCC	GGCTGTAGTTTTATTGTGCT	64	40.00%	-15.2
9	65	CAGCCAAGCACAAUAAAACU	AGTTTTATTGTGCTTGGCTG	66	40.00%	-14.8
10	67	GCGAUCGCAGCCAAGCACAA	TTGTGCTTGGCTGCGATCGC	68	60.00%	-14.7
11	69	GCACAAUAAAACUACAGCCC	GGGCTGTAGTTTTATTGTGC	70	45.00%	-13.6
12	71	AACCAGAUUGAGUGCCACCC	GGGTGGCACTCAATCTGGTT	72	55.00%	-13
13	73	ACCAGAUUGAGUGCCACCCA	TGGGTGGCACTCAATCTGGT	74	55.00%	-13
14	75	ACCUCCCACAAGGAUUACCC	GGGTAATCCTTGTGGGAGGT	76	55.00%	-12.7
15	77	CCUCCCACAAGGAUUACCCC	GGGGTAATCCTTGTGGGAGG	78	60.00%	-12.6
16	79	ACAACCUGAAUACCCUUUUC	GAAAAGGGTATTCAGGTTGT	80	40.00%	-12.3
17	81	CUCCCACAAGGAUUACCCCU	AGGGGTAATCCTTGTGGGAG	82	55.00%	-12.2
18	83	CCAGAUUGAGUGCCACCCAU	ATGGGTGGCACTCAATCTGG	84	55.00%	-12.1
19	85	CAACCUGAAUACCCUUUUCU	AGAAAAGGGTATTCAGGTTG	86	40.00%	-12.1
20	87	AGUACAACCUGAAUACCCUU	AAGGGTATTCAGGTTGTACT	88	40.00%	-11.9
21	89	GUACAACCUGAAUACCCUUU	AAAGGGTATTCAGGTTGTAC	90	40.00%	-11.9
22	91	AAGGCGAUCGCAGCCAAGCA	TGCTTGGCTGCGATCGCCTT	92	60.00%	-11.8
23	93	UCCCACAAGGAUUACCCCUU	AAGGGGTAATCCTTGTGGGA	94	50.00%	-11.8

SUBSTITUTE SHEET (RULE 26)

FIG. 16

24	95	AAGUACAACCUGAAUACCCU	AGGGTATTCAGGTTGTACTT	96	40.00%	-11.8
25	97	AACCUGAAUACCCUUUUCUG	CAGAAAAGGGTATTCAGGTT	98	40.00%	-11.8
26	99	ACCUGAAUACCCUUUUCUGA	TCAGAAAAGGGTATTCAGGT	100	40.00%	-11.7
27	101	UACCUCCCACAAGGAUUACC	GGTAATCCTTGTGGGAGGTA	102	50.00%	-11.5
28	103	AAAGUACAACCUGAAUACCC	GGGTATTCAGGTTGTACTTT	104	40.00%	-11.5
29	105	CCUGAAUACCCUUUUCUGAC	GTCAGAAAAGGGTATTCAGG	106	45.00%	-11.5
30	107	UAACCAGAUUGAGUGCCACC	GGTGGCACTCAATCTGGTTA	108	50.00%	-11.2
31	109	AUUGAGUGCCACCCAUAUCU	AGATATGGGTGGCACTCAAT	110	45.00%	-11.2
32	111	GUGCCACCCAUAUCUCACUC	GAGTGAGATATGGGTGGCAC	112	55.00%	-11.2
33	113	UGCCACCCAUAUCUCACUCA	TGAGTGAGATATGGGTGGCA	114	50.00%	-11.2
34	115	CACAAUAAAACUACAGCCCA	TGGGCTGTAGTTTTATTGTG	116	40.00%	-11.2
35	117	CCCACAAGGAUUACCCCUUC	GAAGGGGTAATCCTTGTGGG	118	55.00%	-11.2
36	119	CUGAAUACCCUUUUCUGACC	GGTCAGAAAAGGGTATTCAG	120	45.00%	-11.2
37	121	GAUUGAGUGCCACCCAUAUC	GATATGGGTGGCACTCAATC	122	50.00%	-11.1
38	123	AGUGCCACCCAUAUCUCACU	AGTGAGATATGGGTGGCACT	124	50.00%	-11.1
39	125	GCCACCCAUAUCUCACUCAG	CTGAGTGAGATATGGGTGGC	126	55.00%	-11.1
40	127	GAGUGCCACCCAUAUCUCAC	GTGAGATATGGGTGGCACTC	128	55.00%	-11
41	129	UGAAUACCCUUUUCUGACCA	TGGTCAGAAAAGGGTATTCA	130	40.00%	-11
42	131	UUGAGUGCCACCCAUAUCUC	GAGATATGGGTGGCACTCAA	132	50.00%	-10.9
43	133	UGAGUGCCACCCAUAUCUCA	TGAGATATGGGTGGCACTCA	134	50.00%	-10.9
44	135	AGAUUGAGUGCCACCCAUAU	ATATGGGTGGCACTCAATCT	136	45.00%	-10.8
45	137	CCACCCAUAUCUCACUCAGG	CCTGAGTGAGATATGGGTGG	138	55.00%	-10.8
46	139	CAGAUUGAGUGCCACCCAUA	TATGGGTGGCACTCAATCTG	140	50.00%	-10.7
47	141	CCACAAGGAUUACCCCUUCC	GGAAGGGGTAATCCTTGTGG	142	55.00%	-10.6
48	143	GAAAGUACAACCUGAAUACC	GGTATTCAGGTTGTACTTTC	144	40.00%	-10.6
49	145	GAAUACCCUUUUCUGACCAA	TTGGTCAGAAAAGGGTATTC	146	40.00%	-10.5
50	147	ACAAUAAAACUACAGCCCAG	CTGGGCTGTAGTTTTATTGT	148	40.00%	-10.4
51	149	GUACCUCCCACAAGGAUUAC	GTAATCCTTGTGGGAGGTAC	150	50.00%	-10.3
52	151	AAACAAACCUGGCUUGAAGU	ACTTCAAGCCAGGTTTGTTT	152	40.00%	-10.1

SUBSTITUTE SHEET (RULE 26)

FIG. 16 CONT.

53	153	UCAAGGCGAUCGCAGCCAAG	CTTGGCTGCGATCGCCTTGA	154	60.00%	-10.1
54	155	AUGGCAAGCCGUCUCCUGCU	AGCAGGAGACGGCTTGCCAT	156	60.00%	-10
55	157	GAUCUUAAACAAACCUGGCU	AGCCAGGTTTGTTTAAGATC	158	40.00%	-10
56	159	UGAUCUUAAACAAACCUGGC	GCCAGGTTTGTTTAAGATCA	160	40.00%	-9.9
57	161	UAAACAAACCUGGCUUGAAG	CTTCAAGCCAGGTTTGTTTA	162	40.00%	-9.8
58	163	AACAAACCUGGCUUGAAGUA	TACTTCAAGCCAGGTTTGTT	164	40.00%	-9.8
59	165	CUCAGCAGUGGGACAGCAAC	GTTGCTGTCCCACTGCTGAG	166	60.00%	-9.8
60	167	UCAGCAGUGGGACAGCAACC	GGTTGCTGTCCCACTGCTGA	168	60.00%	-9.8
61	169	CAGCAGUGGGACAGCAACCU	AGGTTGCTGTCCCACTGCTG	170	60.00%	-9.8
62	171	AGCAGUGGGACAGCAACCUG	CAGGTTGCTGTCCCACTGCT	172	60.00%	-9.8
63	173	GCAGUGGGACAGCAACCUGU	ACAGGTTGCTGTCCCACTGC	174	60.00%	-9.7
64	175	CAGUGGGACAGCAACCUGUA	TACAGGTTGCTGTCCCACTG	176	55.00%	-9.7
65	177	AGUGGGACAGCAACCUGUAG	CTACAGGTTGCTGTCCCACT	178	55.00%	-9.7
66	179	UGUACCUCCCACAAGGAUUA	TAATCCTTGTGGGAGGTACA	180	45.00%	-9.6
67	181	AAGUGACCUAUACCUGUGUU	AACACAGGTATAGGTCACTT	182	40.00%	-9.6
68	183	GUGGGACAGCAACCUGUAGA	TCTACAGGTTGCTGTCCCAC	184	55.00%	-9.6
69	185	UAGUGCCACUAACGGUUGAG	CTCAACCGTTAGTGGCACTA	186	50.00%	-9.6
70	187	AGUGCCACUAACGGUUGAGU	ACTCAACCGTTAGTGGCACT	188	50.00%	-9.6
71	189	AGGUGGAGAUGAUCUUAAAC	GTTTAAGATCATCTCCACCT	190	40.00%	-9.5
72	191	UGGGACAGCAACCUGUAGAG	CTCTACAGGTTGCTGTCCCA	192	55.00%	-9.5
73	193	AUAGUGCCACUAACGGUUGA	TCAACCGTTAGTGGCACTAT	194	45.00%	-9.5
74	195	CAAGUGACCUAUACCUGUGU	ACACAGGTATAGGTCACTTG	196	45.00%	-9.4
75	197	AGUGACCUAUACCUGUGUUU	AAACACAGGTATAGGTCACT	198	40.00%	-9.4
76	199	GCAAGCCGUCUCCUGCUCAA	TTGAGCAGGAGACGGCTTGC	200	60.00%	-9.3
77	201	CAAGCCGUCUCCUGCUCAAC	GTTGAGCAGGAGACGGCTTG	202	60.00%	-9.3
78	203	AAGCCGUCUCCUGCUCAACA	TGTTGAGCAGGAGACGGCTT	204	55.00%	-9.3
79	205	UCUUAAACAAACCUGGCUUG	CAAGCCAGGTTTGTTTAAGA	206	40.00%	-9.3
80	207	UCUGUGACACCAGAACGCAU	ATGCGTTCTGGTGTCACAGA	208	50.00%	-9.3
81	209	CUGUGACACCAGAACGCAUU	AATGCGTTCTGGTGTCACAG	210	50.00%	-9.3

SUBSTITUTE SHEET (RULE 26)

FIG. 16 CONT.

82	211	UGUGACACCAGAACGCAUUG	CAATGCGTTCTGGTGTCACA	212	50.00%	-9.3
83	213	AACUUCAACCAUCUCCAGGU	ACCTGGAGATGGTTGAAGTT	214	45.00%	-9.2
84	215	ACAAACCUGGCUUGAAGUAU	ATACTTCAAGCCAGGTTTGT	216	40.00%	-9.2
85	217	UUAACCAGAUUGAGUGCCAC	GTGGCACTCAATCTGGTTAA	218	45.00%	-9.2
86	219	GUGACACCAGAACGCAUUGC	GCAATGCGTTCTGGTGTCAC	220	55.00%	-9.2
87	221	UGACACCAGAACGCAUUGCU	AGCAATGCGTTCTGGTGTCA	222	50.00%	-9.1
88	223	AUUACCCCUUCCAUGAAGAG	CTCTTCATGGAAGGGGTAAT	224	45.00%	-9.1
89	225	GGGACAGCAACCUGUAGAGU	ACTCTACAGGTTGCTGTCCC	226	55.00%	-9.1
90	227	AUACCCUUUUCUGACCAAAG	CTTTGGTCAGAAAAGGGTAT	228	40.00%	-9.1
91	229	AUCAAGGCGAUCGCAGCCAA	TTGGCTGCGATCGCCTTGAT	230	55.00%	-9
92	231	AGUCUGUGACACCAGAACGC	GCGTTCTGGTGTCACAGACT	232	55.00%	-9
93	233	CUGUACCUCCCACAAGGAUU	AATCCTTGTGGGAGGTACAG	234	50.00%	-9
94	235	CACAAGGAUUACCCCUUCCA	TGGAAGGGGTAATCCTTGTG	236	50.00%	-9
95	237	GAUUACCCCUUCCAUGAAGA	TCTTCATGGAAGGGGTAATC	238	45.00%	-9
96	239	UUACCCCUUCCAUGAAGAGU	ACTCTTCATGGAAGGGGTAA	240	45.00%	-9
97	241	UACCCCUUCCAUGAAGAGUU	AACTCTTCATGGAAGGGGTA	242	45.00%	-9
98	243	CACCCAUAUCUCACUCAGGA	TCCTGAGTGAGATATGGGTG	244	50.00%	-8.9
99	245	GGAUUACCCCUUCCAUGAAG	CTTCATGGAAGGGGTAATCC	246	50.00%	-8.9
100	247	ACUCAGCAGUGGGACAGCAA	TTGCTGTCCCACTGCTGAGT	248	55.00%	-8.9
101	249	AAGCCUGCAGUUAACCAGAU	ATCTGGTTAACTGCAGGCTT	250	45.00%	-8.8
102	251	GUCUGUGACACCAGAACGCA	TGCGTTCTGGTGTCACAGAC	252	55.00%	-8.8
103	253	GCUGUACCUCCCACAAGGAU	ATCCTTGTGGGAGGTACAGC	254	55.00%	-8.8
104	255	AGGAUUACCCCUUCCAUGAA	TTCATGGAAGGGGTAATCCT	256	45.00%	-8.8
105	257	AGCCUGCAGUUAACCAGAUU	AATCTGGTTAACTGCAGGCT	258	45.00%	-8.7
106	259	CCAAGUGACCUAUACCUGUG	CACAGGTATAGGTCACTTGG	260	50.00%	-8.7
107	261	ACUUCAACCAUCUCCAGGUG	CACCTGGAGATGGTTGAAGT	262	50.00%	-8.6
108	263	UUGAGCUGUACCUCCCACAA	TTGTGGGAGGTACAGCTCAA	264	50.00%	-8.6
109	265	UGAGCUGUACCUCCCACAAG	CTTGTGGGAGGTACAGCTCA	266	55.00%	-8.6
110	267	GAGCUGUACCUCCCACAAGG	CCTTGTGGGAGGTACAGCTC	268	60.00%	-8.6

SUBSTITUTE SHEET (RULE 26)

FIG. 16 CONT.

111	269	AGCUGUACCUCCCACAAGGA	TCCTTGTGGGAGGTACAGCT	270	55.00%	-8.6
112	271	ACCCCUUCCAUGAAGAGUUU	AAACTCTTCATGGAAGGGGT	272	45.00%	-8.6
113	273	GGAAAGUACAACCUGAAUAC	GTATTCAGGTTGTACTTTCC	274	40.00%	-8.6
114	275	GGAAUUUUUCCCAUUGGAUG	CATCCAATGGGAAAAATTCC	276	40.00%	-8.5
115	277	GGUGGAGAUGAUCUUAAACA	TGTTTAAGATCATCTCCACC	278	40.00%	-8.5
116	279	GCCUGCAGUUAACCAGAUUG	CAATCTGGTTAACTGCAGGC	280	50.00%	-8.5
117	281	ACAAGGAUUACCCCUUCCAU	ATGGAAGGGGTAATCCTTGT	282	45.00%	-8.5
118	283	AGCCGUCUCCUGCUCAACAA	TTGTTGAGCAGGAGACGGCT	284	55.00%	-8.4
119	285	AUUGGAUGAGUCGGGCAAUG	CATTGCCCGACTCATCCAAT	286	50.00%	-8.4
120	287	UAAGCCUGCAGUUAACCAGA	TCTGGTTAACTGCAGGCTTA	288	45.00%	-8.4
121	289	CCCCAAGUCUGUGACACCAG	CTGGTGTCACAGACTTGGGG	290	60.00%	-8.4
122	291	GUGACCUAUACCUGUGUUUC	GAAACACAGGTATAGGTCAC	292	45.00%	-8.4
123	293	GGACAGCAACCUGUAGAGUG	CACTCTACAGGTTGCTGTCC	294	55.00%	-8.4
124	295	CUUAAACAAACCUGGCUUGA	TCAAGCCAGGTTTGTTTAAG	296	40.00%	-8.3
125	297	CAAUAAAACUACAGCCCAGG	CCTGGGCTGTAGTTTTATTG	298	45.00%	-8.3
126	299	AAGUCUGUGACACCAGAACG	CGTTCTGGTGTCACAGACTT	300	50.00%	-8.3
127	301	GUUGAGCUGUACCUCCCACA	TGTGGGAGGTACAGCTCAAC	302	55.00%	-8.3
128	303	UACCCUUUUCUGACCAAAGA	TCTTTGGTCAGAAAAGGGTA	304	40.00%	-8.3
129	305	ACCCAUAUCUCACUCAGGAG	CTCCTGAGTGAGATATGGGT	306	50.00%	-8.2
130	307	AUCCCCAAGUCUGUGACACC	GGTGTCACAGACTTGGGGAT	308	55.00%	-8.2
131	309	UCCCCAAGUCUGUGACACCA	TGGTGTCACAGACTTGGGGA	310	55.00%	-8.2
132	311	CAAGGAUUACCCCUUCCAUG	CATGGAAGGGGTAATCCTTG	312	50.00%	-8.2
133	313	AAGGAUUACCCCUUCCAUGA	TCATGGAAGGGGTAATCCTT	314	45.00%	-8.2
134	315	AAUAGUGCCACUAACGGUUG	CAACCGTTAGTGGCACTATT	316	45.00%	-8.2
135	317	UUGGAUGAGUCGGGCAAUGU	ACATTGCCCGACTCATCCAA	318	50.00%	-8.1
136	319	CAACUUCAACCAUCUCCAGG	CCTGGAGATGGTTGAAGTTG	320	50.00%	-8.1
137	321	AUAAGCCUGCAGUUAACCAG	CTGGTTAACTGCAGGCTTAT	322	45.00%	-8.1
138	323	CCUGCAGUUAACCAGAUUGA	TCAATCTGGTTAACTGCAGG	324	45.00%	-8.1
139	325	GAUCCCCAAGUCUGUGACAC	GTGTCACAGACTTGGGGATC	326	55.00%	-8.1

SUBSTITUTE SHEET (RULE 26)

FIG. 16 CONT.

140	327	UGUUGAGCUGUACCUCCCAC	GTGGGAGGTACAGCTCAACA	328	55.00%	-8.1
141	329	CACUCAGCAGUGGGACAGCA	TGCTGTCCCACTGCTGAGTG	330	60.00%	-8.1
142	331	UGGAUGAGUCGGGGCAAUGUG	CACATTGCCCGACTCATCCA	332	55.00%	-8
143	333	AAUGUGGUUCCCAGUGACAC	GTGTCACTGGGAACCACATT	334	50.00%	-8
144	335	GAUCAAGGCGAUCGCAGCCA	TGGCTGCGATCGCCTTGATC	336	60.00%	-8

FIG. 16 CONT.

SUBSTITUTE SHEET (RULE 26)

ASO sites in homo sapiens aldo-keto reductase family 1 member B (AKR1B1), exon targets only

Rank	SEQ ID NO:	target sequence (5p --> 3p)	antisense oligo (5p --> 3p)	SEQ ID NO:	GC content	average unpaired probability for target site nucleotides	binding site disruption energy (kcal/mol)
1	337	UCGCAGCCAAGCACAAUAAA	TTTATTGTGCTTGGCTGCGA	338	45.00%	0.819	8.6
2	339	CGCAGCCAAGCACAAUAAAA	TTTTATTGTGCTTGGCTGCG	340	45.00%	0.818	9
3	341	GCCCUUCUUUCUACCCUGCU	AGCAGGGTAGAAAGAAGGGC	342	55.00%	0.735	9.9
4	343	GACCUCACGGGCUAUUUAAA	TTTAAATAGCCCGTGAGGTC	344	45.00%	0.698	7.8
5	345	UACCUCCCACAAGGAUUACC	GGTAATCCTTGTGGGAGGTA	346	50.00%	0.694	7.3
6	347	CCCUUCUUUCUACCCUGCUG	CAGCAGGGTAGAAAGAAGGG	348	55.00%	0.693	9.9
7	349	ACCUCCCACAAGGAUUACCC	GGGTAATCCTTGTGGGAGGT	350	55.00%	0.69	7.4
8	351	ACCUCACGGGCUAUUUAAAG	CTTTAAATAGCCCGTGAGGT	352	45.00%	0.684	9.9
9	353	AUUGAGUGCCACCCAUAUCU	AGATATGGGTGGCACTCAAT	354	45.00%	0.668	6.7
10	355	GAUCUUAAACAAACCUGGCU	AGCCAGGTTTGTTTAAGATC	356	40.00%	0.666	12
11	357	UGAUCUUAAACAAACCUGGC	GCCAGGTTTGTTTAAGATCA	358	40.00%	0.664	12.7
12	359	AAGGCGAUCGCAGCCAAGCA	TGCTTGGCTGCGATCGCCTT	360	60.00%	0.663	9.4
13	361	GAUUGAGUGCCACCCAUAUC	GATATGGGTGGCACTCAATC	362	50.00%	0.649	6.2
14	363	CAGAUUGAGUGCCACCCAUA	TATGGGTGGCACTCAATCTG	364	50.00%	0.644	5.8
15	365	CCAGAUUGAGUGCCACCCAU	ATGGGTGGCACTCAATCTGG	366	55.00%	0.643	5.6
16	367	UCAAGGCGAUCGCAGCCAAG	CTTGGCTGCGATCGCCTTGA	368	60.00%	0.639	10.1
17	369	UAAACAAACCUGGCUUGAAG	CTTCAAGCCAGGTTTGTTTA	370	40.00%	0.636	9.3
18	371	UUACCCCUUCCAUGAAGAGU	ACTCTTCATGGAAGGGGTAA	372	45.00%	0.633	8.6
19	373	AAACAAACCUGGCUUGAAGU	ACTTCAAGCCAGGTTTGTTT	374	40.00%	0.631	8.5
20	375	UACCCCUUCCAUGAAGAGUU	AACTCTTCATGGAAGGGGTA	376	45.00%	0.627	8.6

FIG. 17

ASO sites in homo sapiens aldo-keto reductase family 1 member B (AKR1B1), hg19 dna range=chr7:134127102-134143944 (intronic targets only)

Rank	SEQ ID NO:	target sequence (5p --> 3p)	antisense oligo (5p --> 3p)	SEQ ID NO:	GC content	average unpaired probability for target site nucleotides	binding site disruption energy (kcal/mol)
1	377	AAUACAAAAAUUAGCCCGGC	GCCGGGCTAATTTTTGTATT	378	40.00%	0.859	7.5
2	379	AAUACCAUCUCCUCUUCGGC	GCCGAAGAGGAGATGGTATT	380	50.00%	0.818	3.8
3	381	AAAUACCAUCUCCUCUUCGG	CCGAAGAGGAGATGGTATTT	382	45.00%	0.817	3.8
4	383	AUACCAUCUCCUCUUCGGCU	AGCCGAAGAGGAGATGGTAT	384	50.00%	0.812	3.8
5	385	CACUACCCUUAUUCUUGUCU	AGACAAGAATAAGGGTAGTG	386	40.00%	0.812	4.3
6	387	AUACAAAAAUUAGCCCGGCA	TGCCGGGCTAATTTTTGTAT	388	40.00%	0.811	7.6
7	389	UCACUACCCUUAUUCUUGUC	GACAAGAATAAGGGTAGTGA	390	40.00%	0.805	3
8	391	UACCAUCUCCUCUUCGGCUG	CAGCCGAAGAGGAGATGGTA	392	55.00%	0.802	4.1
9	393	ACACCCAUUCAGUCAUUUUG	CAAAATGACTGAATGGGTGT	394	40.00%	0.795	0.5
10	395	GACACCCAUUCAGUCAUUUU	AAAATGACTGAATGGGTGTC	396	40.00%	0.787	1.9
11	397	UCAUGAUAAUCUCCCAGAAC	GTTCTGGGAGATTATCATGA	398	40.00%	0.783	4
12	399	CAGUUUAUCUUAUCGCUCCU	AGGAGCGATAAGATAAACTG	400	40.00%	0.783	10
13	401	AGUUUAUCUUAUCGCUCCUC	GAGGAGCGATAAGATAAACT	402	40.00%	0.782	9.9
14	403	ACCUCCCACAAGGAUUACCC	GGGTAATCCTTGTGGGAGGT	404	55.00%	0.777	7.3
15	405	CCUCCCACAAGGAUUACCCC	GGGGTAATCCTTGTGGGAGG	406	60.00%	0.767	7.3
16	407	CAUGAGGUCAGAAGAUAGAG	CTCTATCTTCTGACCTCATG	408	45.00%	0.761	7.5
17	409	CUUCAUGAUAAUCUCCCAGA	TCTGGGAGATTATCATGAAG	410	40.00%	0.759	1.6
18	411	AUGAGGUCAGAAGAUAGAGA	TCTCTATCTTCTGACCTCAT	412	40.00%	0.757	8
19	413	ACUGUUUUCUCCUUUCUCCU	AGGAGAAAGGAGAAAACAGT	414	40.00%	0.755	7.2
20	415	UUCUCCUUUCUCCUGACAGC	GCTGTCAGGAGAAAGGAGAA	416	50.00%	0.753	7.2
21	417	AGACCCAGCCUCCUUUCCCU	AGGGAAAGGAGGCTGGGTCT	418	60.00%	0.751	10.9
22	419	CCCUUAUUCUUGUCUGAGCU	AGCTCAGACAAGAATAAGGG	420	45.00%	0.75	3.4

SUBSTITUTE SHEET (RULE 26)

FIG. 18

23	421	CUCUCCCAUUCAUCCGUCUU	AAGACGGATGAATGGGAGAG	422	50.00%	0.749	5
24	423	CAUGAUAAUCUCCCAGAACC	GGTTCTGGGAGATTATCATG	424	45.00%	0.747	8.5
25	425	UCUCUCCCAUUCAUCCGUCU	AGACGGATGAATGGGAGAGA	426	50.00%	0.747	4.3
26	427	CCUUAUUCUUGUCUGAGCUC	GAGCTCAGACAAGAATAAGG	428	45.00%	0.744	3.4
27	429	UCUCUCACUACCCUUAUUCU	AGAATAAGGGTAGTGAGAGA	430	40.00%	0.734	4.8
28	431	CCUUUCUUGCCCUCUCUGUC	GACAGAGAGGGCAAGAAAGG	432	55.00%	0.718	-0.1
29	433	CCAAUCUGUCCAUUCCAUUU	AAATGGAATGGACAGATTGG	434	40.00%	0.716	3.8
30	435	CUCUCUCCUUUAGUACUUCC	GGAAGTACTAAAGGAGAGAG	436	45.00%	0.716	5.6
31	437	UCUCUCCUUUAGUACUUCCU	AGGAAGTACTAAAGGAGAGA	438	40.00%	0.715	4.6
32	439	CCUGAGCCUGAUUAUCUGAA	TTCAGATAATCAGGCTCAGG	440	45.00%	0.709	2.7
33	441	CCAUCUUUUGCCAUGAUCAC	GTGATCATGGCAAAAGATGG	442	45.00%	0.709	1.6
34	443	UUUCUCCAUCUUUUGCCAUG	CATGGCAAAAGATGGAGAAA	444	40.00%	0.708	2.3
35	445	GCCAAUCUGUCCAUUCCAUU	AATGGAATGGACAGATTGGC	446	45.00%	0.708	3.8
36	447	UCCAUCUUUUGCCAUGAUCA	TGATCATGGCAAAAGATGGA	448	40.00%	0.707	1.6
37	449	CUGAGCCUGAUUAUCUGAAA	TTTCAGATAATCAGGCTCAG	450	40.00%	0.706	3
38	451	CUUCUUCGUGACCUCUUGCA	TGCAAGAGGTCACGAAGAAG	452	50.00%	0.696	5.3
39	453	AUUGACUUCCCCAAACAACA	TGTTGTTTGGGGAAGTCAAT	454	40.00%	0.691	13
40	455	CUAGAAAAACCUCUCACAAC	GTTGTGAGAGGTTTTTCTAG	456	40.00%	0.688	5.3
41	457	UUGACUUCCCCAAACAACAG	CTGTTGTTTGGGGAAGTCAA	458	45.00%	0.688	13.1
42	459	UAGCCUGAGCCUGAUUAUCU	AGATAATCAGGCTCAGGCTA	460	45.00%	0.686	2.9
43	461	AACGUAUCACCCACGGCCAU	ATGGCCGTGGGTGATACGTT	462	55.00%	0.684	8.3
44	463	ACACUCAAUACAGCUACACU	AGTGTAGCTGTATTGAGTGT	464	40.00%	0.68	5.9
45	465	GCUUCUUCGUGACCUCUUGC	GCAAGAGGTCACGAAGAAGC	466	55.00%	0.677	6.6
46	467	AUAGCCUGAGCCUGAUUAUC	GATAATCAGGCTCAGGCTAT	468	45.00%	0.676	2.5
47	469	GUAACUAGCAAGACCUGUAA	TTACAGGTCTTGCTAGTTAC	470	40.00%	0.676	5.3
48	471	AUAAGCAUCUCAAGCCGGUA	TACCGGCTTGAGATGCTTAT	472	45.00%	0.672	4.2
49	473	AAACGUAUCACCCACGGCCA	TGGCCGTGGGTGATACGTTT	474	55.00%	0.672	8.7
50	475	CCGUAGCUAGUUGAUAAUUC	GAATTATCAACTAGCTACGG	476	40.00%	0.67	6.8
51	477	AUUUGUUUCUACCCCAGCUC	GAGCTGGGGTAGAAACAAAT	478	45.00%	0.67	7.5

SUBSTITUTE SHEET (RULE 26)

FIG. 18 CONT.

52	479	AAUAAGCAUCUCAAGCCGGU	ACCGGCTTGAGATGCTTATT	480	45.00%	0.669	4.2
53	481	UUUGUUUCUACCCCAGCUCU	AGAGCTGGGGTAGAAACAAA	482	45.00%	0.669	7.6
54	483	ACGUAUCACCCACGGCCAUA	TATGGCCGTGGGTGATACGT	484	55.00%	0.669	9.4
55	485	UAAAACCUCAACACCACACA	TGTGTGGTGTTGAGGTTTTA	486	40.00%	0.668	6.7
56	487	GUCCCCUCUUAACCCACACC	GGTGTGGGTTAAGAGGGGAC	488	60.00%	0.667	11.1
57	489	GUCUCAGCUCCAGCCCGUUU	AAACGGGCTGGAGCTGAGAC	490	60.00%	0.663	8.3
58	491	AGUCUCAGCUCCAGCCCGUU	AACGGGCTGGAGCTGAGACT	492	60.00%	0.656	5.3
59	493	AAAACCUCAACACCACACAG	CTGTGTGGTGTTGAGGTTTT	494	45.00%	0.65	8.6
60	495	CCCGUAGCUAGUUGAUAAUU	AATTATCAACTAGCTACGGG	496	40.00%	0.644	8.9
61	497	UAGUGUCCAUGUCUCCGUCU	AGACGGAGACATGGACACTA	498	50.00%	0.644	9.2
62	499	CUCACAACCAUUCACAGCAU	ATGCTGTGAATGGTTGTGAG	500	45.00%	0.643	13.6
63	501	ACAACCAUUCACAGCAUCAU	ATGATGCTGTGAATGGTTGT	502	40.00%	0.641	12.4
64	503	GCAUUUUGUUAUUCUGUCCC	GGGACAGAATAACAAAATGC	504	40.00%	0.633	8.6
65	505	UCCGUCUGACAGUCUCAGCU	AGCTGAGACTGTCAGACGGA	506	55.00%	0.632	9.5
66	507	CAUUCCAUUUUGUGUCCUCU	AGAGGACACAAAATGGAATG	508	40.00%	0.631	9
67	509	UUAGAGUCCCGUGCUGAUGA	TCATCAGCACGGGACTCTAA	510	50.00%	0.627	6.8
68	511	GUUUUAUUGCACCACAGCAU	ATGCTGTGGTGCAATAAAAC	512	40.00%	0.626	6.1
69	513	UAAGCAUCUCAAGCCGGUAG	CTACCGGCTTGAGATGCTTA	514	50.00%	0.624	6.5
70	515	UGCCCUCACAACCAUUCACA	TGTGAATGGTTGTGAGGGCA	516	50.00%	0.623	11.9
71	517	UAUCACCCACGGCCAUACAG	CTGTATGGCCGTGGGTGATA	518	55.00%	0.621	14.3
72	519	AUGACACCAAGCUAAUUUCC	GGAAATTAGCTTGGTGTCAT	520	40.00%	0.618	9
73	521	UUAUUGCACCACAGCAUAUC	GATATGCTGTGGTGCAATAA	522	40.00%	0.616	6.4
74	523	GCAUGGGCUCUUAGAUUAAU	ATTAATCTAAGAGCCCATGC	524	40.00%	0.616	9.9
75	525	AUUCCAUUUUGUGUCCUCUG	CAGAGGACACAAAATGGAAT	526	40.00%	0.613	11.3
76	527	GGCUAAUCUUUUUUCUUCCC	GGGAAGAAAAAAGATTAGCC	528	40.00%	0.601	14.3
77	528	ACAGAUGCUCGACAGAAGAU	ATCTTCTGTCGAGCATCTGT	530	45.00%	0.6	7.2
78	531	GAUGCUCGACAGAAGAUGUG	CACATCTTCTGTCGAGCATC	532	50.00%	0.599	8.6
79	533	UUGUUUCCUCCAAAAACUCC	GGAGTTTTTGGAGGAAACAA	534	40.00%	0.597	9.6
80	535	GUACUUAACCUAUGUAGGCU	AGCCTACATAGGTTAAGTAC	536	40.00%	0.594	6.6

SUBSTITUTE SHEET (RULE 26)

FIG. 18 CONT.

SEQUENCE LISTING

<110> University of Miami et al.

<120> TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS

<130> 32286/54095A

<150> US 62/844,370
<151> 2019-05-07

<150> US 62/987,151
<151> 2020-03-17

<160> 541

<170> PatentIn version 3.5

<210> 1
<211> 5756
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 1
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcaaag cccgggcgtc 60

gggcgacctt tggtcgcccg gcctcagtga gcgagcgagc gcgcagagag ggagtggcca 120

actccatcac taggggttcc tgcggccgca accgtctagt tattaatagt aatcaattac 180

ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 240

cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc 300

catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 360

tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa 420

tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 480

ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta 540

catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 600

cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa 660

ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 720

agctcgttta gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca 780

tagaagacac cgggaccgat ccagcctccg cggattcgaa tcccggccgg gaacggtgca 840

ttggaacgcg gattccccgt gccaagagtg acgtaagtac cgcctataga gtctataggc 900

ccacaaaaaa tgctttcttc ttttaatata ctttttttgtt tatcttattt ctaatacttt 960

ccctaatctc tttctttcag ggcaataatg atacaatgta tcatgcctct ttgcaccatt 1020

ctaaagaata acagtgataa tttctgggtt aaggcaatag caatatttct gcatataaat 1080

atttctgcat ataaattgta actgatgtaa gaggtttcat attgctaata gcagctacaa 1140

tccagctacc attctgcttt tattttatgg ttgggataag gctggattat tctgagtcca 1200

agctaggccc ttttgctaat catgttcata cctcttatct tcctcccaca gctcctgggc 1260

aacgtgctgg tctgtgtgct ggcccatcac tttggcaaag aattgggatt cgaacatcga 1320

tccgaggaga tctgccgccg cgatcgccgg cgcgccatgg cggcggcggc caagcccaac 1380

aacctttccc tggtggtgca cggaccgggg gacttgcgcc tggagaacta tcctatccct 1440

gaaccaggcc caaatgaggt cttgctgagg atgcattctg ttggaatctg tggctcagat 1500

gtccactact gggagtatgg tcgaattggg aattttattg tgaaaaagcc catggtgctg 1560

ggacatgaag cttcgggaac agtcgaaaaa gtgggatcat cggtaaagca cctaaaacca 1620

ggtgatcgtg ttgccatcga gcctggtgct ccccgagaaa atgatgaatt ctgcaagatg 1680

ggccgataca atctgtcacc ttccatcttc ttctgtgcca cgccccccga tgacgggaac 1740

ctctgccggt tctataagca caatgcagcc ttttgttaca agcttcctga caatgtcacc 1800

tttgaggaag gcgccctgat cgagccactt tctgtgggga tccatgcctg caggagaggc 1860

ggagttaccc tgggacacaa ggtccttgtg tgtggagctg ggccaatcgg gatggtcact 1920

ttgctcgtgg ccaaagcaat gggagcagct caagtagtgg tgactgatct gtctgctacc 1980

cgattgtcca aagccaagga gattggggct gatttagtcc tccagatctc caaggagagc 2040

cctcaggaaa tcgccaggaa agtagaaggt cagctggggt gcaagccgga agtcaccatc 2100

gagtgcacgg gggcagaggc ctccatccag gcgggcatct acgccactcg ctctggtggg 2160

aacctcgtgc ttgtggggct gggctctgag atgaccaccg tacccctact gcatgcagcc 2220

atccgggagg tggatatcaa gggcgtgttt cgatactgca acacgtggcc agtggcgatt 2280

tcgatgcttg cgtccaagtc tgtgaatgta aaacccctcg tcacccatag gtttcctctg 2340

gagaaagctc tggaggcctt tgaaacattt aaaaagggat tggggttgaa aatcatgctc 2400

aagtgtgacc ccagtgacca gaatccctga agatctcaag cttaactagc tagcggaccg 2460

acgcgtacgc ggccgctcgt ttaaacggcc ggccggatct acgggtggca tccctgtgac 2520

ccctccccag tgcctctcct ggccctggaa gttgccactc cagtgcccac cagccttgtc 2580

ctaataaaat taagttgcat cattttgtct gactaggtgt ccttctataa tattatgggg 2640

tggaggggggg tggtatggag caaggggcaa gttgggaaga caacctgtag ggcctgcggg 2700

gtctattggg aaccaagctg gagtgcagtg gcacaatctt ggctcactgc aatctccgcc 2760

tcctgggttc aagcgattct cctgcctcag cctcccgagt tgttgggatt ccaggcatgc 2820

atgaccaggc tcagctaatt tttgtttttt tggtagagac ggggtttcac catattggcc 2880

aggctggtct ccaactccta atctcaggtg atctacccac cttggcctcc caaattgctg 2940

ggattacagg cgtgaaccac tgctcccttc cctgtccttc tgattttgta ggtaaccacg 3000

tgcggaccga gcggccgcag gaacccctag tgatggagtt ggccactccc tctctgcgcg 3060

ctcgctcgct cactgaggcc gggcgaccaa aggtcgcccg acgcccgggc tttgcccggg 3120

cggcctcagt gagcgagcga gcgcgcagct gcctgcaggg gcgcctgatg cggtattttc 3180

tccttacgca tctgtgcggt atttcacacc gcatacgtca aagcaaccat agtacgcgcc 3240

ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga ccgctacact 3300

tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg ccacgttcgc 3360

cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat ttagtgcttt 3420

acggcacctc gaccccaaaa aacttgattt gggtgatggt tcacgtagtg ggccatcgcc 3480

ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata gtggactctt 3540

gttccaaact ggaacaacac tcaactctat ctcgggctat tcttttgatt tataagggat 3600

tttgccgatt tcggtctatt ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa 3660

ttttaacaaa atattaacgt ttacaatttt atggtgcact ctcagtacaa tctgctctga 3720

tgccgcatag ttaagccagc cccgacaccc gccaacaccc gctgacgcgc cctgacgggc 3780

ttgtctgctc ccggcatccg cttacagaca agctgtgacc gtctccggga gctgcatgtg 3840

tcagaggttt tcaccgtcat caccgaaacg cgcgagacga aagggcctcg tgatacgcct 3900

atttttatag gttaatgtca tgataataat ggtttcttag acgtcaggtg gcacttttcg 3960

gggaaatgtg cgcggaaccc ctatttgttt atttttctaa atacattcaa atatgtatcc 4020

gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga agagtatgag 4080

tattcaacat ttccgtgtcg cccttattcc ctttttttgcg gcattttgcc ttcctgtttt 4140

tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt 4200

gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga 4260

acgttttcca atgatgagca cttttaaagt tctgctatgt ggcgcggtat tatcccgtat 4320

tgacgccggg caagagcaac tcggtcgccg catacactat tctcagaatg acttggttga 4380

gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag 4440

tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg 4500

accgaaggag ctaaccgctt ttttgcacaa catgggggat catgtaactc gccttgatcg 4560

ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt 4620

agcaatggca acaacgttgc gcaaactatt aactggcgaa ctacttactc tagcttcccg 4680

gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc 4740

ccttccggct ggctggttta ttgctgataa atctggagcc ggtgagcgtg ggtctcgcgg 4800

tatcattgca gcactggggc cagatggtaa gccctcccgt atcgtagtta tctacacgac 4860

ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact 4920

gattaagcat tggtaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa 4980

acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa 5040

aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg 5100

atcttcttga gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa aaaaaccacc 5160

gctaccagcg gtggtttgtt tgccggatca agagctacca actcttttttc cgaaggtaac 5220

tggcttcagc agagcgcaga taccaaatac tgttcttcta gtgtagccgt agttaggcca 5280

ccacttcaag aactctgtag caccgcctac atacctcgct ctgctaatcc tgttaccagt 5340

ggctgctgcc agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc 5400

ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttggagcg 5460

aacgacctac accgaactga gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc 5520

cgaagggaga aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac 5580

gagggagctt ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct 5640

ctgacttgag cgtcgatttt tgtgatgctc gtcaggggggg cggagcctat ggaaaaacgc 5700

cagcaacgcg gccttttttac ggttcctggc cttttgctgg ccttttgctc acatgt 5756

<210> 2
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 2
caggctggca caaaggag 18

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 3
agtgaggcag gatcggtatg 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 4
agcgtgccat ttagcgtatc 20

<210> 5
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 5
gcagtagact ctgttctcag cctaac 26

<210> 6
<211> 28
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 6
acctttttctc ataaatagat acgaatcc 28

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 7
tcttgttccc tgctgtaccc 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 8
gcatgcaagc cttcataaca 20

<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 9
cgaggtcatt gttgttatga cg 22

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 10
cgtggccatg ttaactcctt 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 11
gttccctgaa ttcccagtca 20

<210> 12
<211> 27
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 12
atgtttaata tttcacgaac atattcc 27

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 13
gctgtttccc agtcaaggag 20

<210> 14
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 14
tgagtcatca gatttctctt gtttg 25

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 15
agcctgggcg actgagtgag 20

<210> 16
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 16
aaaagaaaac atagatggca aaaga 25

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 17
tcccgctcag ttaagtttgg 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 18
gcttcaaaat cccctccttc 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 19
cacctggctc tttcctcttg 20

<210> 20
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 20
ccctgagatc ccaagactg 19

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 21
agguggagau gaucuuaaac 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 22
gtttaagatc atctccacct 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 23

gguggagaug aucuuaaaca 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 24
tgtttaagat catctccacc 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 25
ugaucuuaaa caaaccuggc 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 26
gccaggtttg tttaagatca 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 27
uaaacaaacc uggcuugaag 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 28
cttcaagcca ggtttgttta 20

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 29
cagguggaga ugaucuuaaa ca 22

<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 30
tgtttaagat catctccacc tg 22

<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 31
gaucuuaaac aaaccuggcu ug 22

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 32
caagccaggt ttgtttaaga tc 22

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 33
cuuaaacaaa ccuggcuuga ag 22

<210> 34
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 34
cttcaagcca ggtttgttta ag 22

<210> 35
<211> 22
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 35
aaguauaagc cugcaguuaa cc 22

<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 36
ggttaactgc aggcttatac tt 22

<210> 37
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 37
ucaaggcgau cgcagccaag ca 22

<210> 38
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 38
tgcttggctg cgatcgcctt ga 22

<210> 39
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 39
aaggcgaucg cagccaagca ca 22

<210> 40
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 40
tgtgcttggc tgcgatcgcc tt 22

<210> 41
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 41
accuguguuu cuugccucau uu 22

<210> 42
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 42
aaatgaggca agaaacacag gt 22

<210> 43
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 43
gtagatgccc gcctggatgg aggcctctgc ccccgtgcac tcgatggtga cttccggctt 60

gcaccccagc tga 73

<210> 44
<211> 72
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 44
gtagatgcct gcctggatgg aggcctctgc cccgtgcact cgatggtgac ttccggcttg 60

caccccagca ga 72

<210> 45
<211> 1074
<212> DNA
<213> sorbitol dehydrogenase

<400> 45
atggcggcgg cggccaagcc caacaacctt tccctggtgg tgcacggacc gggggacttg 60

cgcctggaga actatcctat ccctgaacca ggcccaaatg aggtcttgct gaggatgcat 120

tctgttggaa tctgtggctc agatgtccac tactgggagt atggtcgaat tgggaatttt 180

attgtgaaaa agcccatggt gctgggacat gaagcttcgg gaacagtcga aaaagtggga 240

tcatcggtaa agcacctaaa accaggtgat cgtgttgcca tcgagcctgg tgctccccga 300

gaaaatgatg aattctgcaa gatgggccga tacaatctgt caccttccat cttcttctgt 360

```
gccacgcccc ccgatgacgg gaacctctgc cggttctata agcacaatgc agccttttgt      420

tacaagcttc ctgacaatgt cacctttgag gaaggcgccc tgatcgagcc actttctgtg      480

gggatccatg cctgcaggag aggcggagtt accctgggac acaaggtcct tgtgtgtgga      540

gctgggccaa tcgggatggt cactttgctc gtggccaaag caatgggagc agctcaagta      600

gtggtgactg atctgtctgc tacccgattg tccaaagcca aggagattgg ggctgattta      660

gtcctccaga tctccaagga gagccctcag gaaatcgcca ggaaagtaga aggtcagctg      720

gggtgcaagc cggaagtcac catcgagtgc acgggggcag aggcctccat ccaggcgggc      780

atctacgcca ctcgctctgg tgggaacctc gtgcttgtgg ggctgggctc tgagatgacc      840

accgtacccc tactgcatgc agccatccgg gaggtggata tcaagggcgt gtttcgatac      900

tgcaacacgt ggccagtggc gatttcgatg cttgcgtcca agtctgtgaa tgtaaaaccc      960

ctcgtcaccc ataggtttcc tctggagaaa gctctggagg cctttgaaac atttaaaaag     1020

ggattggggt tgaaaatcat gctcaagtgt gaccccagtg accagaatcc ctga           1074
```

<210> 46
<211> 357
<212> PRT
<213> sorbitol dehydrogenase

<400> 46

```
Met Ala Ala Ala Ala Lys Pro Asn Asn Leu Ser Leu Val Val His Gly
1               5                   10                  15


Pro Gly Asp Leu Arg Leu Glu Asn Tyr Pro Ile Pro Glu Pro Gly Pro
            20                  25                  30


Asn Glu Val Leu Leu Arg Met His Ser Val Gly Ile Cys Gly Ser Asp
        35                  40                  45


Val His Tyr Trp Glu Tyr Gly Arg Ile Gly Asn Phe Ile Val Lys Lys
    50                  55                  60


Pro Met Val Leu Gly His Glu Ala Ser Gly Thr Val Glu Lys Val Gly
65                  70                  75                  80


Ser Ser Val Lys His Leu Lys Pro Gly Asp Arg Val Ala Ile Glu Pro
                85                  90                  95


Gly Ala Pro Arg Glu Asn Asp Glu Phe Cys Lys Met Gly Arg Tyr Asn
            100                 105                 110


Leu Ser Pro Ser Ile Phe Phe Cys Ala Thr Pro Pro Asp Asp Gly Asn
        115                 120                 125


Leu Cys Arg Phe Tyr Lys His Asn Ala Ala Phe Cys Tyr Lys Leu Pro
    130                 135                 140
```

```
Asp Asn Val Thr Phe Glu Glu Gly Ala Leu Ile Glu Pro Leu Ser Val
145                 150                 155                 160

Gly Ile His Ala Cys Arg Arg Gly Gly Val Thr Leu Gly His Lys Val
                165                 170                 175

Leu Val Cys Gly Ala Gly Pro Ile Gly Met Val Thr Leu Leu Val Ala
            180                 185                 190

Lys Ala Met Gly Ala Ala Gln Val Val Val Thr Asp Leu Ser Ala Thr
        195                 200                 205

Arg Leu Ser Lys Ala Lys Glu Ile Gly Ala Asp Leu Val Leu Gln Ile
    210                 215                 220

Ser Lys Glu Ser Pro Gln Glu Ile Ala Arg Lys Val Glu Gly Gln Leu
225                 230                 235                 240

Gly Cys Lys Pro Glu Val Thr Ile Glu Cys Thr Gly Ala Glu Ala Ser
                245                 250                 255

Ile Gln Ala Gly Ile Tyr Ala Thr Arg Ser Gly Gly Asn Leu Val Leu
            260                 265                 270

Val Gly Leu Gly Ser Glu Met Thr Thr Val Pro Leu Leu His Ala Ala
        275                 280                 285

Ile Arg Glu Val Asp Ile Lys Gly Val Phe Arg Tyr Cys Asn Thr Trp
    290                 295                 300

Pro Val Ala Ile Ser Met Leu Ala Ser Lys Ser Val Asn Val Lys Pro
305                 310                 315                 320

Leu Val Thr His Arg Phe Pro Leu Glu Lys Ala Leu Glu Ala Phe Glu
                325                 330                 335

Thr Phe Lys Lys Gly Leu Gly Leu Lys Ile Met Leu Lys Cys Asp Pro
            340                 345                 350

Ser Asp Gln Asn Pro
        355


<210>  47
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic Poly nucleotide

<400>  47
tattacagct acatcctgtc                                                20


<210>  48
```

<211> 16843
<212> DNA
<213> Homo Sapiens

<400> 48
agaaggctcc ttcgcgcagc ggcgcgccaa ccgcaggcgc cctttctgcc gacctcacgg 60

gctatttaaa ggtacgcgcc gcggccaagg ccgcaccgta ctgggcgggg gtctggggag 120

cgcagcagcc atggcaagcc gtctcctgct caacaacggc gccaagatgc ccatcctggg 180

gttgggtacc tggaaggtag gtgctcgtgg gggcgcgggc ccggggctcg cctcacactc 240

tccgcgcggc ctgtattggc gagggacccc gagtgaccct gagcagctcg ccccgcggac 300

gcccggcgtg ctgggagcca cgcgcgggct tgcagggtcc ccagcgggct ggggtcggcc 360

ttgcagagac cgggggcctt ggctccccgg gttggccctg ggcgtcaggg cagcatcctg 420

cgagtggggt ttgggagcag ctcacgggag cccccgccct accgcgggca acccttgatg 480

ggcggcccac cagtccgcat tttgggtcct agcgggcgcc ccaagcggca caacgcgaga 540

gggaggcggg gaaagtgggc ttcacagacc ggtggacctc gggcgcagac agggacgtgg 600

agccgtcggc aaggtgtggg agcgcagacc cagcctcctt tccctcgagg cacctgtagc 660

ccggttgcct cacttgtaaa tagttggtct caatcgtttc gattcttgcc ctccctgagg 720

aataagcatc tcaagccggt agagggcaga gaattaggtg gcgcgagttt gcccggaccc 780

agctgttaac aaggcgcagt gcggagctcc tcggccaggc gccgcctcgg ggtgccctgg 840

gtctggaact cgggagaaaa atctgggcac cccgtagcta gttgataatt caggaggcgc 900

caaggttagc attttccctg taaaacctca acaccacaca gcgtccccga gaagtgccta 960

gccggatgag aatgacaata ggacatgaaa catcatagga tatgaaaaat gataatatga 1020

tatgaaaaac caaaaataat agcctgagcc tgattatctg aaaattgagc aacaaaggtg 1080

gtggtatggg agctgaggca aaacctagaa tttttaacct tctaagtatt gcatattata 1140

ttccacagcc ataacctggg tttctcagtt tctgtttttg ttgtttgctt gtttgtttgt 1200

gacagggtct cgttgcccaa gctggggtgc agtggcacaa tcatggttca ttgcagcctg 1260

gaactcctgg gctcaagtga tcctcctgcc tcagcactgc gggtagctgg gactacaggc 1320

gctcaccacc acacctggct aatcttttttt cttccccgca gagacagtct ccgcttgttg 1380

cttagggtga tctccaattc ctgggctcaa agcgctcctc ccacctcgcc tcccaaagct 1440

acaggtgtga accatctggc aggcccacgt cccaggtttt tctcttaaaa tttgaatatg 1500

ggcctgggcg ttggatattt acacacagac aagggaagaa aacaacagaa agaactgagt 1560

gaactgtgag atgtttgaaa taggacagaa gagtttacat gtaccctaaa acctgctgtt 1620

gaaaattagt aaatataagg taagaaaaag gtcatttgca tcagggagag tgtttcttgg 1680

ccagaatgat cagggtacgt gatttgtttc ctccaaaaac tccagtggtg tctctaaggt 1740

tgtaattgaa ttacaaccat gacaccaagc taatttccat ctgttgcatg ttatgctctt 1800

ggaatggatg cagaaggatg ctttcttggc aatagcaaat actttctaag catgatgcaa 1860

cgcacagata tatacatgta actggaataa aaattactta acagtactta acctatgtag 1920

gctgcatttc aatatttttt tctattccat ttttccaaaa attattgtca tacctccaga 1980

agctagtttt gtgacccatc atttgaaaat cactactcta gggtaaataa ggagtaaaag 2040

tttatttttt ttttttgag acaggggctc agtgtcaccc aggctggagt gcagtggcat 2100

gatcatgatt cactgtagcc ttaacctctt gggctcaagt ggtcctcata cctcagcctc 2160

ccaagtagct gggaccacag gtgtgtgcca ccacactcgg gtagtttgtt tttaattttt 2220

tgtagagaca ggtttcccta tgttgtccag gctgaggagt aaaagtttat gaaagagggt 2280

ttcagattat tcacttgagc actcaatgcc ccaaaaagct atgtatttgt ttaagataac 2340

atcacatcat aacatctgta catttaggtt atgcattcca gtagacagag ttcattgaga 2400

aattggataa tgtctgcttc attcattact atttctagca cttctcacag tgcctggcaa 2460

atataggagt aggtatccaa aagttatgtg ttgaattcat atgaagaagt aaaacgactt 2520

tagagatagc tgtatggtga aaacgcccac ttgtattcct gtggatgagg agatcaggtt 2580

ggtgtagaat tgtacggtgg gggcagcggg gaatggtggg tcaaagtaat ggtataagga 2640

tggacttgga atcaacttcc ttttttttt taatgactta aaacctttcc ctgggggccgg 2700

gcgcggtggc tcacacctgt aaccccagca ctttgggagg cagaggcggg cagatcatga 2760

ggtcagaaga tagagaccgt cctggctaac atggtgaaac cccgtctcta ctaaaaatac 2820

aaaaaattag cccggcatcg tggcacgcac ctgtagtccc agctacttgg gaggctgagg 2880

caggaaaatc gcttgaaccc cagatgtgga ggttgcagtg agccgaggtc ccgccactgc 2940

actccagcct gggcgatgga gcaagactcc atctaaaaaa acaaccaaac aaaaaaacct 3000

ttcccttgta tgtgtgtatg tattctttca cagatgctcg acagaagatg tgatcctttg 3060

cctgtctttg tgacagctgg aggaggccct gcaggcaggt gcagttcctt attctcctgg 3120

gtcttcccat gccgtagcgg ctgtgttgta cctttcagac cctcagcagg gctctggtag 3180

tctctactct tgaaggtcct caaactccat tctcttctca ggtgagggtt tcaggcagat 3240

ggggagacca tctctgcccc agacccatgt ggcttggaca gggtttcttt ctggcagtct 3300

tgccttctac attggatagt aaacaattac acctgtaatc ccagcacttt ggaaggccaa 3360

ggcgggtgga tcacctgagg tcaggagttc gagaccagct ggccaacatg gtgaaacccc 3420

ctctctacta aaaatacaaa aattagcccg gcatggtggt gggtgcctgt aatcccagct 3480

gcttgggagg ctgaggcagg agaatcactt gaatccagaa ggtagaggtt gccatgatct 3540

gagattgtgc cactgcactc cagcctaggc gacaagagca aaaaaaaact cggtctcaga 3600

aacaacaaca acaacaaaaa cccatcacag cattgtaaag ccaggaagct tttaaaacag 3660

agatgatgtc tggtgcccac cagtgtcttg ttactgatag tgtttttaat ctagttgaaa 3720

aattgttgga ggtaaaagtc attgtaagtc tcctatgtat gctcacagaa tactcctagg 3780

gctgaaggta caactatgtt tctccatctt ttgccatgat cactacctcc ctcccaccta 3840

ggagccttgt gagacttttt tttcccctaa tttgccccaa aataaaattg taatatcaga 3900

gataatattg tacttctgct tatggccagt agccttctag agggtcacaa gctgttctat 3960

aagctgaggg gggttttttt gccccagaga actaattttt gtctctttgg ggacaatagc 4020

acccacttta agaatgcatg aggtaaaaga aaatgtgcca ggaaagactt gctccacctt 4080

ccccaagtgg ggtaagcttg tgatggccca agatccttgg atggggtgag ggttgaggcg 4140

ctgtgggcat ggaggtaaca caggagccag atttactgtt cacttccctg gtgtctctaa 4200

agcccccatc tcttcctctt caagaccaaa gacatttaaa taagccctgc ccctacaggg 4260

tcagtcctgg tccatgcaca tctcaactag ttggaaacag cagtgtctta gaatttggga 4320

caaattgatt aaaacagaac aggaggaagt taatttctgc tgccaaacct gattctgagt 4380

gatcgtttcc tgttccttgc tccaggatta tcagcacagc attctcatgc ttcctactca 4440

ggaccgtttc tttacccaaa gtgaagtttc ctttgccccc tccccttatc ctttgatttc 4500

agtagtaaca cctgctaact agagaacatt tcaaaaatga agagttccct gttcccagag 4560

atccccgtgg ttaatattgc aaaatatcca atctctgaga tactttggtt ttaccataaa 4620

cactgtcctg tgaccgtctt cctgtttagc actgtggctt gctttttgac ttgcagaggg 4680

aagagaggga ggggtatctt gaagtaacta gcaagacctg taagcaaaag ggaagaagac 4740

taggttttaa aaggagtgtt gtatctgtgt aggagggaga cactgatttt agttatcagt 4800

gtctcagagt tggtattagc cagccggtgt tatcaaagga ggaactagga ccgctgtctt 4860

gaaggaggtg gtggaggact caagggcaga ggcttctcac tgccatcact tggtgccatc 4920

agcccagagc atttcaagtc actgcccaac gtagagcttt gcagagccag aagttctggg 4980

aggaatgggc atgcatggtt ttgcccatca agggcacaca gattagtggc aggatcgggt 5040

tagaaacatg taggatttgt atgattgagc tgtaattgga gtgtttcata tactgcattt 5100

ctacagctct catcagtaat ggctgtgcct ggatgccacc cagcatgttt tcatagttta 5160

ccttcttttt agaagtcaat ctggacccct ccttctgttt gcattttctc tttgttgaca 5220

tggaatgggg agatgttgtc atcctgtgtt ggcattccca agtttagtga atggtttctc 5280

accatagctt aagttggctg cttcattttt cataaggcaa attagtttct ctcagggaag 5340

ggctgtacat tgagatcatt aacatagaat gtggttgtgg atcctcgtac attttcattg 5400

cagaggtgac tttttccctc cagcaccttt gatcagcctc ccagcacaca tgtctccagc 5460

gaatggcaca tatccaagga atgatcagca gcttcttcgt gacctcttgc agtcattgct 5520

gtcttttact tttctagaaa aacctctcac aacttttttt tcatgtcgtg ccaacgcaag 5580

cttgattatc ctagtctgtg ctcttttggt tccaaagaac tgaaaaacca ctttaatctt 5640

aagcaggaaa aaaaaaagtg tgtttggggt ggggattgat tgacttcccc aaacaacagc 5700

cgctgacatt aggtgtttga gattcagggt tgtaaatgtt gtcaccagga tttggcctcc 5760

ctccactttc ctgcagcagc tccaggctga cattctccca gctcagtgac cccagcagaa 5820

ccggggctgg actcaggggt tccaattcaa gtgcaaagat tgagtcttat ggcctggatt 5880

gagtcatgtt cctgtccccg caccagttgc atggcaggca gtgcgtggct aggctgagcc 5940

tgcggagtgt gccctcagca gctcctcaga gaaaaatcaa tcaaggcgcc atcaagcctg 6000

gagaaagttc agtgtgtcct gggcagtttc ctgcctgggc cccagttgtt ctttctgggg 6060

tagggatgtc ctctgctctc cctgctgtca tcagtggtgg ttgtgcccgg acaccactca 6120

gggcctgtgg taaggcattc tttctggaaa ttgagattct ctgttccttc aaccgtgcag 6180

agtggggaag gctgcaagag cagcttctga ggtcctccag tcaaataaga ggtcgccagg 6240

tcctctgagg gtcgtcccct cttaacccac accttcgatg agcatcccca ccctgcctcg 6300

ctgctccctc tgaggtggag agtgagctcc atgctaacag gctctggtaa cgggcttgtt 6360

caactgggcc cctttcttcc ccaaagcctg ttgaaaatag ctgatgtcaa aacacagatg 6420

tctgcagctg ctatggccct ggggggtttt tcttttcatt tgtttctacc ccagctctcc 6480

aaaggaatgt gctctgttca ttcaacagcc cgctgcacat gtttattgct cagctctgtg 6540

atcatagcag gatagtgaaa gttgggggat acgtgtccat gcagcctacc tgggtgccag 6600

tgaagcgcga tgccatgtag gcacttcctc ctcctcttca gtagccaggc tccccacagc 6660

tgttctggtt actcagatgg tcaggtggct tggccatgga cacccattca gtcattttgc 6720

caggtcagcc actaaccatt tggtgatctt ccatgatcca cattcccccc cgtttccctt 6780

taacttattt ctctctgctg atacctctga ggggccatct cccgtgtctc cacccccttga 6840

agcagatcct catacagtga gaattgacac atgggccttt gaataaacat cagtgatgtg 6900

cttaacttca tgataatctc ccagaaccgc ttgaaaacaa gcgactgccg gtatcagaag 6960

ccatgcatga aaagagagcg taaggggcag gcattcactg gctgaactgg ggagccacat 7020

gggaattggg gtccatagga catctatttt tgaaatattt tgagatattt gaaggaaatg 7080

gtttccctta ctatctcagc attcagagtg tggggaaatg tttttaatac agtggtttgc 7140

aaatcagtgg atgtgaagaa gcaagaaaat gagatggctt cagcatatct tttaaaagtg 7200

atctcaccta cacttaagtg gctgtcagat tctcctacag ggcaatgctg tgtggccttt 7260

cacttccatc ccccgcgtct gaggctgata gtccagaatg ctgctgagga agtgcacgtg 7320

gtctgtcttt gctgaacaaa gtggcaggct ggtcagcagg tatcggtggc tgccactgcc 7380

cctcctcctt gctgtgcaga ctctgcattc tgcggggctc acgttctttc tcctttcagt 7440

cccctccagg gcaggtgact gaggccgtga aggtggccat tgacgtcggg taccgccaca 7500

tcgactgtgc ccatgtgtac cagaatgaga atgaggtggg ggtggccatt caggagaagc 7560

tcagggagca ggtggtgaag cgtgaggagc tcttcatcgt cagcaaggta tcgttccgcg 7620

gtggggctgg aaggggctct cggtcccatc atctgttggt gcatcagccc aaagccaagt 7680

ccacactcaa tacagctaca cttttcactg atgggcgatt cttcccgggg aaacgtatca 7740

cccacggcca tacagggctc cagagctcgc ccatccttgg ctctctgttg aatggtcatt 7800

ccatctgggc ccattgctta gagtcccgtg ctgatgaggc tgaggttgtg gattggccct 7860

ccctttccag ggagtcgctt tcaaggatgg aacttggttc ccatctgcaa actgaatctc 7920

cagtgctagc cactgtcttt gacctgagat actgatgcac aaaggacatg aggcaggagg 7980

atggggctgg ctccacaaac accagcccgg ggggaaagtt tcgagagttc ttgcttaggc 8040

ctagggcagg ctagccaatc tgtccattcc attttgtgtc ctctggtcct tgtaagaggt 8100

ctctgtgacc tggtcatcct gcctgccttt ggaaagttag gatccagtac gcagtggaaa 8160

tgccctcaca accattcaca gcatcatggt aaagcaaatg ggttttgggg agaggagact 8220

gctctgtctt tccagccagg aagctgcctt gtggctggca atgatgacat gtgccctctc 8280

gctggcttag ctgtggtgca cgtaccatga gaagggcctg gtgaaaggag cctgccagaa 8340

gacactcagc gacctgaagc tggactacct ggacctctac cttattcact ggccgactgg 8400

ctttaaggta tgggatgcct ggtgcagacc aggtcccttg gggctcaggt gcaacctgtg 8460

gtgtgttttg agctccctta gcagattacg tgtgggtgac tttctgttct tgctgctcaa 8520

ggtatagcca gtggaccatc agcactggca tcacctggga gcgtcttaga aatcacagtc 8580

tcgggcccca cgcaggccat ttgaatccgc accagcagtg actcatacgc acacttcttc 8640

aaagtttgag gagcactgct ctttgccagt tggtagatgt gcaatttaaa actgtcagca 8700

aacacagctg ctgtctgtag tgcacacagc catgaggcac ggtcagccct ggccctcccc 8760

tccaggcacg tgcacacacc aacccccata cacatgagtc cctacccacg ttctacatgc 8820

ataccctgtc ctgtggaggc ccggtaacta tttgcagtct agttgttggc acaagaagaa 8880

cttgagagtt actttgtctt ttgccttttt tctagccact gcctcagttt tctgctgtga 8940

gccaggttca aagtgtgggt ttagctttat cccgtagccc tgttttattg caccacagca 9000

tatcagggct gaagggactt gacttttatc ttttgatttt aggggtaagc tggggaggct 9060

gggccaggtg gtagttttat aggccagtga cccgccaggc cttgggccct gtgagtcctg 9120

gtcttgagtc cttcctgtat ccacacattg cagtcagtgg cggggctagt ctctgtgacc 9180

aagtagtgtc catgtctccg tctgacagtc tcagctccag cccgtttgat aaagaagtgt 9240

tggctatctg cctatttcct tttcatagtg gcacacagat tatccctagc cagctgtggt 9300

ggtttagaat tgttttagat gccagcttcc cccagcaggt ctgtgaagga ctattactga 9360

ttgttttgtt tgtttgtttt ttattgtaat gacagcctgg gaaggaattt ttcccattgg 9420

atgagtcggg caatgtggtt cccagtgaca ccaacattct ggacacgtgg gcggtaagac 9480

agcccctggt tggaccttgt tttcgtgact ggttccctct tcttcttaga agcaatctgc 9540

ctgccatttc tcacattgca ttttgttatt ctgtccctgt tgtttgctct ctctttttt 9600

ttttttgagt tggggtctcc ctctgttgcc caggctggag tgcagtggca caatctcggc 9660

tcactgcaag ctccacctcc tgggttcacg ccattctcct gcctcagcct cctgagtagc 9720

tgggactaca ggtgcccgcc accacgcccg gctaattttt ttgtattttt agtagagacg 9780

gggtttcacc gtgttagcca ggatggtctt gatctcctga cctcgtgatc cgcccgcctc 9840

agcctcccaa agtgctggga ttacaggcgt gagccaccgc gcccggcctg tttgctcttc 9900

ttatctcatt aaagccagcc tggctttcgt ctcactgtct cttagcttct gaaaggtcta 9960

attcactggc actgaagagt gagggcagga cccgttaaac tggtgcaaac gacacttctg 10020

atcctgtcct ttctgggttc gtttctgcac cacacagaca cttttctctg taggccatgg 10080

aagagctggt ggatgaaggg ctggtgaaag ctattggcat ctccaacttc aaccatctcc 10140

aggtggagat gatcttaaac aaacctggct tgaagtataa gcctgcagtt aaccaggtaa 10200

acatccccca acgacactgg cattgcaacg ttgctgtttt actgtctgat gctggtaggg 10260

atttctcgtc cacctcaccc agcaagtggc caggaggcag ctcctgggtg ttggcagagt 10320

cctgagttat gattcagcat gacacagcac atctgggaga ggaaacttac aggaaagaaa 10380

gagtttgagc ctggcttgtg acgatttggg gtctgacaaa gaggcagcca tgagatcctc 10440

agaactgtga tagttgataa gtggctaaag ccaagaaaag cctctagggc ccatgagaac 10500

atctataata agataataat aacaccaagg atactacctg ggaactgtag gaagttacag 10560

cttatctggg aaatagggtg tttgttatac atagttttct gtatggggta gggagggact 10620

ttagcatagg aagcttcatc tgtgtcccat cagcgtgtag ccacagtgct cccatcagct 10680

cttgtttttg catttgcaga ttgagtgcca cccatatctc actcaggaga agttaatcca 10740

gtactgccag tccaaaggca tcgtggtgac cgcctacagc cccctcggct ctcctgacag 10800

gccctggtga gcttcccaca ggctcatgct cctgtgtcac ttggtgaaga ttagaaaaga 10860

ctaaaaagaa caattcagcc tcaaggaaga tgtttctggg ggtgatctgc aaaacttccc 10920

ctgagcctct tgctggtttt cctggaaggg ttggagtttc tagtagcaag acacctactc 10980

tttttccaaa gggttggggg ttcttaaccc agctctgagg aggagactgg tggctgccct 11040

ctgaggtcga tgggaggatt agggttgggg tttctggctg ctgtgagtgg tggccatgat 11100

ggtgtgacct ggactgtctt tctatcctca gggccaagcc cgaggaccct tctctcctgg 11160

aggatcccag gatcaaggcg atcgcagcca agcacaataa aactacagcc caggtacagc 11220

cacttcaggt gttgctgacc gtccacaact gcctgcattc ctgacagtcc tgttagccaa 11280

gaggaggaag tgactgagcc tgttacaccc tcacaggaag tatggttagg ggtcctcaag 11340

tacagagtgg aaagggcaca gatcggggtt ttagaagact ctggcatggg ctcttagatt 11400

aatagtgcct gcccccacta ctgcaagggt gactgccacg agggccagcg cttgttcatt 11460

catgtggaac ctcatctgta caaatgtaag agctcttagc cgtgcaggga atgttctttc 11520

tcctgagtgg tagtgtgcat ttctagccag tggagggcct catgtggtct catgatatgc 11580

ctgagacact gaagcgtgtg gcacagtggc tagcgcagga ctctggagtc agatctggac 11640

ctgaatgcgt cgcctacctg ttgctagctg tgacctgaca tcttggagcc cctctctgat 11700

cacctgtgga gttctagcac gtccttctgc aggttgtgtg tgtgagagac tgagatgatg 11760

ggtgcgagtg cctggcatgt atacacactc actgtctcct tgggctcaca ggtcctgatc 11820

cggttcccca tgcagaggaa cttggtggtg atccccaagt ctgtgacacc agaacgcatt 11880

gctgagaact ttaaggtaag atcttggctg gtcaggcctg gccctcctcc atggagtggg 11940

ggatggggga ggcctctcat cctgtctctg gagtgtcatc tgtgggatca ccaccatcct 12000

ctcttctgag gccagggagc tgtggcgagc aagccaagac tgagactgac acctcaccag 12060

tggagccgtg tgcaggggca ggccttgggc ctccagggcc ccgtgctgtg cacgcataca 12120

cctacacctt tgctcaggcc cttcagccac accgagaggt tacccgggga gaatctcgct 12180

cttgagcttc actgcctgga cctgccctgc actggagctc tgtcagctac cagctgcata 12240

accctgggca agtcgcttaa ctgctcgatg cctcagcttc cctatctata aaataatatc 12300

```
cattttgagg gttgttacga agattaagtg atgcatcaga gcacttcaca tggtgcttaa    12360

taccttagta agtgatcgag aaatgttgct gtgctgataa gtccagggac tgcaaaggac    12420

cctctgggcc atttagtcca ttcaccagct ctgcaaggag ttcgtgtgat gatgggcaga    12480

gcctagacct gtgtcaggac tctggcgaag cgctcagtgt ggcagctgga gcagctcagg    12540

ctacttggcg ccacctccct ccctgcctgc ccttgcagca ttggtggcgg gggtgtgggg    12600

gagggggggg gcacgcccaa aggagagcag ctcaggggag tcctgatggc ccaagagcct    12660

ctgttctcac tgagcaaagt ggctctgcca gggatgctct gtctttatcc aagatctgtg    12720

ccgagcgcag cacagccatg ggcctggggc tcttgggcag gccccagctt aggtgagcag    12780

ctgattttgc ccaattccac tgcccaaaga ctgtggccat agtgcctgcc acctgtcaca    12840

tatgagacag ggatgagagt gatccctgaa gagggaagtg gagctcattg tttaggagag    12900

gagacgtttt tcttcttacg tgcaggtaga tgttctaagt acacaagata aaatggcaaa    12960

acagtggcca ctgagggaaa ggcatatccc accagagatg catcgtttgt ttcgtatttc    13020

atttttaag gaattaggaa agaaaaaata aatgactaat ctcaaaatgc taacctaatt    13080

attttatttt tgcatcttac tgtatagctt ttgcacattt ttctgtgatc ataaccacag    13140

agcctgtagc agactctctt tctgcacatt ctgtgatcat ctgaagctaa gagcccttcg    13200

gctctgggag tgtgtgtcag cctcttgtgg gtctcaccca gtggtgcctg cctgcctccc    13260

tccctcccag cctccatgcc agctgagttc tgtaccgtct gctgccttca tgcaggtggt    13320

tctcttctcc cagtatacct ttcttgccct ctctgtcaaa atcttatact tcttaggcca    13380

tgtcaaatac catctcctct tcggctgtgg ttgttcagtt tcccggctgg aatccctttg    13440

gaatacctct gcccttcctg tgctgttgag tgtcttatac agtgtgtgat tagttatttg    13500

tattacagtt gtagaaatac ctctgccctt tgtttgcttc ataaaataga ggcaaagaca    13560

catcttaccc ataattatat tcctcactgc aacttatcac aatagaagtg ctcagtagtg    13620

ttttttgaaa tgaaataaaa tgtatcattt ccctgggagg ttctggaaag gaaggactgt    13680

ttccatcgtt ccatatatta tctagcccaa catgcacatt tcctgaatac taatatatca    13740

gcttttccta agttcagttt atcttatcgc tcctctctgc tcaaagccat ggaagacatc    13800

tgggtcctgc acagtatttt gtcttttatt tttatttgca gagcttactg gatttttttg    13860

tttgtttttt aggtctttga ctttgaactg agcagccagg atatgaccac cttactcagc    13920

tacaacagga actggagggt ctgtgccttg ttgaggtgag tgagccccag tgtgaggagc    13980

agttcccagg agatattcag atgctgcaca gcaagagagt gatccctgca ggcctcagcg    14040

ccaatgtgct ctcgtcacag ctgttcttgc tttgcacatt accttgcttt ctcagccacg    14100

tgacttgcat cagctgaact gcatggagcc aagatgccaa gagatccgct cttgatatct    14160

tcttccagcc ctggggcatt gttggcctgg cctgaagtaa ctacatattt tggctttcca    14220

ttcaattttt aaatcctagc agttcatctg aaactaggtg atcccaggtg accctggatc    14280

aaactctgga agaatttgcc tgtgactttt tgtcttaatg accctaatga aaggggtttg    14340
```

gtcgggagcc cctggggctg aggtttgaga cagtcccggc tctgacctgg taagccacat 14400

ggctccaaaa caggccctcc ctctgagcag caggcacctc agttcctcca gccacacatc 14460

ctctggttct gtttcctctg catggtagtt tggaaggagc tgcctaggaa ggttttctgt 14520

ggggttttct cttttcctac cattacaata actaggtgac gcatgtaact cactttctgc 14580

tttcaagaag gaacttctca ttttgcagtg gagactgaga ctctgtttct ctctcactac 14640

ccttattctt gtctgagctc tgtgtttcca cactctctcc tttagtactt cctcttctaa 14700

gcaaaatgtg aacattccct aagatggggt gggctaccag ctttcccttt ccagcgtctg 14760

tcccatctcc ctccccggag tttgcactgc tggtggcttc agccaccgcc ccaggcagat 14820

gtttgcccag tctgcgtcct ggacaataac tctggccctg cttcaggcat atgcgtgcct 14880

ggcaagcctg ctgctgccac actgtggcct cacactcaaa ataggccgca aacagagcat 14940

gtcacaggca gccccaggcc agtgcccttt cagacatctc tgttaatgct acttagccct 15000

agacattaaa atcatttttg gatctagtgg acaaggagga gaggagtgaa tcagtcacca 15060

agctacattc gttctccttt cagaatctct cccattcatc cgtcttcctt ttcccctccc 15120

acttgagaca gagtggattg aagctttcag ggctgaggaa acacagtggt tttctcattg 15180

ctccctttac agttaggctc ctctgccctc cagtattgtg ctagaaactt ctgttcgatt 15240

atcctgttgc gtggcggtga gtgggaggaa gaggctagcc ctgacatgct caggtctcct 15300

agggagtttt cgctaactac acacacacca cccctctggc agataatgct ttactgagcc 15360

tgacctgctg atgtcagtgt cactgtgggt atacaaaaaa ggcagaccat ggagaacttt 15420

tgaataagag ttacagactg taagcaccca gctcagatta cataactctg gccttgcgtg 15480

agctgcccag ctatctgtcc agtgttcctg cctttatgtt cctagcacag ccattggccc 15540

tactagatgg acagtgagtg agccttgaca aacacgtctg cacctgtgct ccctgccatg 15600

tgctccctgc cctgtgctcc ctgccctgtt tccaatataa aatcgccgac cgttgattgg 15660

gctcacttca gcccccactg atacaaggag gctccctctg tcctcagagc acttgccgtt 15720

gcttctctta tcctttgaga ttcagtcaca tacagacttt taacatccct ttttttttt 15780

gaaatgggct cctactctgt cacccaggct ggaatgtaat ggcatgatca cagctcactg 15840

cagccttgac ctcctgggct caaatgatcc tcccacctca gcctcccaag tagctggggc 15900

catgggcatg caccaccatg cctggttaat ttaaaaagtt tttttattaa gatggaaatc 15960

ttgctatgtt gcccaggcta gtcgcaaacc cctagcctca agtgatcctc tcgcttcagc 16020

ctgggattac aggcgtgagc cactgtgtct ggcctgcctt ctcatattat tacacaagat 16080

gtttaagacc acaaaatact gtctggtcct gccagctaga ctgagttact ggaaggcaga 16140

aatcgtgttg ccgtcctgca cggcccaggc acagtgctgg gcacatgggg agggtggtgt 16200

ccctcacaca tgtgctgctt gatgacagta gtggtagagg ggtctggagg gtgagttgct 16260

tcccccagct gcagaaccat catctgcaca ctcagaacta gcttgttgcc tctgaggttc 16320

tattttattt cttcagtgag acacatcatt tctctgttgg gagttgggta tagtcaaaat 16380

cacctcttca aaaagcaact gttttctcct ttctcctgac agctgtacct cccacaagga 16440

ttacccttc catgaagagt tttgaagctg tggttgcctg ctcgtcccca agtgacctat 16500

acctgtgttt cttgcctcat ttttttcctt gcaaatgtag tatggcctgt gtcactcagc 16560

agtgggacag caacctgtag agtggccagc gagggcgtgt ctagcttgat gttggatctc 16620

aagagccctg tcagtagagt agaagtctct tccagtttgc tttgcccttc tttctaccct 16680

gctggggaaa gtacaacctg aatacccttt tctgaccaaa gagaagcaaa atctaccagg 16740

tcaaaatagt gccactaacg gttgagtttt gactgcttgg aactggaatc ctttcagcaa 16800

gacttctctt tgcctcaaat aaaaagtgct tttgtgagct tgg 16843

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 49
ucgcagccaa gcacaauaaa 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 50
tttattgtgc ttggctgcga 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 51
gcagccaagc acaauaaaac 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 52
gttttattgt gcttggctgc 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 53
gaucgcagcc aagcacaaua 20

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 54
tattgtgctt ggctgcgatc 20

<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 55
aucgcagcca agcacaauaa 20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 56
ttattgtgct tggctgcgat 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 57
cgcagccaag cacaauaaaa 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 58
ttttattgtg cttggctgcg 20

<210> 59
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 59
gccaagcaca auaaaacuac 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 60
gtagttttat tgtgcttggc 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 61
cgaucgcagc caagcacaau 20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 62
attgtgcttg gctgcgatcg 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 63
agcacaauaa aacuacagcc 20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 64
ggctgtagtt ttattgtgct 20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 65
cagccaagca caauaaaacu 20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 66
agttttattg tgcttggctg 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 67
gcgaucgcag ccaagcacaa 20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 68
ttgtgcttgg ctgcgatcgc 20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 69
gcacaauaaa acuacagccc 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 70
gggctgtagt tttattgtgc 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 71
aaccagauug agugccaccc 20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 72
gggtggcact caatctggtt 20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 73
accagauuga gugccaccca 20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 74
tgggtggcac tcaatctggt 20

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 75
accucccaca aggauuaccc 20

<210> 76
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 76
gggtaatcct tgtgggaggt 20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 77
ccucccacaa ggauuacccc 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 78
ggggtaatcc ttgtgggagg 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 79
acaaccugaa uacccuuuuc 20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 80
gaaaagggta ttcaggttgt 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 81
cucccacaag gauuaccccu 20

<210> 82
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 82
aggggtaatc cttgtgggag 20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 83
ccagauugag ugccacccau 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 84
atgggtggca ctcaatctgg 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 85
caaccugaau acccuuuucu 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 86
agaaaagggt attcaggttg 20

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 87
aguacaaccu gaauacccuu 20

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 88
aagggtattc aggttgtact 20

<210> 89
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 89
guacaaccug aauacccuuu 20

<210> 90
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 90
aaagggtatt caggttgtac 20

<210> 91
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 91
aaggcgaucg cagccaagca 20

<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 92
tgcttggctg cgatcgcctt 20

<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 93
ucccacaagg auuaccccuu 20

<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 94
aaggggtaat ccttgtggga 20

<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 95
aaguacaacc ugaauacccu 20

<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 96
agggtattca ggttgtactt 20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 97
aaccugaaua cccuuuucug 20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 98
cagaaaaggg tattcaggtt 20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 99
accugaauac ccuuuucuga   20

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 100
tcagaaaagg gtattcaggt   20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 101
uaccucccac aaggauuacc   20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 102
ggtaatcctt gtgggaggta   20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 103
aaaguacaac cugaauaccc   20

<210> 104
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 104
gggtattcag gttgtacttt   20

<210> 105
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 105
ccugaauacc cuuuucugac 20

<210> 106
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 106
gtcagaaaag ggtattcagg 20

<210> 107
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 107
uaaccagauu gagugccacc 20

<210> 108
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 108
ggtggcactc aatctggtta 20

<210> 109
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 109
auugagugcc acccauaucu 20

<210> 110
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 110
agatatgggt ggcactcaat 20

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 111
gugccaccca uaucucacuc 20

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 112
gagtgagata tgggtggcac 20

<210> 113
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 113
ugccacccau aucucacuca 20

<210> 114
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 114
tgagtgagat atgggtggca 20

<210> 115
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 115
cacaauaaaa cuacagccca 20

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 116
tgggctgtag ttttattgtg 20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 117
cccacaagga uuaccccuuc 20

<210> 118
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 118
gaaggggtaa tccttgtggg 20

<210> 119
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 119
cugaauaccc uuuucugacc 20

<210> 120
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 120
ggtcagaaaa gggtattcag 20

<210> 121
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 121
gauugagugc cacccauauc 20

<210> 122
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 122
gatatgggtg gcactcaatc   20

<210> 123
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 123
agugccaccc auaucucacu   20

<210> 124
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 124
agtgagatat gggtggcact   20

<210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 125
gccacccaua ucucacucag   20

<210> 126
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 126
ctgagtgaga tatgggtggc   20

<210> 127
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 127
gagugccacc cauaucucac   20

<210> 128
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 128
gtgagatatg ggtggcactc 20

<210> 129
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 129
ugaauacccu uuucugacca 20

<210> 130
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 130
tggtcagaaa agggtattca 20

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 131
uugagugcca cccauaucuc 20

<210> 132
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 132
gagatatggg tggcactcaa 20

<210> 133
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 133
ugagugccac ccauaucuca 20

<210> 134
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 134
tgagatatgg gtggcactca 20

<210> 135
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 135
agauugagug ccacccauau 20

<210> 136
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 136
atatgggtgg cactcaatct 20

<210> 137
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 137
ccacccauau cucacucagg 20

<210> 138
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 138
cctgagtgag atatgggtgg 20

<210> 139
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 139
cagauugagu gccacccaua 20

<210> 140
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 140
tatgggtggc actcaatctg 20

<210> 141
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 141
ccacaaggau uaccccuucc 20

<210> 142
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 142
ggaaggggta atccttgtgg 20

<210> 143
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 143
gaaaguacaa ccugaauacc 20

<210> 144
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 144
ggtattcagg ttgtactttc 20

<210> 145
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 145
gaauacccuu uucugaccaa 20

<210> 146
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 146
ttggtcagaa aagggtattc 20

<210> 147
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 147
acaauaaaac uacagcccag 20

<210> 148
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 148
ctgggctgta gttttattgt 20

<210> 149
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 149
guaccuccca caaggauuac 20

<210> 150
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 150
gtaatccttg tgggaggtac 20

<210> 151
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 151
aaacaaaccu ggcuugaagu 20

<210> 152
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 152
acttcaagcc aggtttgttt 20

<210> 153
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 153
ucaaggcgau cgcagccaag 20

<210> 154
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 154
cttggctgcg atcgccttga 20

<210> 155
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 155
auggcaagcc gucuccugcu 20

<210> 156
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 156
agcaggagac ggcttgccat 20

<210> 157
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 157
gaucuuaaac aaaccuggcu 20

<210> 158
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 158
agccaggttt gtttaagatc 20

<210> 159
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 159
ugaucuuaaa caaaccuggc 20

<210> 160
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 160
gccaggtttg tttaagatca 20

<210> 161
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 161
uaaacaaacc uggcuugaag 20

<210> 162
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 162
cttcaagcca ggtttgttta 20

<210> 163
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 163
aacaaaccug gcuugaagua 20

<210> 164
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 164
tacttcaagc caggtttgtt 20

<210> 165
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 165
cucagcagug ggacagcaac 20

<210> 166
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 166
gttgctgtcc cactgctgag 20

<210> 167
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 167
ucagcagugg gacagcaacc 20

<210> 168
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 168
ggttgctgtc ccactgctga 20

<210> 169
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 169
cagcaguggg acagcaaccu 20

<210> 170
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 170
aggttgctgt cccactgctg 20

<210> 171
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 171
agcaguggga cagcaaccug 20

<210> 172
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 172
caggttgctg tcccactgct 20

<210> 173
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 173
gcagugggac agcaaccugu 20

<210> 174
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 174
acaggttgct gtcccactgc 20

<210> 175
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 175
caguggga gcaaccugua 20

<210> 176
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 176
tacaggttgc tgtcccactg 20

<210> 177
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 177
agugggacag caaccuguag 20

<210> 178
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 178
ctacaggttg ctgtcccact 20

<210> 179
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 179
uguaccuccc acaaggauua 20

<210> 180
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 180
taatccttgt gggaggtaca 20

<210> 181
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 181
aagugaccua uaccuguguu 20

<210> 182
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 182
aacacaggta taggtcactt 20

<210> 183
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 183
gugggacagc aaccuguaga 20

<210> 184
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 184
tctacaggtt gctgtcccac 20

<210> 185
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 185
uagugccacu aacgguugag 20

<210> 186
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 186
ctcaaccgtt agtggcacta 20

<210> 187
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 187
agugccacua acgguugagu 20

<210> 188
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 188
actcaaccgt tagtggcact 20

<210> 189
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 189
agguggagau gaucuuaaac 20

<210> 190
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 190
gtttaagatc atctccacct 20

<210> 191
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 191
ugggacagca accuguagag 20

<210> 192
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 192
ctctacaggt tgctgtccca 20

<210> 193
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 193
auagugccac uaacgguuga 20

<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 194
tcaaccgtta gtggcactat 20

<210> 195
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 195
caagugaccu auaccugugu 20

<210> 196
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 196
acacaggtat aggtcacttg 20

<210> 197
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 197
agugaccuau accuguguuu 20

<210> 198
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 198
aaacacaggt ataggtcact 20

<210> 199
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 199
gcaagccguc uccugcucaa 20

<210> 200
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 200
ttgagcagga gacggcttgc 20

<210> 201
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 201
caagccgucu ccugcucaac 20

<210> 202
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 202
gttgagcagg agacggcttg 20

<210> 203
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 203
aagccgucuc cugcucaaca 20

<210> 204
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 204
tgttgagcag gagacggctt 20

<210> 205
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 205
ucuuaaacaa accuggcuug 20

<210> 206
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 206
caagccaggt ttgtttaaga 20

<210> 207
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 207
ucugugacac cagaacgcau 20

<210> 208
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 208
atgcgttctg gtgtcacaga 20

<210> 209
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 209
cugugacacc agaacgcauu 20

<210> 210
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 210
aatgcgttct ggtgtcacag 20

<210> 211
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 211
ugugacacca gaacgcauug 20

<210> 212
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 212
caatgcgttc tggtgtcaca 20

<210> 213
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 213
aacuucaacc aucuccaggu 20

<210> 214
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 214
acctggagat ggttgaagtt 20

<210> 215
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 215
acaaaccugg cuugaaguau 20

<210> 216
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 216
atacttcaag ccaggtttgt 20

<210> 217
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 217
uuaaccagau ugagugccac 20

<210> 218
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 218
gtggcactca atctggttaa 20

<210> 219
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 219
gugacaccag aacgcauugc 20

<210> 220
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 220
gcaatgcgtt ctggtgtcac 20

<210> 221
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 221
ugacaccaga acgcauugcu 20

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 222
agcaatgcgt tctggtgtca 20

<210> 223
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 223
auuaccccuu ccaugaagag 20

<210> 224
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 224
ctcttcatgg aaggggtaat 20

<210> 225
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 225
gggacagcaa ccuguagagu 20

<210> 226
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 226
actctacagg ttgctgtccc 20

<210> 227
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 227
auacccuuuu cugaccaaag 20

<210> 228
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 228
ctttggtcag aaaagggtat 20

<210> 229
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 229
aucaaggcga ucgcagccaa 20

<210> 230
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 230
ttggctgcga tcgccttgat 20

<210> 231
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 231
agucugugac accagaacgc 20

<210> 232
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 232
gcgttctggt gtcacagact 20

<210> 233
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 233
cuguaccucc cacaaggauu 20

<210> 234
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 234
aatccttgtg ggaggtacag 20

<210> 235
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 235
cacaaggauu accccuucca 20

<210> 236
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 236
tggaaggggt aatccttgtg 20

<210> 237
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 237
gauuaccccu uccaugaaga 20

<210> 238
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 238
tcttcatgga aggggtaatc 20

<210> 239
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 239
uuaccccuuc caugaagagu 20

<210> 240
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 240
actcttcatg gaaggggtaa 20

<210> 241
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 241
uaccccuucc augaagaguu 20

<210> 242
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 242
aactcttcat ggaaggggta 20

<210> 243
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 243
cacccauauc ucacucagga 20

<210> 244
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 244
tcctgagtga gatatgggtg 20

<210> 245
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 245
ggauuacccc uuccaugaag 20

<210> 246
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 246
cttcatggaa ggggtaatcc 20

<210> 247
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 247
acucagcagu gggacagcaa 20

<210> 248
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 248
ttgctgtccc actgctgagt 20

<210> 249
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 249
aagccugcag uuaaccagau 20

<210> 250
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 250
atctggttaa ctgcaggctt 20

<210> 251
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 251
gucugugaca ccagaacgca 20

<210> 252
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 252
tgcgttctgg tgtcacagac 20

<210> 253
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 253
gcuguaccuc ccacaaggau 20

<210> 254
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 254
atccttgtgg gaggtacagc 20

<210> 255
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 255
aggauuaccc cuuccaugaa 20

<210> 256
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 256
ttcatggaag gggtaatcct 20

<210> 257
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 257
agccugcagu uaaccagauu 20

<210> 258
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 258
aatctggtta actgcaggct 20

<210> 259
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 259
ccaagugacc uauaccugug 20

<210> 260
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 260
cacaggtata ggtcacttgg 20

<210> 261
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 261
acuucaacca ucuccaggug 20

<210> 262
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 262
cacctggaga tggttgaagt 20

<210> 263
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 263
uugagcugua ccucccacaa 20

<210> 264
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 264
ttgtgggagg tacagctcaa 20

<210> 265
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 265
ugagcuguac cucccacaag 20

<210> 266
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 266
cttgtgggag gtacagctca 20

<210> 267
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 267
gagcuguacc ucccacaagg 20

<210> 268
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 268
ccttgtggga ggtacagctc 20

<210> 269
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 269
agcuguaccu cccacaagga 20

<210> 270
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 270
tccttgtggg aggtacagct 20

<210> 271
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 271
accccuucca ugaagaguuu 20

<210> 272
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 272
aaactcttca tggaaggggt 20

<210> 273
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 273
ggaaaguaca accugaauac 20

<210> 274
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 274
gtattcaggt tgtactttcc 20

<210> 275
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 275
ggaauuuuuc ccauuggaug 20

<210> 276
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 276
catccaatgg gaaaaattcc 20

<210> 277
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 277
gguggagaug aucuuaaaca 20

<210> 278
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 278
tgtttaagat catctccacc 20

<210> 279
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 279
gccugcaguu aaccagauug 20

<210> 280
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 280
caatctggtt aactgcaggc 20

<210> 281
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 281
acaaggauua ccccuuccau 20

<210> 282
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 282
atggaagggg taatccttgt 20

<210> 283
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 283
agccgucucc ugcucaacaa   20

<210> 284
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 284
ttgttgagca ggagacggct   20

<210> 285
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 285
auuggaugag ucgggcaaug   20

<210> 286
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 286
cattgcccga ctcatccaat   20

<210> 287
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 287
uaagccugca guuaaccaga   20

<210> 288
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 288
tctggttaac tgcaggctta   20

<210> 289
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 289
ccccaagucu gugacaccag 20

<210> 290
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 290
ctggtgtcac agacttgggg 20

<210> 291
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 291
gugaccuaua ccuguguuuc 20

<210> 292
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 292
gaaacacagg tataggtcac 20

<210> 293
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 293
ggacagcaac cuguagagug 20

<210> 294
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 294
cactctacag gttgctgtcc 20

<210> 295
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 295
cuuaaacaaa ccuggcuuga 20

<210> 296
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 296
tcaagccagg tttgtttaag 20

<210> 297
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 297
caauaaaacu acagcccagg 20

<210> 298
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 298
cctgggctgt agttttattg 20

<210> 299
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 299
aagucuguga caccagaacg 20

<210> 300
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 300
cgttctggtg tcacagactt 20

<210> 301
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 301
guugagcugu accucccaca 20

<210> 302
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 302
tgtgggaggt acagctcaac 20

<210> 303
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 303
uacccuuuuc ugaccaaaga 20

<210> 304
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 304
tctttggtca gaaaagggta 20

<210> 305
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 305
acccauaucu cacucaggag 20

<210> 306
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 306
ctcctgagtg agatatgggt 20

<210> 307
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 307
aucccaagu cugugacacc 20

<210> 308
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 308
ggtgtcacag acttggggat 20

<210> 309
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 309
uccccaaguc ugugacacca 20

<210> 310
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 310
tggtgtcaca gacttgggga 20

<210> 311
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 311
caaggauuac cccuuccaug 20

<210> 312
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 312
catggaaggg gtaatccttg 20

<210> 313
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 313
aaggauuacc ccuuccauga 20

<210> 314
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 314
tcatggaagg ggtaatcctt 20

<210> 315
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 315
aauagugcca cuaacgguug 20

<210> 316
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 316
caaccgttag tggcactatt 20

<210> 317
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 317
uuggaugagu cgggcaaugu 20

<210> 318
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 318
acattgcccg actcatccaa 20

<210> 319
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 319
caacuucaac caucuccagg 20

<210> 320
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 320
cctggagatg gttgaagttg 20

<210> 321
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 321
auaagccugc aguuaaccag 20

<210> 322
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 322
ctggttaact gcaggcttat 20

<210> 323
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 323
ccugcaguua accagauuga 20

<210> 324
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 324
tcaatctggt taactgcagg 20

<210> 325
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 325
gaucccaag ucugugacac 20

<210> 326
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 326
gtgtcacaga cttggggatc 20

<210> 327
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 327
uguugagcug uaccucccac 20

<210> 328
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 328
gtgggaggta cagctcaaca 20

<210> 329
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 329
cacucagcag ugggacagca 20

<210> 330
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 330
tgctgtccca ctgctgagtg 20

<210> 331
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 331
uggaugaguc gggcaaugug 20

<210> 332
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 332
cacattgccc gactcatcca 20

<210> 333
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 333
aaugugguuc ccagugacac 20

<210> 334
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 334
gtgtcactgg gaaccacatt 20

<210> 335
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 335
gaucaaggcg aucgcagcca 20

<210> 336
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 336
tggctgcgat cgccttgatc 20

<210> 337
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 337
ucgcagccaa gcacaauaaa 20

<210> 338
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 338
tttattgtgc ttggctgcga 20

<210> 339
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 339
cgcagccaag cacaauaaaa 20

<210> 340
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 340
ttttattgtg cttggctgcg 20

<210> 341
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 341
gcccuucuuu cuacccugcu 20

<210> 342
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 342
agcagggtag aaagaagggc 20

<210> 343
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 343
gaccucacgg gcuauuuaaa 20

<210> 344
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 344
tttaaatagc ccgtgaggtc 20

<210> 345
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 345
uaccucccac aaggauuacc 20

<210> 346
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 346
ggtaatcctt gtgggaggta 20

<210> 347
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 347
cccuucuuuc uacccugcug 20

<210> 348
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 348
cagcagggta gaaagaaggg 20

<210> 349
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 349
accucccaca aggauuaccc 20

<210> 350
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 350
gggtaatcct tgtgggaggt 20

<210> 351
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 351
accucacggg cuauuuaaag 20

<210> 352
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 352
ctttaaatag cccgtgaggt 20

<210> 353
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 353
auugagugcc acccauaucu 20

<210> 354
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 354
agatatgggt ggcactcaat 20

<210> 355
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 355
gaucuuaaac aaaccuggcu 20

<210> 356
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 356
agccaggttt gtttaagatc 20

<210> 357
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 357
ugaucuuaaa caaaccuggc 20

<210> 358
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 358
gccaggtttg tttaagatca 20

<210> 359
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 359
aaggcgaucg cagccaagca 20

<210> 360
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 360
tgcttggctg cgatcgcctt 20

<210> 361
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 361
gauugagugc cacccauauc 20

<210> 362
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 362
gatatgggtg gcactcaatc 20

<210> 363
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 363
cagauugagu gccacccaua 20

<210> 364
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 364
tatgggtggc actcaatctg 20

<210> 365
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 365
ccagauugag ugccacccau 20

<210> 366
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 366
atgggtggca ctcaatctgg 20

<210> 367
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 367
ucaaggcgau cgcagccaag 20

<210> 368
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 368
cttggctgcg atcgccttga 20

<210> 369
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 369
uaaacaaacc uggcuugaag 20

<210> 370
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 370
cttcaagcca ggtttgttta 20

<210> 371
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 371
uuaccccuuc caugaagagu 20

<210> 372
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 372
actcttcatg gaaggggtaa 20

<210> 373
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 373
aaacaaaccu ggcuugaagu 20

<210> 374
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 374
acttcaagcc aggtttgttt 20

<210> 375
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 375
uaccccuucc augaagaguu 20

<210> 376
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 376
aactcttcat ggaaggggta 20

<210> 377
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 377
aauacaaaaa uuagcccggc 20

<210> 378
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 378
gccgggctaa tttttgtatt 20

<210> 379
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 379
aauaccaucu ccucuucggc 20

<210> 380
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 380
gccgaagagg agatggtatt 20

<210> 381
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 381
aaauaccauc uccucuucgg 20

<210> 382
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 382
ccgaagagga gatggtattt 20

<210> 383
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 383
auaccaucuc cucuucggcu 20

<210> 384
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 384
agccgaagag gagatggtat 20

<210> 385
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 385
cacuacccuu auucuugucu 20

<210> 386
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 386
agacaagaat aagggtagtg 20

<210> 387
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 387
auacaaaaau uagcccggca 20

<210> 388
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 388
tgccgggcta atttttgtat 20

<210> 389
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 389
ucacuacccu uauucuuguc 20

<210> 390
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 390
gacaagaata agggtagtga 20

<210> 391
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 391
uaccaucucc ucuucggcug 20

<210> 392
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 392
cagccgaaga ggagatggta 20

<210> 393
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 393
acacccauuc agucauuuug 20

<210> 394
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 394
caaaatgact gaatgggtgt 20

<210> 395
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 395
gacacccauu cagucauuuu 20

<210> 396
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 396
aaaatgactg aatgggtgtc 20

<210> 397
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 397
ucaugauaau cucccagaac 20

<210> 398
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 398
gttctgggag attatcatga 20

<210> 399
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 399
caguuuaucu uaucgcuccu 20

<210> 400
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 400
aggagcgata agataaactg 20

<210> 401
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 401
aguuuaucuu aucgcuccuc 20

<210> 402
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 402
gaggagcgat aagataaact 20

<210> 403
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 403
accucccaca aggauuaccc 20

<210> 404
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 404
gggtaatcct tgtgggaggt 20

<210> 405
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 405
ccucccacaa ggauuacccc 20

<210> 406
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 406
ggggtaatcc ttgtgggagg 20

<210> 407
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 407
caugagguca gaagauagag 20

<210> 408
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 408
ctctatcttc tgacctcatg 20

<210> 409
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 409
cuucaugaua aucucccaga 20

<210> 410
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 410
tctgggagat tatcatgaag 20

<210> 411
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 411
augaggucag aagauagaga 20

<210> 412
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 412
tctctatctt ctgacctcat 20

<210> 413
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 413
acuguuuucu ccuuucuccu 20

<210> 414
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 414
aggagaaagg agaaaacagt 20

<210> 415
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 415
uucuccuuuc uccugacagc 20

<210> 416
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 416
gctgtcagga gaaaggagaa 20

<210> 417
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 417
agacccagcc uccuuucccu 20

<210> 418
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 418
agggaaagga ggctgggtct 20

<210> 419
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 419
cccuuauucu ugucugagcu 20

<210> 420
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 420
agctcagaca agaataaggg 20

<210> 421
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 421
cucucccauu cauccgucuu 20

<210> 422
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 422
aagacggatg aatgggagag 20

<210> 423
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 423
caugauaauc ucccagaacc 20

<210> 424
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 424
ggttctggga gattatcatg 20

<210> 425
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 425
ucucucccau ucauccgucu 20

<210> 426
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 426
agacggatga atgggagaga 20

<210> 427
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 427
ccuuauucuu gucugagcuc 20

<210> 428
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 428
gagctcagac aagaataagg 20

<210> 429
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 429
ucucucacua cccuuauucu 20

<210> 430
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 430
agaataaggg tagtgagaga 20

<210> 431
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 431
ccuuucuugc ccucucuguc 20

<210> 432
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 432
gacagagagg gcaagaaagg 20

<210> 433
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 433
ccaaucuguc cauuccauuu 20

<210> 434
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 434
aaatggaatg gacagattgg 20

<210> 435
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 435
cucucuccuu uaguacuucc 20

<210> 436
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 436
ggaagtacta aaggagagag 20

<210> 437
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 437
ucucuccuuu aguacuuccu 20

<210> 438
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 438
aggaagtact aaaggagaga 20

<210> 439
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 439
ccugagccug auuaucugaa 20

<210> 440
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 440
ttcagataat caggctcagg 20

<210> 441
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 441
ccaucuuuug ccaugaucac 20

<210> 442
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 442
gtgatcatgg caaaagatgg 20

<210> 443
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 443
uuucuccauc uuuugccaug 20

<210> 444
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 444
catggcaaaa gatggagaaa   20

<210> 445
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 445
gccaaucugu ccauuccauu   20

<210> 446
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 446
aatggaatgg acagattggc   20

<210> 447
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 447
uccaucuuuu gccaugauca   20

<210> 448
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 448
tgatcatggc aaaagatgga   20

<210> 449
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 449
cugagccuga uuaucugaaa   20

<210> 450
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 450
tttcagataa tcaggctcag 20

<210> 451
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 451
cuucuucgug accucuugca 20

<210> 452
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 452
tgcaagaggt cacgaagaag 20

<210> 453
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 453
auugacuucc ccaaacaaca 20

<210> 454
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 454
tgttgtttgg ggaagtcaat 20

<210> 455
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 455
cuagaaaaac cucucacaac 20

<210> 456
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 456
gttgtgagag gtttttctag 20

<210> 457
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 457
uugacuuccc caaacaacag 20

<210> 458
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 458
ctgttgtttg gggaagtcaa 20

<210> 459
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 459
uagccugagc cugauuaucu 20

<210> 460
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 460
agataatcag gctcaggcta 20

<210> 461
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 461
aacguaucac ccacggccau 20

<210> 462
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 462
atggccgtgg gtgatacgtt 20

<210> 463
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 463
acacucaaua cagcuacacu 20

<210> 464
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 464
agtgtagctg tattgagtgt 20

<210> 465
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 465
gcuucuucgu gaccucuugc 20

<210> 466
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 466
gcaagaggtc acgaagaagc 20

<210> 467
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 467
auagccugag ccugauuauc 20

<210> 468
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 468
gataatcagg ctcaggctat 20

<210> 469
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 469
guaacuagca agaccuguaa 20

<210> 470
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 470
ttacaggtct tgctagttac 20

<210> 471
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 471
auaagcaucu caagccggua 20

<210> 472
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 472
taccggcttg agatgcttat 20

<210> 473
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 473
aaacguauca cccacggcca 20

<210> 474
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 474
tggccgtggg tgatacgttt 20

<210> 475
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 475
ccguagcuag uugauaauuc 20

<210> 476
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 476
gaattatcaa ctagctacgg 20

<210> 477
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 477
auuuguuucu accccagcuc 20

<210> 478
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 478
gagctggggt agaaacaaat 20

<210> 479
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 479
aauaagcauc ucaagccggu 20

<210> 480
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 480
accggcttga gatgcttatt 20

<210> 481
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 481
uuuguuucua ccccagcucu 20

<210> 482
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 482
agagctgggg tagaaacaaa 20

<210> 483
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 483
acguaucacc cacggccaua 20

<210> 484
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 484
tatggccgtg ggtgatacgt 20

<210> 485
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 485
uaaaaccuca acaccacaca 20

<210> 486
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 486
tgtgtggtgt tgaggtttta 20

<210> 487
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 487
gucccucuu aacccacacc 20

<210> 488
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 488
ggtgtgggtt aagaggggac 20

<210> 489
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 489
gucucagcuc cagcccguuu 20

<210> 490
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 490
aaacgggctg gagctgagac   20

<210> 491
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 491
agucucagcu ccagcccguu   20

<210> 492
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 492
aacgggctgg agctgagact   20

<210> 493
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 493
aaaaccucaa caccacacag   20

<210> 494
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 494
ctgtgtggtg ttgaggtttt   20

<210> 495
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 495
cccguagcua guugauaauu   20

<210> 496
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 496
aattatcaac tagctacggg 20

<210> 497
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 497
uaguguccau gucuccgucu 20

<210> 498
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 498
agacggagac atggacacta 20

<210> 499
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 499
cucacaacca uucacagcau 20

<210> 500
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 500
atgctgtgaa tggttgtgag 20

<210> 501
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 501
acaaccauuc acagcaucau 20

<210> 502
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 502
atgatgctgt gaatggttgt 20

<210> 503
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 503
gcauuuuguu auucuguccc 20

<210> 504
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 504
gggacagaat aacaaaatgc 20

<210> 505
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 505
uccgucugac agucucagcu 20

<210> 506
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 506
agctgagact gtcagacgga 20

<210> 507
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 507
cauuccauuu uguguccucu 20

<210> 508
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 508
agaggacaca aaatggaatg 20

<210> 509
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 509
uuagaguccc gugcugauga 20

<210> 510
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 510
tcatcagcac gggactctaa 20

<210> 511
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 511
guuuuauugc accacagcau 20

<210> 512
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 512
atgctgtggt gcaataaaac 20

<210> 513
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 513
uaagcaucuc aagccgguag 20

<210> 514
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 514
ctaccggctt gagatgctta 20

<210> 515
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 515
ugcccucaca accauucaca 20

<210> 516
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 516
tgtgaatggt tgtgagggca 20

<210> 517
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 517
uaucacccac ggccauacag 20

<210> 518
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 518
ctgtatggcc gtgggtgata 20

<210> 519
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 519
augacaccaa gcuaauuucc 20

<210> 520
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 520
ggaaattagc ttggtgtcat 20

<210> 521
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 521
uuauugcacc acagcauauc 20

<210> 522
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 522
gatatgctgt ggtgcaataa 20

<210> 523
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 523
gcaugggcuc uuagauuaau 20

<210> 524
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 524
attaatctaa gagcccatgc 20

<210> 525
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 525
auuccauuuu guguccucug 20

<210> 526
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 526
cagaggacac aaaatggaat 20

<210> 527
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 527
ggcuaaucuu uuuucuuccc 20

<210> 528
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 528
gggaagaaaa aagattagcc 20

<210> 529
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 529
acagaugcuc gacagaagau 20

<210> 530
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 530
atcttctgtc gagcatctgt 20

<210> 531
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 531
gaugcucgac agaagaugug 20

<210> 532
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 532
cacatcttct gtcgagcatc 20

<210> 533
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 533
uuguuuccuc caaaaacucc 20

<210> 534
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 534
ggagtttttg gaggaaacaa 20

<210> 535
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 535
guacuuaacc uauguaggcu 20

<210> 536
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 536
agcctacata ggttaagtac   20

<210> 537
<211> 28
<212> PRT
<213> Homo Sapiens

<400> 537

Pro Asn Asn Leu Ser Leu Val Lys Met Gly Arg Tyr Asn Leu Glu Glu
1   5   10   15

Gly Ala Leu Ile Glu Lys Pro Leu Val Thr His Arg
            20   25

<210> 538
<211> 28
<212> PRT
<213> Macaca mulatta

<400> 538

Pro Lys Asn Leu Ser Leu Val Lys Ser Gly Arg Tyr Asn Leu Glu Glu
1   5   10   15

Gly Ala Leu Ile Glu Lys Pro Leu Val Thr His Arg
            20   25

<210> 539
<211> 28
<212> PRT
<213> Mus Musculus

<400> 539

Gly Glu Asn Leu Ser Leu Val Lys Ile Gly Arg Tyr Asn Leu Glu Glu
1   5   10   15

Gly Ala Leu Ile Glu Lys Pro Leu Val Thr His Arg
            20   25

<210> 540
<211> 28
<212> PRT
<213> Canis lupus familiaris

<400> 540

Ala Glu Asn Leu Thr Leu Val Lys Ile Gly Arg Tyr Asn Leu Glu Glu
1   5   10   15

Gly Ala Leu Ile Glu Lys Pro Leu Val Thr His Arg
            20   25

<210> 541
<211> 28

<212> PRT
<213> Drosophila

<400> 541

Lys Asp Asn Leu Thr Ala Val Lys Gln Gly Arg Tyr Asn Leu Glu Glu
1   5   10   15

Gly Ala Leu Leu Glu Lys Arg Leu Val Thr His His
            20   25